GlobalFoundries rozšiřuje kapacity pro silicon photonics a SiGe, protože poptávka z AI a datových center převyšuje nabídku až do roku 2027. UMC zároveň hlásí silnější poptávku a růst spolupráce na 12nm procesu s Intelem.
Key Takeaways GlobalFoundries is expanding silicon photonics and SiGe capacity amid strong AI and data center demand.UMC is seeing stronger specialty technology demand while advancing 12-nanometer work with Intel.Both companies expect higher 2026 sales and earnings as foundry demand continues to improve. The global semiconductor foundry industry continues to benefit from rising demand for chips used in artificial intelligence, automotive electronics, industrial automation and connected devices. As chipmakers increasingly outsource manufacturing, foundries with advanced technologies, diverse customer bases and expanding production capacity are well positioned to capture long-term growth.
Against this backdrop, GLOBALFOUNDRIES Inc. (GFS - Free Report) and United Microelectronics Corporation (UMC - Free Report) stand out as two prominent players. While GlobalFoundries focuses on specialized process technologies and strategic manufacturing partnerships, UMC leverages its mature-node expertise and cost-efficient operations to serve a broad range of customers. Which semiconductor foundry stock offers the better investment opportunity today? Let's compare the two.
The Case for GFSGlobalFoundries is strengthening its long-term growth profile by capitalizing on rising demand from artificial intelligence and data center applications. The company reported robust double-digit growth in its Communications Infrastructure & Data Center and Automotive businesses during the first quarter, while highlighting strong momentum in silicon photonics and silicon-germanium (SiGe) technologies. Management noted that demand for its SiGe solutions has exceeded available capacity well into 2027, prompting capacity expansion. The company also expects its silicon photonics revenues to roughly double in 2026 and target a run rate exceeding $1 billion by the end of 2028, supported by increasing customer wins and new optical networking products.
Another positive is GlobalFoundries' improving profitability and expanding customer relationships. The company posted a record first-quarter gross margin of about 29%, up more than five percentage points year over year, reflecting a richer product mix, cost improvements and contributions from higher-margin technology services. Design wins climbed 50% from the prior-year period, while strategic partnerships with companies such as Renesas and Apple reinforce its position in automotive, industrial and U.S.-based semiconductor manufacturing. Management also emphasized that its diversified manufacturing footprint across the United States, Germany and Singapore is attracting customers seeking resilient supply chains amid ongoing geopolitical uncertainty.
Despite these strengths, GlobalFoundries continues to face headwinds in its Smart Mobile Devices business, which remains the largest revenue contributor. Management expects the segment to decline at a high-single-digit rate in 2026 as the broader smartphone market weakens, although it believes the business will outperform overall industry trends. The company also warned that geopolitical disruptions could raise supply-chain costs, with additional spending on critical materials expected to weigh on margins through the remainder of the year. These challenges suggest that sustained growth in AI, automotive and communications markets will be essential to offset weakness in mobile demand.
The Case for UMCUnited Microelectronics is benefiting from improving demand across its mature-node foundry business, supported by rising utilization and strong momentum in specialty technologies. During the first quarter, wafer shipments increased sequentially, lifting utilization to 79%, while 22-nanometer revenues reached another record and accounted for 14% of total sales. Management expects more than 50 customers to complete tape-outs on its 22-nanometer platform by the end of 2026, spanning applications such as display driver ICs, networking chips and microcontrollers. Looking ahead, UMC guided for high-single-digit shipment growth and low-single-digit ASP improvement in the second quarter, reflecting healthy demand across communications, consumer, industrial and AI-related markets.
UMC is also investing to expand its long-term growth opportunities beyond traditional mature-node manufacturing. The company continues to advance its 12-nanometer collaboration with Intel, which is expected to provide customers with U.S.-based manufacturing and pave the way for commercial production in 2027. At the same time, management highlighted growing traction in emerging businesses such as silicon photonics and advanced packaging, with more than 10 customer engagements and over 35 expected tape-outs in 2026. These initiatives, combined with disciplined pricing actions planned for the second half of the year and a strategy focused on higher-value specialty technologies, should strengthen UMC's competitive position over time.
On the downside, UMC's profitability continues to face cost pressures despite improving demand. Management cautioned that higher depreciation from the Singapore fab expansion, along with rising raw material, energy and logistics costs, is expected to offset much of the benefit from stronger utilization in 2026. While the company plans to implement wafer price increases in the second half, executives acknowledged that margin expansion is likely to remain constrained until depreciation expenses begin to ease, making sustained earnings growth dependent on continued demand recovery and successful execution of its higher-value technology roadmap.
How Does the Zacks Consensus Estimate Compare for GFS & UMC?The Zacks Consensus Estimate for GFS’ 2026 sales and earnings per share implies a 7.3% and 9.9%, respectively, year-over-year increase. Moreover, in the past 60 days, earnings estimates have witnessed upward revisions.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for UMC’s 2026 sales and EPS implies year-over-year growth of 10.9% and 32.1%, respectively. Earnings estimates for 2026 have increased in the past 60 days.
Image Source: Zacks Investment Research
Price Performance & ValuationGFS stock has gained 140.2% in the past six months compared with its sector’s growth of 49.5%. Conversely, UMC’s shares have surged 247.9% in the same time frame.
Price Performance
Image Source: Zacks Investment Research
GFS is trading at a forward 12-month price-to-earnings ratio of 48.92X, above its median of 32.37X over the last year. UMC’s forward earnings multiple sits at 36.23X, above its median of 18.79X over the same time frame.
P/E (F12M)
Image Source: Zacks Investment Research
Which Stock to Buy Now?Both companies are well positioned to benefit from long-term semiconductor demand, but UMC appears to have the stronger investment case at this stage. The company is seeing broad-based improvement across core businesses, healthy momentum in the specialty technology portfolio and encouraging progress in emerging areas such as silicon photonics, advanced packaging and its collaboration with Intel.
In addition, analysts have become increasingly optimistic about UMC's earnings outlook, while it is expected to deliver faster growth than GlobalFoundries. Although both stocks trade at premium valuations after strong rallies, UMC's stronger earnings trajectory, improving demand environment and expanding technology roadmap give it an edge. This makes it the more compelling semiconductor foundry stock to buy now.
UMC currently has a Zacks Rank #2 (Buy), whereas GFS carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Kinder Morgan těží z rostoucího exportu LNG a vyšší poptávky po plynové elektřině v USA. Její objednávkový backlog ve výši 10,1 miliardy USD míří hlavně na LNG, výrobu elektřiny a utility.
Key Takeaways Kinder Morgan transports about 40% of U.S. natural gas and has stable, contracted cash flows.Rising LNG exports and gas-fired power demand are driving Kinder Morgan's natural gas growth story.A $10.1B project backlog targets LNG, power generation and utility demand to support cash flows. Kinder Morgan (KMI - Free Report) is a leading energy infrastructure company in North America that transports approximately 40% of U.S. natural gas. The company owns an extensive asset base, including approximately 78,000 miles of pipelines, 136 terminals and more than 700 billion cubic feet (Bcf) of working natural gas storage capacity. While KMI generates stable cash flows, supported by its highly contracted business model, its growth story is backed by the rising demand for natural gas and power consumption in the United States.
The rising demand for natural gas is driven by two major factors – growth in liquefied natural gas (LNG) exports and increasing gas-fired power demand in the U.S. Kinder Morgan’s assets. These assets are well-positioned to support LNG export growth, particularly at the export hubs in Texas and the Louisiana Gulf Coast. Additionally, the expansion of data centers, the retirement of coal-fired power plants, industrial reshoring, population migration and economic growth in the Southern U.S. are resulting in increased electricity consumption, boosting the need for reliable natural gas-fired power generation.
The company’s $10.1 billion project backlog is primarily focused on natural gas infrastructure, with more than 20% directed toward serving the growing LNG demand, whereas about 60% is directed toward power generation and utility demand. This should enable the midstream player to convert these demand trends into stable, predictable cash flows. These trends enhance the strategic value of KMI’s pipeline and storage assets and provide investors with a low-risk path to gain exposure to the structural growth in U.S. natural gas demand.
Energy Sector Players to Benefit From Rising Natural Gas DemandThe rise of data centers and higher gas-fired power demand presents an opportunity for Enbridge Inc. (ENB - Free Report) to capitalize on. Data centers require a huge amount of electricity, which is driving rapid growth in gas demand. The shift from coal to gas for power generation is increasing the demand for gas. Enbridgeis expected to gain from the expansion of its natural gas storage facilities.
Venture Global (VG - Free Report) is one of the largest U.S.-based exporters of liquefied natural gas (LNG) and is currently operating and developing multiple LNG export projects in Louisiana. The company anticipates that the total production capacity across its projects will account for approximately 68 million tons per annum, upon completion, with potential upside from optimization initiatives. Being an LNG export company, VG is expected to benefit from the rise in LNG demand, driven by the expansion of data centers, replacement of coal and the global shift toward lower-emission fuels.
KMI’s Price Performance, Valuation & EstimatesShares of KMI have jumped 14.2% over the past year compared with the 18.7% improvement of the composite stocks belonging to the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, KMI trades at a trailing 12-month enterprise value to EBITDA (EV/EBITDA) of 14.47X. This is below the broader industry average of 15.2X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for KMI’s 2026 earnings hasn’t seen any revisions over the past seven days.
Image Source: Zacks Investment Research
KMI currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Quanta Services plánuje investovat 500–700 milionů USD do rozšíření kapacity transformátorů a výrobní stopy. Firma zároveň oznámila rekordní backlog 48,5 miliardy USD.
Key Takeaways PWR is expanding beyond construction to support utilities across engineering, manufacturing and supply chains.PWR plans to invest $500-$700 million to expand transformer capacity and manufacturing footprint.Quanta ended Q1 with a record $48.5 billion backlog, strengthening multiyear revenue visibility. Quanta Services, Inc. (PWR - Free Report) is increasingly aligning its business with one of the largest infrastructure opportunities in North America as utilities modernize aging power grids to meet rising electricity demand. The expansion of artificial intelligence, data centers, advanced manufacturing and electrification is placing greater pressure on transmission networks, making grid upgrades a long-term investment priority. This creates a favorable backdrop for companies with the expertise and scale to deliver complex infrastructure projects.
Grid modernization is becoming a key growth driver for Quanta because it has expanded well beyond traditional construction services. PWR now supports customers across engineering, procurement, construction, manufacturing and supply-chain solutions, allowing utilities to execute larger and more complex capital programs with greater certainty. The company is also working alongside customers much earlier in the planning process, strengthening its role in multiyear infrastructure investments.
Quanta is reinforcing this position through targeted manufacturing investments. The company plans to invest $500-$700 million over the next several years to double the power transformer manufacturing capacity while nearly doubling its off-site manufacturing, fabrication and logistics footprint to approximately 6.7 million square feet. These investments are designed to reduce equipment constraints, improve project execution and accelerate grid expansion as transmission demand grows.
The strategy is already translating into greater project visibility. Quanta ended the first quarter with a record backlog of $48.5 billion, up from $35.3 billion a year ago, including a 12-month backlog of $28.2 billion, up 45.4%, reinforcing strong multiyear revenue visibility. With utilities expected to invest heavily in transmission infrastructure for years to come, grid modernization has the potential to become one of Quanta's most durable long-term growth drivers.
How Does Quanta Compare With Infrastructure Peers?Quanta has established a leading position in North America's power infrastructure market, benefiting from growing investments in grid modernization, transmission expansion and electrification. As investors assess whether the company can sustain the long-term growth, comparisons with EMCOR Group, Inc. (EME - Free Report) and MasTec, Inc. (MTZ - Free Report) highlight its differentiated exposure to the evolving utility infrastructure landscape.
EMCOR is also benefiting from robust demand across electrical and mechanical construction, supported by data centers, manufacturing, health care and institutional projects. The company ended the first quarter with remaining performance obligations of $15.62 billion, reflecting strong project visibility. However, its growth remains more closely tied to building construction and facility-related services than utility transmission infrastructure.
MasTec is a closer peer, with exposure to power delivery, telecom, clean energy, pipeline and data center infrastructure. The company reported a record backlog of $20.3 billion and continues to benefit from investments in grid reliability, transmission expansion and AI-driven electricity demand. However, Quanta's integrated solutions platform, manufacturing investments and larger $48.5 billion backlog position it to capture a broader share of North America's multiyear grid modernization opportunity.
PWR’s Price Performance, Valuation & EstimatesPWR stock has surged 70.2% in the year-to-date (“YTD”) period, outperforming the Zacks Engineering - R and D Services industry, the broader Construction sector and the S&P 500 index.
PWR YTD Share Price Performance
Image Source: Zacks Investment Research
From a valuation standpoint, PWR trades at a forward 12-month price-to-earnings ratio of 47.53X, well above the industry’s 32.03X, as shown below.
PWR Valuation
Image Source: Zacks Investment Research
Quanta’s earnings estimates for 2026 and 2027 have decreased in the past 30 days. However, the revised estimates for 2026 and 2027 imply year-over-year growth of 30.5% and 17.3%, respectively.
Image Source: Zacks Investment Research
PWR’s Zacks RankQuanta currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Winnebago Industries má oporu v segmentu motorhome RV: tržby segmentu vzrostly o 10,1 % na 320,7 mil. USD a provozní marže se zlepšila na 3 % z -1,1 %.
Key Takeaways WGO's 2026 outlook hinges on whether Motorhome RV strength can offset towable RV and marine weakness.Motorhome RV revenues rose 10.1% to $320.7M, with operating margin improving to 3% from negative 1.1%.Affordability pressure, cautious dealer ordering and weak big-ticket demand still weigh on Winnebago. Winnebago Industries, Inc. (WGO - Free Report) is navigating a split 2026 backdrop. Motorhome improvement is helping, but the broader outdoor recreation market remains pressured.
The key question is whether product breadth and brand expansion can outweigh weak discretionary demand. For now, investors have to balance a visible bright spot against still-fragile towable RV and marine trends.
Winnebago's Segmental SplitWinnebago’s business is organized around three reportable segments: Towable RV, Motorhome RV and Marine. That mix matters because the company is not moving through the cycle evenly.
Towable RV represented 45.2% of fiscal 2025 revenues, while Motorhome RV accounted for 43.7%. Marine contributed 11.1%, making it smaller but still relevant to earnings quality, dealer demand and the company’s broader outdoor recreation identity.
Thor Industries, Inc. (THO - Free Report) remains a direct RV peer because it also competes across towable and motorized recreational vehicles. Patrick Industries, Inc. (PATK - Free Report) adds a supply-chain lens, since its component exposure to RV and marine markets makes it sensitive to the same production and dealer-order trends affecting Winnebago.
WGO Finds Support in New ProductsWinnebago continues to lean on new products to defend share and broaden price-point coverage. In towables, the Access and Thrive platforms under the Winnebago brand and Grand Design’s Transcend Lite are aimed at expanding participation among buyers who remain price conscious.
The company is also refreshing the higher end of its portfolio. The ARKA off-grid adventure truck, updated Newmar offerings and Grand Design’s Worry-Free Roof technology support product differentiation in motorhomes and towables.
Marine is part of the same strategy. Barletta’s Sanza line creates a more accessible entry point into the brand while Barletta continues to build share in the U.S. aluminum pontoon segment.
Winnebago Gets a Lift From MotorhomesThe Motorhome RV segment is the clearest support point in Winnebago’s latest results. Segment revenues rose 10.1% year over year to $320.7 million in the fiscal third quarter of 2026.
The profit improvement was more important than the sales gain. Motorhome RV generated operating income of $9.6 million and a 3% operating margin, compared with an operating loss of $3.2 million and a negative 1.1% margin in the year-ago quarter.
Higher unit volume and selective price adjustments helped the segment, partly offset by higher input costs. Management also cited traction at Grand Design Motorized, execution at Newmar and broader share gains across key motorhome categories.
WGO Still Faces Demand HeadwindsThe bullish case still runs into a difficult retail backdrop. Consumers remain interested in outdoor recreation, but affordability pressure, cumulative inflation, elevated interest rates and uncertainty around geopolitical events are delaying big-ticket purchases.
Dealer behavior is another drag. Management pointed to more deliberate ordering, with dealers focused on inventory quality, carrying costs and retail sell-through rather than adding wholesale volume.
These pressures are showing up outside motorhomes. Towable RV revenues fell 26.1% year over year in the fiscal third quarter of 2026, while Marine revenues declined 8.3%. Both segments also saw lower operating margins as volume deleverage, product mix and higher input costs weighed on performance.
What Winnebago’s Stock Signals Say NowThe bottom line is that Winnebago has one meaningful operating bright spot, but the stock still carries a weak short-term profile. Motorhome strength gives WGO a recovery argument, while towables, marine and consumer affordability keep that argument from looking clean.
WGO currently carries a Zacks Rank #4 (Sell). The Value Score of A supports the view that valuation screens well, and the Growth Score of B and VGM Score of B are not dismissive of the company’s broader financial profile.
Image Source: Zacks Investment Research
The Momentum Score of D keeps the signal mix cautious. Since Zacks Style Scores are designed to complement the Zacks Rank, the unfavorable rank makes it harder to treat WGO’s valuation as enough on its own. Investors may need clearer evidence that motorhome strength can spread across the portfolio before becoming more constructive.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Standard Commercial Lines je hlavním tahounem Selective Insurance Group: v roce 2025 tvořil 71 % tržeb a 79 % čistého předepsaného pojistného. Růst podporuje expanze do nových států a vyšší nové obchody i retence.
Key Takeaways The Standard Commercial Lines segment generated 71% of total revenues and 79% of net premiums written in 2025.Expansion into new states, including Kansas in 2025, supports premium growth and broader market presence.Higher new business, pricing, renewal exposure and retention continue to drive growth in the segment. Selective Insurance Group, Inc. (SIGI - Free Report) has a strong presence in the standard commercial lines market, focusing primarily on small and middle-market businesses. SIGI sells the Standard Commercial Lines property and casualty insurance products and services to commercial enterprises, typically businesses, non-profit organizations, and local government agencies, primarily in 36 states and the District of Columbia.
Selective Insurance continues to expand its Standard Commercial Lines footprint with the goal of a near national presence, while maintaining an agent-driven distribution model. Since 2017, SIGI has added 14 states to the Standard Commercial Lines footprint, including Kansas in 2025. In the first quarter of 2026, these expansion states produced $125 million in premiums, representing approximately 9% of total direct premiums written and 1% marginal total premium growth. SIGI expects to write new business in Montana and Wyoming by the end of 2026, pending regulatory approvals.
Standard Commercial Lines is the core revenue driver for Selective Insurance Group, making it the company's primary earnings engine. It generates the majority of the company's premium revenue, supplies the investment float that supports investment income, and serves as the foundation of the long-term growth strategy. This segment accounted for 71% of total revenues and 79% of total net premiums written in 2025. Higher new business, renewal pure price increases, exposure growth on renewal policies, and higher retention should continue to drive premiums in the segment.
Selective Insurance's standard commercial lines strategy centers on profitable underwriting rather than market-share expansion. By concentrating on well-understood industries, maintaining strong independent agency partnerships and exercising disciplined pricing, SIGI has consistently generated underwriting results that compare favorably with many peers across the commercial property and casualty insurance industry.
What About Its Peers?Axis Capital Holdings Limited (AXS - Free Report) , a global specialty underwriter, has a strategic focus on specialty products, including professional liability, cyber insurance, marine and aviation. AXS has been witnessing an increase in its top line over a considerable period of time on the back of higher net premiums. Its well-performing Insurance segment largely contributes to improving premiums. It continues to boost shareholder value through stock buybacks and dividend hikes.
Palomar Holdings, Inc. (PLMR - Free Report) has been displaying a good track record of net written premiums due to increased volume of policies written across the lines of business, driven by new business generated with existing partners, strong premium retention rates for existing business, expansion of its products’ geographic and distribution footprint, and new partnerships. Backed by a sustained operational performance, the company has maintained a solid capital position.
SIGI’s Price PerformanceShares of SIGI have gained 9.9% in the past year, outperforming the industry.
Image Source: Zacks Investment Research
SIGI’s Expensive ValuationThe stock is overvalued compared with its industry. It is currently trading at a price-to-book ratio of 1.67, above the industry average of 1.42. It carries a Value Score of A.
Image Source: Zacks Investment Research
Estimate Movement for SIGIThe Zacks Consensus Estimate for SIGI’s second-quarter 2026 EPS has moved up 2.4% in the past 60 days. The same for full-year 2026 and 2027 EPS has moved up 1.9% and 0.4%, respectively, in the past 30 days.
Ubiquiti ve 3. fiskálním čtvrtletí zvýšila výnosy o 18,7 % na 788,2 mil. USD, tažená růstem Enterprise Technology o 22,6 %. V Severní Americe výnosy stouply o 27 %.
Key Takeaways Ubiquiti's Q3 fiscal 2026 revenues rose 18.7% year over year, led by Enterprise Technology growth.UI's Enterprise Technology revenues climbed 22.6%, with North America revenues up 27% year over year.Ubiquiti expects product innovation and operations investments to support higher-value sales and expansion. Ubiquiti, Inc. (UI - Free Report) delivered impressive results in the third quarter of fiscal 2026, with revenues rising to $788.2 million from $664.2 million a year ago. The 18.7% year over year surge was driven by robust demand across its Enterprise Technology portfolio, while profitability also improved.
The Enterprise Technology segment generated $717.9 million in revenues, up from $585.7 million in the prior-year quarter, up 22.6% year over year. The company is benefiting from rising enterprise networking demand, increasing adoption of IoT-connected devices and continued deployment of unified IT infrastructure solutions. The North America region, which is Ubiquiti’s largest market, generated $410.2 million in revenues, up 27% year over year. Europe, the Middle East and Africa continued to post steady growth. Despite a lower market share, the company has witnessed improved traction in the Asia Pacific and South America regions.
The company continues to enhance the UniFi ecosystem and broaden its networking and unified IT management offerings. Management believes investments in product innovation, inventory management and operations will help maintain its competitive position while supporting higher-value product sales and long-term market expansion. Per our estimate, the company is set to report $2.83 billion in revenues from this segment in 2026, indicating a growth of 26% year over year.
How Are Competitors Faring?Ubiquiti faces competition from Cisco Systems (CSCO - Free Report) and Hewlett Packard Enterprise (HPE - Free Report) . Cisco enables enterprises and service providers to deliver highly secure connectivity from workplaces to data centers worldwide. During the recent quarter, the company’s total revenues increased 12% year over year, while networking revenues rose 25% year over year. Accelerating demand for Cisco’s switching and routing portfolio is driving this growth.
HPE reported revenue growth of 40.4% year over year. The Networking segment generated $2.7 billion in revenues in the second quarter of fiscal 2026, up 148.2% year over year. Management highlighted record campus and branch orders, with nearly 20% normalized growth in enterprise data center switching orders and nearly 30% normalized growth in routing orders. HPE also launched new autonomous, agentic AI operations capabilities and raised its cumulative Networks for AI order target to at least $2 billion by the end of fiscal 2026, reflecting confidence in AI-driven demand for high-performance networking.
UI’s Price Performance, Valuation and EstimatesUbiquiti has gained 36.7% in the past year compared with the Wireless Equipment industry’s growth of 42.5%.
Image Source: Zacks Investment Research
Going by the price/earnings ratio, the company’s shares currently trade at 34.57 forward earnings, higher than 31.44 for the industry.
Image Source: Zacks Investment Research
Earnings estimates for UI for 2026 have improved over the past 60 days.
Image Source: Zacks Investment Research
Ubiquiti carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
JPMorgan uvedl, že více než 60 % plánované kapacity datacenter pro rok 2027 ještě nezačalo a dalších 7 % projektů se zpožďuje kvůli dodavatelským řetězcům, povolování a nedostatku energie.
A popular saying in professional sports is that Father Time is undefeated. The clock stops for no professional athlete. The same can be true of the current data center buildout.
A recent JPMorgan Chase report states that more than 60% of the planned data center capacity for 2027 has not yet been started. An additional 7% of projects under construction are being delayed by supply chain bottlenecks, permitting hurdles, and power shortages.
Investors who focus on FUD (fear, uncertainty, and doubt) argue that the shift out of technology stocks, particularly hyperscaler stocks, is evidence that the data center story is falling apart.
Get Eaton alerts:
But the recent earnings season refuted that point of view. Demand is real. The money is committed. In the last quarter, the four major hyperscalers raised their combined AI-related capital expenditures to $750 billion for this calendar year. That demand is expected to reach $1 trillion in 2027.
But the one factor that investors can’t control is the time it takes to actually build the data centers. The story has gotten ahead of the shovels.
Data Center Backlog Stocks Could Be the Bigger AI TradeA more likely reason for the selloff is rotation into the stocks of companies that are essential to filling this backlog. The companies supplying the equipment needed to build new facilities stand to be the largest beneficiaries.
One option for investors is to look at exchange-traded funds (ETFs) tied to physical data center infrastructure. One example is the Global X U.S. Infrastructure Development ETF BATS: PAVE, which is up 22% in 2026 as of this writing.
However, investors may do better by investing in individual stocks within these funds. That can provide the opportunity for market-beating gains and, in some cases, dividends that can beat the performance of a single fund.
Eaton Is Turning AI Data Center Spend Into Backlog GrowthEaton Today
$403.94 -15.93 (-3.79%)
As of 11:43 AM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range$311.92▼
$436.74Dividend Yield1.09%
P/E Ratio39.35
Price Target$420.95
Eaton NYSE: ETN sells the electrical guts inside an AI data center. Think of switchgear, UPS systems, busways, and power distribution units that connect the grid to the server racks. The Q1 2026 numbers tell the story. In Eaton’s Electrical Americas segment, data center orders surged roughly 240% year over year, while data center revenue in the segment grew about 50%.
That growth is likely to accelerate. Eaton closed the Boyd Thermal acquisition to expand into liquid cooling. The company is also collaborating with NVIDIA NASDAQ: NVDA on the Beam Rubin DSX platform for AI factories. Plus, a planned Reverse Morris Trust deal will spin off Eaton's Mobility Group. That leaves a more focused Electrical and Aerospace business aligned squarely with AI buildout demand.
ETN is up 28% year-to-date, which lands it within 5% of its consensus price target. However, since the company’s Q1 2026 earnings report, analysts have been aggressively raising their price targets.
Why Quanta Services Offers the Clearest Backlog VisibilityQuanta Services Today
PWR
Quanta Services
$701.12 -17.47 (-2.43%)
As of 11:43 AM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range$363.01▼
$788.75Dividend Yield0.06%
P/E Ratio95.86
Price Target$733.87
Quanta Services NYSE: PWR does the physical work that turns a data center site plan into delivered power. The company builds high-voltage transmission lines, substations, and load centers. At its 2026 Investor Day, management outlined a $2.4 trillion addressable market through 2030.
The backlog supports that forecast. Quanta exited Q4 with a $44 billion backlog, up 27.5% year-over-year. Management now guides for 15% to 20% annual EPS (earnings per share) growth through 2030. Internal training programs have built a skilled-labor moat that smaller rivals struggle to match. That gives PWR pricing power as electricians and linemen become scarce.
PWR is up over 65% year-to-date, and like ETN, it’s within about 5% of its consensus price target. But analyst sentiment is bullish, and the chart is constructive, with support at the 50-day simple moving average (SMA) and a MACD on the cusp of reversing.
Vertiv Turns AI Heat and Power Demand Into Backlog GrowthVertiv Today
$306.74 -18.83 (-5.78%)
As of 11:43 AM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range$110.06▼
$379.93Dividend Yield0.08%
P/E Ratio76.48
Price Target$326.39
Vertiv NYSE: VRT sells the power and thermal infrastructure inside the building. Once Quanta finishes the grid work, Vertiv's UPS systems, switchgear, racks, and liquid cooling take over. Roughly 75% of revenue now comes from data center customers. Q1 2026 revenue grew 30% to $2.65 billion. Project backlog more than doubled to over $15 billion.
Management raised its full-year guidance to $13.5 to $14 billion in net sales. Recent acquisitions of Strategic Thermal Labs and ThermoKey extend Vertiv from chip-level cold plates to facility-scale heat rejection. Vertiv was also named a Tier 1 partner on Hut 8's NASDAQ: HUT gigawatt-scale Beacon Point AI campus. Each hyperscaler win reinforces the picks-and-shovels thesis.
VRT is up over 95% in 2026 and is also trading within 5% of its consensus price target. The company also has the most mixed analyst picture of the three stocks on this list. But investors willing to play the long game should consider VRT's potential for strong dividend growth in the coming years.
Should You Invest $1,000 in Eaton Right Now?Before you consider Eaton, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eaton wasn't on the list.
While Eaton currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Duolingo (DUOL) za poslední měsíc vzrostlo o více než 20 % a těží z AI, která výrazně zrychlila tvorbu obsahu. V 1. čtvrtletí zvýšilo čistý zisk o 24 % a tržby o 27 %.
It's been tough for long-term investors to hold Duolingo (DUOL +4.04%). The stock is down more than 70% over the past year, and while it was overvalued at over $400 per share, the current price is at bargain-basement levels, and some investors are finally noticing.
The stock has rallied more than 20% over the past month, and there are several reasons for Duolingo investors to feel optimistic that this is just the beginning.
Image source: Getty Images.
Duolingo isn't just for learning new languages Duolingo's original specialty was gamifying the language-learning experience. However, it is expanding into teaching other subjects, including chess, its fastest-growing subject.
Chess is a notable addition since it expands Duolingo's offerings beyond academic areas. The edtech company introduced math and music a few years ago and continues to expand its inventory. Duolingo is turning into an app that helps people master high-demand skills, not just new languages.
Its recent artificial intelligence (AI) investments also play a role here. Duolingo told investors in its Q1 shareholder letter that AI has "fundamentally changed how quickly we can create content." The company was able to publish 20,500 course units in Q1, compared to an average of 7,100 per quarter in 2025 and 1,800 per quarter in 2024.
Duolingo explained that this dramatic scaling helped it improve its popular Chinese, Japanese, and Korean courses. However, this same increase in content production makes it substantially easier for Duolingo to create new courses on high-demand skills that attract more users.
Today's Change
(
4.04
%) $
4.84
Current Price
$
124.78
Net income is still growing Almost tripling quarterly course unit production in a single year gives customers more options. That helps with revenue, but surprisingly, Duolingo's net income has marched higher as well. It truly demonstrates that Duolingo's AI efforts are cost-efficient, which makes the growth sustainable.
For instance, Duolingo delivered 24% year-over-year net income growth in Q1. Revenue was up by 27%, so there was a slight contraction in the net profit margin. Duolingo still walked away from the quarter with a double-digit profit margin, which has become the norm.
All of this financial growth is fueled by steady user acquisition. Duolingo's daily active users and paid subscribers were both up by 21% year over year. With 56.5 million and 12.5 million people, respectively, in those segments, Duolingo can still gain more market share. A side focus on hot, broader subjects like chess can expand Duolingo's footprint and keep users more engaged.
Intentional revenue slowdown is for long-term gains Although Duolingo's numbers were good, they were a downgrade from what investors have come to expect. Last year, Duolingo was exceeding 40% year-over-year revenue growth. A drop to 27% would explain the decline if Duolingo traded at over $400 per share then. However, Duolingo released Q1 results in early May, when almost all of the damage was already done.
Duolingo is aiming to become a company that will be around for 100 years and change how the world learns everything. This long-term vision comes with a medium-term goal of reaching 100 million daily active users in 2028.
The company could make more revenue by pushing its subscriptions or establishing a hard paywall, but Duolingo said its scale wouldn't be possible with a paywall model. Getting to 100 million daily active users with a freemium model will give Duolingo more options and financial growth in the future when it maximizes its average revenue per user.
In the meantime, Duolingo continues to improve its subscriptions so more people feel inclined to become paying customers. The company cited its subscription-only Video Call feature, which has more than doubled the average number of words spoken per user who takes advantage of it.
Duolingo anticipates 17.1% year-over-year revenue growth in Q2 and 16.1% in full-year 2026. The guidance figures imply deceleration and aren't glamorous for a growth stock, but Duolingo's correction is long overdue. Its efforts to attract 100 million daily active users in 2028 should pay off tremendously and give the company more opportunities to reignite revenue growth when the time calls for it.
Edwards Lifesciences na konferenci New York Valves 2026 představila nová data podporující její vedení v oblasti strukturální kardiologie. Studie PROGRESS, PARTNER 3, EARLY TAVR i registry PASCAL a SAPIEN M3 posilují důkazy pro platformu SAPIEN.
NEW YORK--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's leadership in advancing high-quality scientific evidence and innovating for patients. These new data – spanning aortic, mitral and tricuspid therapies – provide further understanding of the complexity of structural heart disease and the need for innovative treatment options.
Ahead of the planned full clinical presentation at TCT later this year, the baseline characteristics of the PROGRESS trial presented today provide new insights into the heterogeneous nature of moderate aortic stenosis (AS) patients. Research has shown that approximately half of moderate AS patients present with at least one at-risk feature, which includes symptoms, progressive cardiac damage, declining health and elevated risk of hospitalization. The PROGRESS trial is designed to evaluate whether patients with moderate AS and at least one risk factor may benefit from transcatheter aortic valve replacement (TAVR) earlier than current guidelines, which recommend clinical surveillance with echocardiographic follow-up every 1-2 years. Details of the PROGRESS trial design were recently published in the American Heart Journal and baseline characteristics of the PROGRESS trial are listed below:
More than 95% were symptomatic More than 70% had 2 or more at-risk features More than 90% had a normal left ventricular function Mean age was 78 ± 6 years Mean KCCQ score was 64 ± 24 Broad surgical risk distribution (46% low risk) Additional late-breaking clinical science presentations strengthen the evidence base for the SAPIEN 3 platform, including seven-year benchmark durability data from the PARTNER 3 trial, simultaneously published in JAMA Cardiology. Also presented were new findings from the EARLY TAVR trial, reinforcing the shift toward proactive disease management and providing continued long-term reassurance for physicians and patients. These data on Edwards’ SAPIEN platform underscore the benchmark valve performance and differentiated long-term durability of the therapy.
“Edwards remains focused on addressing the significant unmet needs of the many structural heart patients who remain untreated today,” said Bernard Zovighian, Edwards’ CEO. “Our expanding evidence base reflects Edwards’ clear and sustained commitment to advancing care through partnership with the physician community. From building a deeper understanding of the moderate AS population and advancing evidence about asymptomatic patients to demonstrating distinguished SAPIEN platform durability and strategies for lifetime disease management, we are strengthening confidence in long-term outcomes and increasing access for patients worldwide.”
Also at the meeting, new data highlighted clinical trial and real-world outcomes across Edwards’ mitral and tricuspid portfolio. Data from more than 4,500 patients treated with the PASCAL system in the STS/ACC Transcatheter Valve Therapy Registry helps highlight the sustained safety and effectiveness of the technology for patients with mitral regurgitation (MR). One-year data from the ENCIRCLE trial Mitral Annular Calcification (MAC) Registry support the safety, effectiveness and quality of life improvements with SAPIEN M3, the first and only transcatheter transseptal mitral valve replacement system, in patients with symptomatic valve dysfunction associated with MAC who are deemed unsuitable for surgery or TEER therapy by a heart team.
Zovighian added, “Together, our differentiated technology and world-class evidence reflect Edwards’ leadership in elevating the standard of care for structural heart patients and improving outcomes across the care continuum.”
About Edwards Lifesciences
Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements made by Mr. Zovighian and statements regarding the benchmark performance and differentiated long-term durability of Edwards’ SAPIEN platform, elevating the standard of care, our leadership in advancing our growing body of high-quality scientific and clinical evidence, long-term reassurance for physicians and patients, our commitment to advance care through partnerships with the physician community, strengthen confidence in long-term outcomes and expanding access for patients, innovating for patients with structural heart disease, the safety and effectiveness and quality of life improvements of our products, and improving outcomes across the care continuum, and other statements that are not historical facts. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission. These filings, along with important safety information about our products, may be found at Edwards.com.
Edwards, Edwards Lifesciences, the stylized E logo, EARLY TAVR, ENCIRCLE, PARTNER, PARTNER 3, PASCAL, PROGRESS, SAPIEN, SAPIEN 3 and SAPIEN M3 are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.
Intuitive Machines rozšiřuje byznys prostřednictvím akvizic v oblasti navigace, výroby kosmických lodí a komunikací. Nejnověji plánuje koupit Goonhilly Earth Station a její dceřinou společnost COMSAT a přidat 44 antén i významnou deep-space komunikační infrastrukturu ve Spojeném království a USA.
Key Takeaways Intuitive Machines expanded through acquisitions in navigation, spacecraft manufacturing, and communications.LUNR agreed to acquire Goonhilly Earth Station, adding 44 antennas and deep-space communications assets.LUNR shares rose 7.5% in three months and trade at a forward P/S premium to the industry. Intuitive Machines, Inc. (LUNR - Free Report) has long been associated with lunar landers and NASA's Commercial Lunar Payload Services program. However, recent acquisitions suggest management is pursuing a much broader vision.
The acquisition strategy began to accelerate in 2025 when the company acquired KinetX Aerospace, a leader in deep-space navigation and flight dynamics services. It added expertise in spacecraft navigation, mission design, and constellation management. KinetX has supported numerous NASA planetary missions, giving LUNR valuable technical capabilities that complement its lunar operations.
LUNR’s most transformative transaction came in November 2025 when it announced the acquisition of Lanteris Space Systems, formerly Maxar Space Systems, from Advent International. The deal was valued at $800 million, and was closed in January 2026. The business brings decades of spacecraft manufacturing experience and serves national security, civil, and commercial customers.
Lanteris provides proven capabilities in satellite manufacturing, missile-warning systems, secure communications, Earth observation, and space-domain awareness missions. These capabilities position Intuitive Machines to compete for larger defense and civil-space programs while expanding its presence in rapidly growing national security markets.
Management continued its acquisition-driven expansion in May 2026 by announcing plans to acquire Goonhilly Earth Station and its COMSAT subsidiary. The acquisition is expected to add 44 antennas and substantial deep-space communications infrastructure across the United Kingdom and the United States.
Through targeted acquisitions, the company is building capabilities across navigation, manufacturing, communications, and operations. If management successfully integrates these assets, acquisitions could become one of the company's most important drivers of long-term growth.
Space Companies Using Acquisitions to Expand GrowthSeveral space companies have pursued similar acquisition-driven strategies to broaden capabilities and accelerate expansion:
Rocket Lab Corporation (RKLB - Free Report) has acquired businesses across spacecraft components, solar power systems, software, and satellite technologies, helping transform the company from a launch provider into a diversified space systems company.
Redwire Corporation (RDW - Free Report) has completed numerous acquisitions spanning in-space manufacturing, digital engineering, mission systems, and spacecraft technologies, creating a broad portfolio serving commercial and government customers.
LUNR Stock’s Earnings EstimatesThe Zacks Consensus Estimate for 2026 earnings per share implies a decrease of 2.38% year over year.
Image Source: Zacks Investment Research
LUNR Stock Trades at a PremiumIn terms of valuation, LUNR’s forward 12-month price-to-sales (P/S) is 4.09X, a premium to the industry’s average of 2.59X.
Image Source: Zacks Investment Research
LUNR Stock’s Price PerformanceIn the past three months, the company’s shares have risen 7.5% compared with the industry’s 1.2% growth.
Alto Ingredients se v 1. čtvrtletí 2026 vrátila k ziskovosti a upravený EBITDA vzrostl na 4,7 milionu USD. Firma čeká zhruba 15 milionů USD ročních čistých výnosů z daňových kreditů 45Z.
Key Takeaways Alto Ingredients returned to profitability in Q1 2026 as adjusted EBITDA improved to $4.7 million.Alto Ingredients expects about $15 million in annual net proceeds from qualifying 45Z production volumes.Green Plains produced 174 million gallons of ethanol in Q1 2026 while operating at 97% of capacity. Alto Ingredients, Inc. (ALTO - Free Report) and Green Plains Inc. (GPRE - Free Report) are two prominent players in the U.S. biofuels industry, with business models centered on producing ethanol and other value-added agricultural products. While Alto Ingredients has increasingly diversified into specialty alcohols and essential ingredients for industrial and consumer applications, Green Plains has focused on transforming itself into a higher-margin producer of sustainable ingredients, renewable corn oil and low-carbon products.
The comparison between ALTO and GPRE is especially relevant as investors reassess the outlook for ethanol producers amid volatile corn prices, evolving renewable fuel policies and growing demand for low-carbon energy solutions. Both companies are navigating the same macroeconomic and regulatory environment but pursuing different strategic paths, making them an intriguing pair for evaluating growth potential, profitability and long-term positioning in the energy transition.
Let's discuss in detail.
The Case for Alto Ingredients StockAlto Ingredients operates as a diversified producer of renewable fuels, specialty alcohols and essential ingredients, supplying customers across health, beauty, food, beverage, industrial and agricultural markets. The company's diversified portfolio and focus on higher-value products are contributing to a meaningful improvement in operating performance. In the first quarter of 2026, Alto Ingredients returned to profitability with earnings of 5 cents per share, against a loss of 16 cents a year earlier, while adjusted EBITDA improved to $4.7 million from negative $4.4 million, reflecting the benefits of its strategic realignment, stronger export demand and improved crush margins.
Another major catalyst has been stronger industry fundamentals and a more favorable product mix. Robust export demand, higher export premiums relative to domestic renewable fuel sales and improving corn oil prices supported margins. The company's crush margins increased to 17 cents per gallon from just 2 cents a year ago, while essential ingredients returns improved to 53.4% from 48.2%. Management also remains optimistic about demand growth from export markets and year-round E15 adoption.
Operational improvements and expansion projects are further supporting the company’s long-term outlook. Alto Ingredients is investing in projects to improve reliability, increase utilization and expand capacity. A debottlenecking project at the Pekin dry mill is expected to raise annual production capacity by about 5 million gallons, while additional CO2 infrastructure investments are expected to enhance operational flexibility and support higher-value opportunities. The company is also evaluating carbon capture and sequestration initiatives that could provide additional earnings opportunities over time.
Alto Ingredients is benefiting from growing opportunities tied to Section 45Z tax credits and improving financial flexibility. The company recognized $3.9 million in tax-credit earnings in the first quarter and expects roughly $15 million in annual net proceeds from qualifying production volumes. Positive operating cash flow, lower debt and more than $94 million in borrowing capacity have further strengthened the company's balance sheet and financial flexibility.
The Case for Green Plains StockGreen Plains has established itself as a prominent player in the U.S. biofuels industry, operating a network of eight ethanol plants and maintaining a significant presence in domestic biofuel production. The company produced 174 million gallons of ethanol in the first quarter of 2026 while operating at 97% of capacity, underscoring the scale, utilization rates and efficiency of its production platform.
The business has evolved beyond conventional ethanol manufacturing into a diversified portfolio of value-added products and services. Alongside ethanol, Green Plains generates revenues from renewable corn oil, ultra-high protein ingredients, grain handling, commodity marketing and carbon-related activities. This broader product mix expands the company's exposure across agricultural, feed, energy and low-carbon markets.
Green Plains continues to focus on improving plant reliability, increasing processing yields and lowering carbon intensity across its facilities. The company is directing capital toward grain storage expansion, low-energy distillation upgrades and yield-enhancement technologies designed to improve efficiency and strengthen operating performance. Benchmarking initiatives and data-driven analytics are also helping identify productivity gains across the production network.
Green Plains is also benefiting from the growing contribution of its carbon platform and Section 45Z production tax credits. Net production tax credits contributed $55.2 million to adjusted EBITDA in the first quarter, supported by the first full quarter of carbon sequestration operations at its three Nebraska facilities. The company expects its carbon strategy to contribute between $200 million and $225 million of EBITDA in 2026, while strong liquidity provides additional financial flexibility.
Valuation & Price Performance of ALTO & GPREAlto Ingredients currently trades at a forward price-to-sales ratio of 0.38, representing a modest discount to Green Plains, which trades at 0.52.
P/S Ratio (Forward 12 Months)
Image Source: Zacks Investment Research
Over the last three months, Alto Ingredients has emerged as the stronger performer, rising 10.4% while Green Plains lost 11.8%.
Three Months Price Performance
Image Source: Zacks Investment Research
Bottom Line: ALTO Appears Better Positioned for GrowthBoth Alto Ingredients and Green Plains are evolving beyond traditional ethanol production, but the former currently offers a more compelling turnaround and valuation story. Its improving profitability, stronger crush margins, growing specialty alcohol and ingredients business, and exposure to Section 45Z incentives provide multiple avenues for earnings growth. While Green Plains continues to advance its low-carbon and carbon capture initiatives and benefits from greater scale, ALTO's improving operational execution, strengthening balance sheet and leverage to improve industry fundamentals could position the stock to deliver stronger upside potential over the near to medium term.
Both ALTO and GPRE sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
CoreWeave čelí rostoucím nákladům na datová centra, které mohou zkomplikovat plán zvýšit kapacitu zhruba z 1 GW na 8 GW do roku 2030. Její backlog meziročně vzrostl téměř o 300 % na 99,4 miliardy USD.
Cloud-computing specialist CoreWeave (CRWV 4.13%) has seen its order book grow nearly 300% year over year to a staggering $99.4 billion. At the same time, the capital required to build an artificial intelligence (AI) data center is rising, with costs estimated at $15 to $25 million per megawatt to build AI-ready facilities.
On a recent episode of the All-In Podcast, venture capitalist Chamath Palihapitiya remarked that building a modern 1-gigawatt (GW) AI data center now runs closer to $100 billion fully loaded.
As land fees rise and the scarcity of electrical engineers and components intensifies, specialized AI cloud providers like CoreWeave find themselves in a hyperinflationary infrastructure race to build scale.
Image source: Getty Images.
A purpose-built platform for AI CoreWeave operates a vertically integrated platform designed for the performance demands of AI workloads. The company buys the latest graphics processing units (GPUs) from its partner Nvidia and combines them with other computing hardware and its own software to deliver performance that general-purpose clouds often struggle to match.
CoreWeave acts as a middleman, renting the compute capacity to AI model companies and hyperscalers. This type of operation keeps capital costs down by leasing the physical data center facilities from third-party developers rather than owning them.
The specialization has made it a key partner to major AI labs, securing multi-year, take-or-pay contracts with clients such as Meta Platforms and OpenAI. CoreWeave's customer concentration is improving, with 10 customers committed to spending at least $1 billion each, and non-investment-grade AI labs now represent less than 30% of its backlog.
The cost of rapid expansion To fund its expansion, CoreWeave has taken on $25 billion in debt in the form of delayed-draw term loans (DDTLs). It signs a customer contract, uses it as collateral to borrow against future cash flows, and draws money only as capacity is deployed.
Lenders consider the credit-worthiness of the end customer, such as Meta, resulting in better terms. This structure has helped reduce its average borrowing rate from the mid-teens to just below 10% by the end of 2025.
Today's Change
(
-4.13
%) $
-4.08
Current Price
$
94.68
Capital expenditures are expected to exceed $30 billion this year, up from $15 billion last year. The company is on a capital-intensive campaign that is sustainable only as long as it can keep signing new deals and tapping capital markets.
The rising cost of data center construction could weigh on its ability to scale economically as it attempts to grow from around one gigawatt today to 8 GW of capacity by 2030. One factor that helps balance the risk of owning depreciating hardware is the rising demand for inference, which keeps older, less powerful GPUs more valuable for longer than usual.
If AI inference remains highly profitable for providers over the next three to five years, pricing for compute capacity should hold up well. If demand underwhelms or the world moves toward low-cost open-source models, it could put pressure on compute rates for future contracts.
While CoreWeave offers a unique and compelling way for investors to play the AI infrastructure build-out, there's still plenty of uncertainty around who the winners and losers will be over the long run. As the cost of memory chips and other inputs rises, the capital burden on neoclouds and its partners gets heavier. Given the wide range of potential outcomes, investors interested in this stock should keep in mind that taking a reasonable approach to position sizing can help reduce the risk involved with any single stock in a rapidly evolving industry.
Figma po IPO prudce klesla na 16 USD, zatímco tržby v 1. čtvrtletí vzrostly o 46 % na 334 milionů USD. Firma zároveň zvýšila výhled díky poptávce a růstu počtu uživatelů.
Figma's stock price has imploded since its initial public offering (IPO) last year as the exuberance that fueled its private-market valuation collided with the realities of life as a publicly traded company. FIG dropped to $16 on Thursday, down sharply from the all-time high of $142.
Figma is one of the best-known software companies in the corporate world. Over the years it has become a beloved name among designers because of the collaborative aspect.
This popularity surged before it became a publicly traded company. At its peak, it reached a $20 billion valuation when Adobe placed a bid. Adobe terminated the agreement after it faced opposition in the UK and the EU, forcing it to pay a $1 billion breakup fee.
Figma’s popularity helped its valuation to surge to over $60 billion following its IPO. Today, the figure has tumbled to $8.9 billion, and the situation is getting worse by the day.
The rise and fall of Figma is emblematic of what has been going on in the market today. It is common for highly valued companies to suffer a rude awakening when they go public. A good example of this is Klarna, whose valuation peaked at $17 billion following its IPO. Today, the company is valued at $7.2 billion.
Another example of this phenomenon is Circle Internet Group whose valuation peaked at $60 billion before plummeting to $17 billion today.
The main reason why the Figma stock price is imploding is known as SaaSpocalypse, a situation where investors are dumping software stocks in fear that their businesses will be disrupted by AI tools.
These fears explain why other companies in the software industry like Salesforce, Adobe, Intuit, and ServiceNow are in a freefall this year.
However, in reality, some popular individuals, including Jensen Huang, argues that the fear that AI will disrupt software companies is not backed by reality.
Instead, AI will improve these companies by helping them reduce their operational costs and improve their service offerings.
Indeed, the most recent results showed that Figma’s business is still firing on all cylinders this year. Its revenue surged by 46% in the first quarter to $334 million, with the management boosting its forward guidance citing demand and seat expansion.
The management now expects that its second-quarter revenue will jump by 40% to between $348 million and $350 million. For the year, the company is expected to make between $1.42 billion and $1.428 billion.
Therefore, there are signs that Figma is being punished unfairly, as the management is also predicting that profitability will happen soon. It is also showing that more companies are subscribing to its services.
FIG stock price chart | Source: TradingView
The daily chart shows that the FIG stock price has imploded and is now sitting at a crucial support level of $16.85. A closer look shows that this price coincides with the lowest swing in April this year. That is a sign that it has formed a double-bottom pattern whose neckline is at $27.80.
The double-bottom pattern suggests that a rebound is possible. However, the most likely scenario is where the stock continues falling for a while before bouncing back eventually. This view will be confirmed if it drops below the double-bottom level of $16.85.
Ondas přes Sentrycs navázala spolupráci s Lockheed Martin na integraci technologie Cyber-over-RF do protidronového systému Sanctum. Cílem je posílit detekci, sledování a neutralizaci bezpilotních hrozeb.
Ondas Inc. (ONDS - Free Report) recently announced that its subsidiary, Sentrycs, has collaborated with Lockheed Martin to integrate Sentrycs' Cyber-over-RF technology into Sanctum, Lockheed Martin's next-generation Counter-Unmanned Aerial Systems (C-UAS) solution. The deal is aimed at strengthening protection for military forces, homeland security and critical assets against evolving unmanned aerial threats.
Sanctum is designed to address complex drone threats, including coordinated swarms and rapidly evolving unmanned aerial system (UAS) tactics, by combining artificial intelligence, cloud-enabled data fusion and a modular defense architecture. The platform is built to detect, track, analyze and neutralize aerial threats in real time while integrating multiple sensors, effectors and command-and-control systems into a unified framework that supports interoperability, mission flexibility and scalable protection across a broad range of defense environments.
As part of the collaboration, Sentrycs' Cyber-over-RF technology will add a cyber-based detection and mitigation layer to Sanctum's multi-domain architecture. Operating directly at the communication protocol layer, the technology enables operators to detect, identify, track and take control of unauthorized drones without relying on jamming, spoofing or kinetic engagement, while avoiding collateral interference with surrounding communications and infrastructure. The capability also allows operators to safely guide unauthorized drones to a controlled landing, providing a targeted and non-disruptive mitigation option that enhances layered response capabilities and supports mission-adaptable counter-drone operations.
Management stated that modern defense against unmanned aerial threats requires integrated, layered solutions that combine advanced detection, rapid decision-making and precise mitigation capabilities. Management also stated that integrating Sentrycs' technology into Lockheed Martin's modular defense architecture creates a stronger and more comprehensive operational capability for countering evolving aerial threats. The collaboration represents another step toward more integrated and interoperable Counter-UAS architectures as defense organizations increasingly prioritize flexible, layered solutions to address rapidly evolving unmanned aerial threats.
Ondas is benefiting from robust demand for its ISR and counter-UAS solutions, supported by higher defense spending, growing investor interest and expanding market opportunities. Demand for its proven ISR platforms remains strong, while acquisitions have broadened its ISR capabilities, expanded its customer base and strengthened its multi-domain surveillance and reconnaissance portfolio. Its partnership with Palantir is further advancing layered ISR capabilities and expanding ISR-as-a-service opportunities.
Taking a Look at ONDS Competitors’Draganfly (DPRO - Free Report) is gaining from strong demand for its drone solutions, particularly in the military sector, supported by growing defense spending and expanding opportunities across domestic and international markets. The company is strengthening its position through strategic collaborations with partners such as Palladyne AI on swarming technologies, Global Ordnance and Babcock to expand its defense reach and multi-platform capabilities. Its interoperable, modular drone platform and partner-centric approach enable customers to integrate multiple payloads and mission requirements, while increasing adoption among military and public safety users. The company also continues to build relationships with key defense customers and strategic partners to support long-term growth.
Red Cat Holdings, Inc. (RCAT - Free Report) is benefiting from rising defense spending on drones, expanding demand for autonomous systems and a growing opportunity pipeline across military customers. The company expects annual revenues of $150-$180 million in the near to medium term, supported by strong demand for its Black Widow, Blue Ops and FlightWave platforms. It is also expanding its capabilities through the acquisition of Quaze Technologies, adding wireless power transfer technology for unmanned and autonomous systems. Management highlighted a nearly $700 million opportunity pipeline for Black Widow and expects its expansion into unmanned surface vessels through Blue Ops to create an additional revenue opportunity in 2026.
ONDS’ Price Performance, Valuation and EstimatesShares of ONDS have gained a whopping 338.6% in the past year against the Zacks Wireless-National industry’s decline of 11.8%.
Image Source: Zacks Investment Research
ONDS seems overvalued, as suggested by the Value Score of F. In terms of the forward 12-month Price/Sales ratio, ONDS is trading at 7.2, considerably higher than the industry’s multiple of 1.62.
Image Source: Zacks Investment Research
For ONDS, earnings estimates for the current year have been revised upwards in the past 60 days.
Image Source: Zacks Investment Research
ONDS currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
SpaceX Corp (NASDAQ:SPCX) is considering launching a Starlink-branded mobile phone service in the United States, according to a Financial Times report published on Friday, potentially expanding the company's role in the telecommunications market.
The report cited comments from SpaceX President Gwynne Shotwell during a recent investor roadshow, where she reportedly discussed plans for a direct-to-consumer wireless offering and the possibility of building a terrestrial mobile network in the US.
SpaceX currently works with T-Mobile to provide direct-to-cell satellite connectivity aimed at extending coverage to remote areas. A standalone mobile service would place the Elon Musk-led company in more direct competition with established wireless carriers including Verizon, AT&T and T-Mobile.
According to the Financial Times, SpaceX has told investors that a retail Starlink mobile product could allow the company to capture a larger share of customer revenue by combining satellite capabilities with terrestrial wireless infrastructure.
The company strengthened its wireless spectrum holdings through acquisitions of EchoStar licenses totaling about $19.6 billion, including a roughly $17 billion purchase in September 2025 and an additional $2.6 billion transaction in November.
Starlink has more than 10 million subscribers worldwide and has become a key contributor to SpaceX's record valuation.
Shares of SpaceX traded hands at $153 on Friday, after debuting at $135 per share on June 12.
Tesla (NASDAQ: TSLA | TSLA Price Prediction) and Google (NASDAQ: GOOGL) both reported Q1 FY2026 earnings that sharpened the autonomy debate in opposite directions. Tesla leaned on a global fleet streaming video into its training clusters. Alphabet leaned on Waymo collecting paid driverless miles across real city streets. Both want the robotaxi crown. Only one is already cashing fares.
Camera Fleet Funds Tesla. Cloud Demand Funds Alphabet. Tesla posted $22.39 billion in revenue, up 15.78% year over year, and EPS of $0.41, beating consensus by 14.14%. Automotive gross margin expanded to 21.1% from 16.2%, and active FSD subscriptions hit 1.28 million, up 51%. R&D climbed to $1.95 billion, much of it pointed at AI5 silicon and the unsupervised Robotaxi rides launched in Dallas and Houston.
Alphabet’s quarter was a different magnitude. Revenue reached $109.90 billion, EPS landed at $5.11 versus a $2.63 consensus, and Google Cloud jumped 63% to $20.03 billion with backlog nearly doubling to over $460 billion. CEO Sundar Pichai noted, “I’m pleased to see Waymo surpass 500,000 fully autonomous rides a week.” That is paid, unmonitored throughput.
Mass Market Fleet vs. Metro by Metro Rollout The strategic split is visible in how each company spends. Tesla pushed millions of customer-owned vehicles streaming real-world video directly into its Cortex training clusters, financed by its own auto margins and a $44.74 billion cash pile. Alphabet, meanwhile, guided 2026 capex to $175 to $185 billion, funded by Search and YouTube ads that still grew 19% and 11% respectively.
Lens Tesla Alphabet Autonomy data source Supervised consumer fleet 10 metro regions of Level 4 driverless Operating margin 4.6% 36.1% Free cash flow (Q1) $1.44B $10.12B Key vulnerability Robotaxi regulatory approval Capex compressing FCF Tesla’s vision-only approach scales cheaply per car. Waymo’s stack is expensive per car, but it is already booking fare revenue while Tesla’s Cybercab is still in pilot production at Gigafactory Texas.
The Next Test Is Commercial Driverless Miles Polymarket traders price a Tesla robotaxi launch in California by June 30 at just 2.3%, and assign a 46.9% probability to Q2 deliveries clearing 475,000 units. I will be watching whether Dallas and Houston unsupervised rides scale into recurring revenue, and whether Waymo’s 500,000 weekly rides keep doubling without safety setbacks.
Alphabet’s Commercial Lead in Context Alphabet currently presents the more commercially proven autonomy exposure. You get a Search and Cloud engine that already funds Waymo, a P/E around 15, and a Cloud backlog that signals demand visibility years out. TSLA is down 16.59% year to date while GOOGL is up 9.95%, a meaningful divergence in year-to-date performance. Tesla still suits investors betting on FSD v14, Optimus, and Cybercab economics arriving on schedule. The view would shift once Tesla demonstrates recurring, unsupervised fare revenue at Waymo’s scale.
Amazon tvrdí, že jeho vlastní čipy pro datová centra jsou jedním z největších byznysů v oboru a mají roční tempo tržeb 50 miliard USD. Trainium2 je už téměř vyprodaný a Trainium3 je téměř plně rezervovaný.
CANADA - 2026/06/19: In this photo illustration, the AWS (Amazon Web Services) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)
SOPA Images/LightRocket via Getty Images
This article was written by Doug Nathman, with research by his team at Trefis.
Worries in the market regarding Amazon's significant investment in AI might underestimate the impressive proprietary technology being developed to support it.
Despite a history of fast surges, Amazon has felt rather constrained as of late, trading sideways for nearly six months. A key question among investors is: will the company’s significant investment in artificial intelligence yield a substantial return, or will this expenditure not produce adequate returns?
However, concentrating on the spending overlooks the more critical narrative. Amazon’s approach in the fiercely competitive AI arena encompasses more than just simple purchases; the firm is constructing the vital infrastructure. In doing so, it is stealthily establishing itself as one of the most significant semiconductor manufacturers globally.
Is Amazon Among The Top Three Global Chip Firms?Buried within the most recent earnings call was a striking claim from management: if its custom silicon division operated independently, its yearly revenue run rate would be $50 billion. To provide context, the company asserts its “custom silicon segment is now one of the top three data center chip enterprises worldwide.” This isn’t merely a secondary endeavor. This is a strategic cornerstone slowly materializing in plain view, centered on two primary products: Graviton for general computing and Trainium for AI applications.
While the public perceives AWS primarily as a cloud service provider, it is swiftly transforming into a vertically integrated powerhouse. It has progressed from simply leasing server space to designing and implementing its own high-performance, cost-effective silicon to operate that space. And customers are eagerly awaiting their turn.
MORE FOR YOU
Demand Has Already Surpassed SupplyThis isn’t a theoretical edge; the demand is tangible and urgent. The company’s Trainium2 AI chip is already “primarily sold out.” Its successor, Trainium3, which has just commenced shipping, is “almost fully subscribed.” Most notably, Amazon reports that “a large portion of Trainium4, which is still approximately 18 months from widespread availability, has already been booked.”
When clients are reserving hardware that is set to be available in a year and a half, it indicates a strong demand for the unique price-performance ratio that Amazon is presenting. The customer base extends far beyond AI startups. Tech titan Meta recently “committed to utilizing tens of millions of Graviton cores” to advance its own AI initiatives, opting for Amazon’s custom CPU that delivers up to “40% superior price performance” compared to alternatives.
How Is This Addressing The Spending Concern?This is the vital connection. The bearish argument against Amazon is predicated on the massive cost of its AI expansion. However, creating its own chips fundamentally alters the cost dynamics of that investment. Management has been clear about the benefits, indicating that at scale, it anticipates Trainium will “save us tens of billions of dollars in capital expenditures every year.”
In addition to the cost savings, it establishes a robust competitive advantage. The company forecasts that its in-house silicon will “yield several hundred basis points of operating margin advantage compared to relying on external chips.” In a business as substantial as AWS, which currently operates at a $150 billion annualized revenue run rate, such margin enhancement is a powerful catalyst for profit.
While investors have been closely examining every dollar of capital spending, Amazon has been developing the very technology that could significantly enhance that capital's efficiency. It answers the market's most pressing question, suggesting that the company is evolving beyond mere participation in the AI revolution to construct a foundational, high-margin engine to sustain it for years ahead.
Where Will An Opportunity Like This First Manifest?An opportunity of this nature only counts once it begins to reflect in the financial figures, and the first concrete indication is in management’s outlook. The instant a company can actually anticipate new revenue, it adjusts its forecast, and an upward adjustment that the market is already rewarding serves as some of the clearest evidence that a narrative like this is becoming a reality.
A growth narrative this credible warrants action, but investing through a single stock means accepting all the fluctuations that one company experiences. A more intelligent strategy is to maintain a collection of stocks where the long-term perspective is equally robust, ensuring that the sustainable upside remains intact and no unexpected event can compromise it. This is how patient capital flourishes.
Differentiating the genuinely sustainable narratives from the merely appealing ones is the foundation of the Trefis methodology. The Trefis High Quality (HQ) Portfolio assesses the complete picture of quality across thousands of stocks, not just a single factor, retains the 30 strongest selections, and re-balances them with careful discipline. It possesses a track record of outperforming a benchmark that merges the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.
Nokia rozšiřuje spolupráci s AWS na autonomních sítích pro éru AI, s dostupností produktu později v letošním roce. Akcie v premarketu klesly o 3,79 % na 13,45 USD.
Nokia stock is among today’s weakest performers. Why is NOK stock falling? What Is Driving Nokia’s AWS Collaboration?Nokia’s latest catalyst is the expanded AWS collaboration aimed at "autonomous networks built for the AI era," with its Autonomous Networks Fabric set to run on AWS so telecom operators can move more of their operational stack into the cloud. The companies are positioning the integration around Level 4 autonomy using AI and cloud services, with product availability expected later this year.
Nokia’s pitch leans on unifying data management, agentic AI, digital twin simulations, and intent-based networking to drive "step-change efficiency," with the company’s CTO for AI and Autonomous Networks saying, "This is how telcos will compete in the AI era."
Nokia also has a separate AI-automation thread running through its Google Cloud partnership, where it’s building six specialized Gemini-powered agents for telecom workflows like event triage, anomaly detection, KPI analysis, and remediation recommendations. The companies said the system can cut troubleshooting times 50% to 80%, a concrete efficiency claim that can influence how investors model software-led margin upside.
Nokia Stock: Key Technical Levels To WatchEven with the premarket dip, the longer-term trend still leans bullish: the stock is up 170.93% over the past 12 months and remains well above its 100-day SMA ($10.75) and 200-day SMA ($8.39). The golden cross that formed in October 2025 (50-day SMA above the 200-day SMA) is still intact, which often keeps dip-buyers engaged as long as price holds near those longer averages.
Near-term, the chart looks more like a digestion phase than a breakdown, with price at $13.45 sitting just under the 50-day SMA ($13.49) and below the 20-day SMA ($14.69). That matters because the 20-day SMA is still above the 50-day SMA (a bullish alignment), but the stock needs to reclaim the short-term average to signal that buyers are taking control again.
RSI is the cleaner momentum read right now: at 48.90, it’s neutral and suggests the prior upside momentum has cooled rather than flipped into an oversold washout. In plain terms, RSI helps gauge whether a move is getting stretched, and this reading points to balance—neither panic selling nor overheated buying.
Key Resistance: $15.00 — a round-number ceiling that lines up with a nearby rebound-stall zone if the stock tries to bounce back above its short-term averages – Key Support: $13.00 — a nearby floor that sits close to the 50-day moving-average area where trend buyers often defend pullbacks
What Does Nokia Corporation Do?Nokia is a networking equipment vendor focused primarily on supporting wireless networks and, to a growing extent, Internet Protocol and optical systems. The firm operates three segments spanning mobile infrastructure (wireless core and related software), network infrastructure (IP routing/switching, optical, and fixed-network gear), and a portfolio bucket of businesses it views as less central longer term.
That mix is why the AWS tie-up matters to the stock narrative: it’s aimed at pushing more telecom operations into the cloud while layering in AI-driven automation (including agentic AI, digital twin simulations, and intent-based networking). If operators adopt that approach, it can support a more software- and services-oriented angle alongside the company’s traditional hardware footprint.
Nokia Earnings Preview: July 2026 EstimatesLooking further out, the next major catalyst for the stock arrives with the July 23, 2026 (confirmed) earnings report.
EPS Estimate: 7 cents (Up from 4 cents YoY) Revenue Estimate: $5.59 Billion (Up from $5.15 Billion YoY) Valuation: P/E of 87.8x (Indicates premium valuation relative to peers) Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price target of $14.67. Recent analyst moves include:
JP Morgan: Overweight (Raises Target to $21.00) (June 12) Argus Research: Upgraded to Buy (Target $15.00) (April 27) Morgan Stanley: Initiated with Overweight (Target $8.00) (Feb. 9) Nokia Benzinga Edge Rankings OverviewBelow is the Benzinga Edge scorecard for Nokia, highlighting its strengths and weaknesses compared to the broader market:
The Verdict: Nokia’s Benzinga Edge signal reveals a momentum-led setup with supportive quality, but a less forgiving valuation backdrop. For longer-term bulls, the key is whether the stock can hold the $13.00 area and rebuild strength back toward $15.00 without losing the 50-day trend zone.
Nokia Stock Price Action in Premarket TradingNOK Stock Price Activity: Nokia shares were down 3.79% at $13.45 during premarket trading on Friday, according to Benzinga Pro data.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
Citigroup prošla stresovým testem Fedu a plánuje zvýšit kvartální dividendu o 12 % na 67 centů na akcii. Spustila také víceleté zpětné odkupy akcií za 30 miliard USD.
Key Takeaways Citigroup cleared the Fed's 2026 stress test, reinforcing capital strength and shareholder return plans.C plans a 12% dividend increase to 67 cents and launched a $30B multi-year buyback program.C expects higher repurchases in 2026 than in 2025, backed by strong capital and liquidity positions. Citigroup Inc.'s (C - Free Report) successful completion of the Federal Reserve's 2026 stress test underscores the bank's financial resilience and strengthens its ability to reward shareholders. While passing the annual stress test is a regulatory milestone, the bigger takeaway for investors is the capital flexibility it creates. A strong capital position allows banks to return more cash through dividend payments and share repurchases while continuing to invest in growth initiatives.
Along with Citigroup, 31 banks like Wells Fargo (WFC - Free Report) and JPMorgan (JPM - Free Report) also cleared the Fed’s 2026 stress test.
C's Lower Capital Requirement Creates More Financial FlexibilityCitigroup’s Stress Capital Buffer remains unchanged at 3.6% after the Federal Reserve’s 2026 supervisory stress test. However, C stated that its latest stress-test results would have supported a lower SCB of 3.3% had the Fed not extended the existing requirements through Oct. 1, 2027. The Fed is maintaining current SCB levels while it finalizes updates to its stress-testing framework, enabling citigroup to continue operating under its existing capital buffer until the revised rules are implemented.
Even with the current requirement, Citigroup remains comfortably above regulatory minimums. As of March 31, 2026, its Standardized Common Equity Tier 1 capital ratio was 12.7%, 110 basis points above the required level of 11.6%. This excess capital provides a meaningful cushion against economic stress and highlights the progress the company has made in simplifying its operations, strengthening risk controls and improving earnings quality.
C’s liquidity position also remains solid. As of March 31, 2026, cash and due from banks, along with total investments, aggregated $467.8 billion, exceeding total debt, including short-term and long-term borrowings, of $379.6 billion.
This strength is translating directly into enhanced shareholder returns. Citigroup plans to raise its quarterly common stock dividend 12% to 67 cents per share from 60 cents, beginning in the third quarter of 2026, subject to board approval. The company has also initiated a $30-billion multi-year common stock repurchase program.
The broader banking sector is also moving to reward shareholders following the stress test results. JPMorgan plans to lift its quarterly dividend to $1.65 per share from $1.50 and authorized a $50-billion share repurchase program. Wells Fargo, meanwhile, plans to increase its quarterly dividend 11% to 50 cents per share, subject to board approval in July.
Coming back to Citigroup, its Investor Day financial overview reinforces this capital-return narrative. C has noted that it has returned roughly $45 billion of capital to shareholders since the beginning of 2022 and expects repurchases to be higher in 2026 than in 2025. This reflects disciplined capital deployment, improving profitability and continued progress in reshaping Citigroup into a simpler and more resilient company.
Final Words on Citigroup Capital StrengthIn conclusion, C’s stress test performance reinforces the strength of its franchise and the continued momentum in executing its transformation strategy. The results show that efforts to reshape the bank into a simpler and more resilient firm are translating into tangible progress, including stronger earnings capacity, enhanced capital resilience and a consistent reduction in its stress capital buffer.
Overall, Citigroup appears well-positioned to deliver steady long-term shareholder returns across varying economic conditions.
C’s Price Performance & Zacks RankCitigroup shares have surged 71.8% in the past year compared with the industry’s growth of 26.2%.
Image Source: Zacks Investment Research
The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
NVIDIA má objednávky na dodávky za 145 miliard USD, které mají zajistit výrobu čipů pro další čtvrtletí i rok 2027. Firma tím podporuje výhled na 1 bilion USD tržeb z Blackwell a Rubin do roku 2027.
A woman takes a picture at the NVIDIA booth during the China International Supply Chain Expo (CISCE) in Beijing on June 25, 2026. (Photo by Pedro PARDO / AFP via Getty Images)
AFP via Getty Images
This article was written by Doug Nathman, with research by his team at Trefis.
While investors concentrate on NVIDIA's staggering growth rate, an even more revealing figure resides in its supply commitments, illustrating a calculated strategy to satisfy demand that skeptics argue may not be viable.
Following a remarkable ascent, NVIDIA (NVDA) shares have cooled. The stock price has dipped below recent peaks, and discussions have transitioned from celebration to doubt. Is it possible for any corporation, even one at the forefront of the AI surge, to sustain this growth rate? While many analysts are examining the latest earnings figures or its trailing multiple, a crucial piece of information for an optimistic perspective is not found on the income statement at all.
The figure is $145 billion. This amount signifies NVIDIA’s overall supply, comprising existing inventory and, more critically, its future purchase commitments.
What Does $145 Billion In Commitments Represent?This amount signifies much more than merely a stockpile of chips stored away; it embodies a substantial, strategic commitment to future production. These pledges secure the necessary manufacturing capacity and raw materials required to create its upcoming generation of processors. Management has affirmed that this is a calculated initiative, reflecting the enhanced demand visibility we possess and a choice to secure capacity farther in advance than is normally standard. In a sector where a single shortage of components can disrupt production, NVIDIA is investing now to ensure it can manufacture the products it anticipates selling over the next several quarters, and even extending into the year 2027.
How This Assures Future RevenueThe underlying principle is straightforward: one cannot sell what cannot be produced. The primary physical limitation on NVIDIA's expansion is not demand, but rather the intricate supply chain necessary for its AI accelerators. By securing $145 billion worth of supply, the company is establishing the groundwork for its forecasts. This strategy is proactive, acting as the concrete basis for management's proclaimed confidence in achieving $1 trillion in Blackwell and Rubin revenue through 2027. That projection appears abstract until one observes the nine-figure commitments being undertaken to ensure the components needed for chip production.
MORE FOR YOU
The Resolution To The Major Concern?The foremost risk looming over the stock is its sustainability. The stock is currently facing pressure precisely because the market is questioning the duration of this level of growth. The company’s price-to-earnings multiple of 30.3, although high in relative terms, lies toward the lower end of its own 10-year spectrum of 19.6 to 143.1, indicating that investors are reluctant to factor in future growth at a rate comparable to the past. These purchase commitments represent a direct and significant response to that apprehension. A corporation that fears an approaching cyclical peak would not engage in long-term supply agreements of this magnitude. This indicates that management perceives a demand trajectory that justifies the undertaking of risk to secure capacity well in advance.
Of course, a commitment does not equate to a sale. The ultimate benchmark is converting that secured supply into revenue. However, for investors attempting to evaluate the resilience of NVIDIA’s market position, this $145 billion figure offers a concrete, forward-looking metric that the headline growth rates do not convey.
Typically, one figure does not drive a decision independently, but recognizing which number is crucial and the rationale behind it constitutes a significant portion of the challenge. Arriving at the aforementioned figure required looking beyond the surface level of fear to what was genuinely occurring beneath—an analysis that is difficult to perform once and exceedingly challenging to replicate consistently.
The Trefis High Quality (HQ) Portfolio is constructed on executing precisely that, continuously, across 30 quality enterprises, and then maintaining them with rule-based discipline so that no single entity dominates your outcome. You acquire a selection of well-researched advantages rather than a sole all-or-nothing gamble, with a proven record of surpassing a benchmark that aggregates the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. If a figure like this one merits action, that form of disciplined quality deserves serious consideration.
Nvidia vykázala tržby 81,61 miliardy USD za Q1 FY27 a těží z CUDA. Cerebras sice nabízí až 21násobně rychlejší inference, ale pro celý rok čeká provozní marže v rozmezí -28 % až -32 %.
NVIDIA (NASDAQ: NVDA | NVDA Price Prediction) and Cerebras Systems (NASDAQ: CBRS) just delivered earnings that frame the same question from opposite ends. Nvidia posted another blowout quarter built on its CUDA software stack. Cerebras, fresh off its May IPO, showed jaw-dropping inference speed yet guided full-year operating margins negative. The moat is developer gravity.
One Sells Platforms. The Other Sells Speed. Nvidia’s Q1 FY27 hit $81.61 billion in revenue, up 85.2% YoY, with Data Center alone reaching $75.25 billion on 92% growth. Networking soared 199% as InfiniBand, NVLink and Spectrum-X locked customers deeper into the stack. Jensen Huang told investors NVIDIA is “the only platform that runs in every cloud, powers every frontier and open source model, and scales everywhere AI is produced”, and the numbers back the claim.
Cerebras’ first report as a public company landed differently. Q1 GAAP revenue reached $193.4 million, up 94% YoY, with cloud services growing 178%. A multi-year, $20 billion-plus OpenAI inference deal covering 750 megawatts anchors near-term growth. Yet management guided full-year operating margins to negative 28% to negative 32%. Speed sells. Scaling it economically is harder.
Software Gravity Beats Wafer-Scale Throughput Independent benchmarks show Cerebras’ wafer-scale design delivering a 21x speed advantage over Nvidia hardware for latency-sensitive, low-batch inference. The catch is that every major LLM framework and enterprise developer stack is natively optimized for Nvidia architecture out of the box, while Cerebras requires specialized compilation and custom engineering support for anything off the well-trodden path.
Lens NVIDIA Cerebras Core Bet CUDA full-stack platform Wafer-scale inference speed Q1 Gross Margin 75.0% non-GAAP 44.6% GAAP Anchor Customers Meta, OpenAI, Anthropic, Google OpenAI, AWS, G42 Biggest Vulnerability OpenAI’s Jalapeño custom chip Negative operating margins Nvidia’s $119 billion in supply commitments and $80 billion added to its buyback authorization signal management is doubling down on the platform. Cerebras raised $5.6 billion at IPO and is funneling it into data center capacity for OpenAI’s decode workloads while AWS Trainium 3 handles prefill. That is a focused inference bet riding on one customer’s roadmap.
The Next Test Is Whether Developers Defect Two catalysts matter into the back half of 2026. For Nvidia, the OpenAI Jalapeño chip, built with Broadcom, is the most credible threat to CUDA stickiness. NVDA shares are already down 8.79% over the past month, even with the stock up 27.01% YoY. For Cerebras, the bar is executing the OpenAI ramp without further margin slippage. Q2 core gross margin guidance of 36% to 38% telegraphs how steep the infrastructure build will be.
Why The Setup Still Favors Nvidia For AI infrastructure exposure with a self-funding moat, Nvidia remains the cleaner expression of the thesis. The 75% gross margin, $48.55 billion in quarterly free cash flow, and the developer install base are tough to dislodge in a single product cycle. Cerebras has the faster chip and a marquee anchor customer. A forward P/E of 23 on NVDA already prices in some software erosion. If CUDA defections spread beyond OpenAI, my view changes.
JPMorgan Chase zvýší kvartální dividendu na 1,65 USD na akcii ve 3. čtvrtletí z 1,50 USD a spustí nový program zpětného odkupu akcií za 50 miliard USD s účinností od 1. července. Akcie se drží poblíž historického maxima.
JPMorgan Chase stock is trading near recent highs. Where is JPM stock headed? What Is JPMorgan’s New Capital-Return Plan?The board plans to raise the quarterly common dividend to $1.65 per share in the third quarter from $1.50, and it authorized a new $50 billion share repurchase program effective July 1. CEO Jamie Dimon framed the move as enabled by excess capital and liquidity, positioning the bank to keep returning cash while maintaining balance-sheet strength.
JPMorgan’s after-hours pop earlier in the week put the stock near its prior record around $338.09, reinforcing why traders are treating the payout reset as a near-term floor for sentiment. The bank also ended March 31 with $4.9 trillion in assets and $364 billion in stockholders’ equity, giving the capital-return plan more credibility than a one-off headline.
JPMorgan is also navigating tighter internal controls around AI tooling, after restricting Hong Kong staff access to Anthropic’s Claude models tied to export-control pressure on "Fable 5" and "Mythos 5." That operational friction sits in the background even as the stock pushes higher on a new $50B repurchase authorization.
JPM Stock: Critical Levels To WatchJPM is extended versus its trend gauges, trading 6.4% above the 20-day SMA ($316.41) and 9.4% above the 200-day SMA ($307.82), which keeps the longer-term uptrend intact but increases the odds of a pause or sideways digestion. The trend stack is still constructive, with the 20-day SMA above the 50-day SMA and the golden cross that formed in June (50-day SMA above the 200-day SMA) reinforcing the intermediate bullish regime after the death cross in March.
For momentum, MACD is the cleaner read here: it’s above its signal line with a positive histogram, which points to improving upside pressure versus the prior downswing. RSI previously entered overbought territory in June, so the setup can stay bullish while still being vulnerable to short, sharp pullbacks.
Key Resistance: $337.50 — a nearby pivot area just above the current price where breakouts can stall, especially with the stock pressing the top end of its 52-week range Key Support: $293.50 — a prior demand zone well below current levels that traders may treat as a larger "line in the sand" if the uptrend unwinds How JPMorgan Chase Operates GloballyJPMorgan is a leading global financial services firm with operations in 66 countries and over 318,000 employees as of year-end 2025. Under the JPMorgan brands, the bank holding company boasts a $4.9 trillion balance sheet and $2.68 trillion in deposits, as of March 2026.
JPM Earnings Preview: What Analysts ExpectLooking further out, the next major catalyst for the stock arrives with the July 14, 2026 (confirmed) earnings report.
EPS Estimate: $5.42 (Up from $4.96 YoY) Revenue Estimate: $48.61 Billion (Up from $45.68 Billion YoY) Valuation: P/E of 16.0x (Suggests fair valuation relative to peers) Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price target of $343.88. Recent analyst moves include:
Evercore ISI Group: Outperform (Raises Target to $340.00) (April 17) Jefferies: Hold (Raises Target to $320.00) (April 15) Truist Securities: Hold (Raises Target to $332.00) (April 15) JPMorgan Chase: Benzinga Edge Scorecard BreakdownBelow is the Benzinga Edge scorecard for JPMorgan Chase &, highlighting its strengths and weaknesses compared to the broader market:
The Verdict: JPMorgan Chase &’s Benzinga Edge signal reveals a growth-leaning profile with moderate momentum but a weaker quality score. For longer-term bulls, the setup works best if price can hold above the rising short-term averages while it digests gains near resistance.
JPM Stock Price ActivityJPM Stock Price Activity: JPMorgan Chase shares were down 0.80% at $332.44 at the time of publication on Friday, according to Benzinga Pro data.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
Chevron uvedl, že všichni zaměstnanci ve Venezuele jsou v pořádku a provoz po silných zemětřeseních pokračuje bez narušení. Normálně fungují i klíčové těžební projekty, rafinerie Paraguaná a exportní terminál José.
Key Takeaways Chevron confirmed employees are safe and Venezuelan operations continue without earthquake disruptions. CVX said key crude projects, refining and export facilities continue operating normally. Chevron is supporting communities while monitoring safety and recovery across Venezuela. Chevron Corporation (CVX - Free Report) has confirmed that its operations in Venezuela remain unaffected despite two powerful earthquakes that caused widespread destruction and significant loss of life, underscoring the company's commitment to employee safety, operational resilience and support for local communities during challenging times.
Employee Safety Remains the Top Priority for CVXChevron reported that all of its employees in Venezuela are safe and accounted for following the twin earthquakes, which measured 7.2 and 7.5 in magnitude. The company expressed solidarity with the Venezuelan people and reaffirmed its commitment to supporting employees, neighboring communities and maintaining safe operations.
With a long-standing presence in the country, Chevron emphasized that protecting its workforce remains its highest priority while continuing to monitor the evolving situation closely.
CVX's Operations Continue Without DisruptionDespite the severe impact of the earthquakes, Chevron, currently carrying a Zacks Rank #3 (Hold), confirmed that its Venezuelan assets continue to operate normally. The company's three onshore heavy crude projects in western and eastern Venezuela have not experienced operational disruptions.
Key oil infrastructure also remained functional following the seismic events. Venezuela's Paraguaná refining complex, located near the affected region, continued normal refining activities, while the José export terminal maintained regular crude export operations.
These developments demonstrate the resilience of critical energy infrastructure even under difficult circumstances.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Industry Maintains StabilityChevron was not the only energy company to report uninterrupted operations. Other international operators, including Eni S.p.A. (E - Free Report) and Repsol, S.A. (REPYY - Free Report) , also confirmed that their Venezuelan assets remain operational.
Eni continues supplying natural gas that supports approximately half of Venezuela's gas-fired power generation, while Repsol's projects, including its partnership with Eni in the Perla gas field, continue contributing to the country's energy supply.
Although operations have remained stable, authorities and industry operators like CVX, E and REPYY continue assessing petrochemical facilities located closer to the earthquake's epicenter to ensure long-term safety.
Recovery Efforts Continue Across VenezuelaEmergency response teams remain engaged in rescue and recovery efforts following one of the strongest earthquakes recorded in Venezuela in more than a century. Authorities continue evaluating damage to industrial facilities, public infrastructure and residential areas.
Meanwhile, the Morón Petrochemical Complex has begun restoring operations after temporarily suspending activities to complete safety inspections. The precautionary shutdown reflects the industry's emphasis on protecting personnel and ensuring facility integrity before resuming operations.
Chevron's Long-Term Commitment to VenezuelaChevron has maintained a presence in Venezuela through years of political and economic uncertainty. It is making major developments in Venezuela, where production from its joint ventures has been steadily rising, reinforcing its position as a critical partner to PDVSA. The company currently contributes roughly a quarter of the country’s total crude output, underscoring both its operational importance and long-term strategic interest in the region. Chevron's ability to continue operating safely following this natural disaster reflects its focus on operational excellence, risk management and responsible energy production.
By prioritizing employee safety while maintaining reliable operations, Chevron continues to support Venezuela's energy sector during a period of significant national hardship.
Chevron's Ongoing Commitment to Safety and RecoveryAs Venezuela continues recovery efforts, Chevron remains focused on safeguarding its workforce, supporting affected communities and ensuring the safe operation of its assets. The company's swift response and operational resilience demonstrate the importance of strong safety practices and infrastructure preparedness in the face of unexpected natural disasters.
With ongoing assessments across the country's energy sector, Chevron continues working alongside stakeholders to provide reliable energy while contributing to recovery efforts wherever possible.
Nebius zvýšil smluvní kapacitu napájení na více než 3,5 GW a do konce roku očekává přes 4 GW. Digital Realty hlásí rekordní leasing v oblasti AI a backlog ve výši 1,8 mld. USD.
Key Takeaways NBIS is expanding its AI infrastructure, targeting more than 4 GW of contracted power capacity by year-end. DLR is seeing record AI-driven leasing, expanding its data center pipeline through 2027 and beyond.Both NBIS and DLR are investing heavily in AI infrastructure, but differ in growth pace and business models. Nebius Group N.V. (NBIS - Free Report) and Digital Realty Trust, Inc. (DLR - Free Report) are benefiting from the rapid expansion of AI infrastructure as enterprises and hyperscalers accelerate investments in high-performance computing, AI cloud platforms and next-generation data centers. Growing demand for AI training and inference workloads is driving the need for large-scale GPU capacity, power-rich data center campuses and globally connected infrastructure, positioning both companies to capitalize on the ongoing buildout of the AI ecosystem.
While Nebius is expanding its AI-native cloud platform by adding GPU capacity, securing long-term customer commitments and investing heavily in new AI infrastructure, Digital Realty is scaling its global data center platform through record leasing activity, hyperscale developments and expanded connectivity to support increasingly AI-driven workloads. Both companies continue to invest aggressively to meet rising AI infrastructure demand, although they are executing through different business models within the AI infrastructure value chain.
Let’s evaluate their fundamentals, growth prospects, market challenges and valuations to determine which stock presents a stronger investment opportunity.
The Case for NBISNebius is rapidly scaling its AI infrastructure footprint by expanding data center capacity and strengthening its AI-native hyperscaler platform. Within the past three months, the company has increased its contracted power capacity from more than 2 gigawatts to over 3.5 gigawatts and now expects to exceed 4 gigawatts by year-end. It also announced a new data center site in Pennsylvania, which is expected to support 1.2 gigawatts of power at full build-out. More than 75% of the company's contracted power capacity is now owned, reflecting its strategy of building and operating an integrated AI infrastructure platform with greater control over long-term capacity.
The company continues to enhance its full-stack AI cloud platform by offering services across the AI lifecycle, including bare-metal infrastructure, multi-tenant cloud, inference and agentic capabilities. The acquisitions of Tavily, Eigen AI and Clarifai have strengthened its engineering capabilities while improving inference optimization and agentic search technologies. The company also expanded its collaboration with NVIDIA and achieved NVIDIA Exemplar Cloud status for GB300 training workloads, placing it among a limited number of cloud providers recognized across multiple GPU generations.
Demand for Nebius' AI infrastructure remains strong across a broad range of industries, with management stating that several customers typically compete for every GPU brought online. During the first quarter, pipeline generation increased 3.5 times sequentially, supported by growing demand from AI-native companies, enterprises and software vendors. Customers spanning fintech, physical AI, life sciences, manufacturing, energy and pharmaceuticals are increasingly adopting the company's AI cloud platform. Nebius also delivered a strong first-quarter financial performance, with group revenue rising 684% year over year and the AI business recording 841% revenue growth, reaching an annualized run-rate revenue of $1.9 billion.
For 2026, Nebius expects annualized run-rate revenue of $7 billion to $9 billion, group revenue of $3 billion to $3.4 billion and an adjusted EBITDA margin of around 40%. However, management expects quarterly EBITDA margins to fluctuate during the year as investments in infrastructure and capacity expansion are incurred ahead of revenue generation. Margins are expected to decline in the second quarter due to the back-half weighted deployment of new capacity before recovering to first-quarter levels in the third quarter and improving further in the fourth quarter.
The company has also raised its 2026 capital expenditure guidance to between $20 billion and $25 billion from the earlier range of $16 billion to $20 billion to support additional AI infrastructure capacity planned for 2027. The increased investment is backed by customer commitments but will require incremental financing through asset-backed structures, corporate debt and other funding alternatives. The company continues to evaluate multiple financing sources while maintaining a disciplined approach to funding its long-term data center expansion strategy.
The Case for DLRDigital Realty is gaining from robust AI infrastructure and data center demand, with enterprises and hyperscalers increasingly deploying AI workloads across its global PlatformDIGITAL ecosystem. The company said digital infrastructure has become foundational as AI adoption accelerates compute intensity, cloud demand remains resilient and enterprises continue investing in technology. This drove one of the strongest leasing quarters in the company's history, supported by rising demand for both interconnection services and large-scale hyperscale capacity.
The company continues to strengthen its position in AI-ready infrastructure through record leasing activity and an expanding global footprint. The company signed its largest-ever lease, a 200-megawatt AI inference deployment with a hyperscale customer in Charlotte, while also securing multiple 10-plus megawatt AI-related leases across major global markets. AI-oriented bookings represented a record share of the 0-1 megawatt category, reflecting growing enterprise adoption. To support future demand, the company expanded its development pipeline to 1.2 gigawatts under construction, increased investments in hyperscale campuses and added new connectivity hubs and land acquisitions across North America, Europe and the Asia-Pacific.
Digital Realty is also benefiting from strong long-term visibility supported by a record backlog and continued investments in AI-focused data center capacity. Management highlighted that customers are shifting AI deployments from pilot projects to production environments, particularly for inference workloads, while enterprise AI demand continues to expand. Record bookings lifted the backlog to $1.8 billion, with lease commencements extending into 2027 and beyond. Digital Realty is simultaneously scaling its private capital platform, expanding hyperscale development funding and securing additional land and power resources to meet customers' long-term AI infrastructure requirements.
However, the rapid expansion of AI infrastructure continues to face industry-wide execution challenges. Management noted that limited power availability, labor shortages, supply chain constraints and community opposition are restricting the pace at which new data center capacity can be delivered. These factors are widening the gap between customer demand and deployable capacity, while utilities, equipment availability and construction timelines remain key variables across major markets.
Digital Realty is also navigating higher development costs as inflation in land values, construction expenses, supply chains and liquid-cooling infrastructure increases capital requirements for new AI data centers. The company acknowledged elevated operating expenses during the quarter and expects continued investment spending to support hyperscale growth. While management believes market rental rates are strong enough to offset rising development costs and preserve targeted returns, higher capital intensity and ongoing infrastructure investments remain important considerations.
Share Performance for NBIS & DLRIn the past three months, NBIS stock has surged 154.5% while DLR gained 10.4%.
Image Source: Zacks Investment Research
Valuation for NBIS & DLRIn terms of Price/Book, NBIS shares are trading at 8.97X, higher than DLR’s 2.93X.
Image Source: Zacks Investment Research
How Do Estimates Compare for NBIS & DLR?Over the past 60 days, analysts have significantly revised estimates for NBIS’ bottom line for the current year.
Image Source: Zacks Investment Research
For DLR, estimates have been revised marginally upward over the past 60 days.
Image Source: Zacks Investment Research
NBIS or DLR: Which Stock is the Better Investment?Both NBIS and DLR currently carry a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
While Digital Realty provides a more established and stable data center platform supported by strong leasing activity and long-term backlog, Nebius' faster growth profile, improving earnings outlook and expanding AI-native platform make it the more compelling choice for investors seeking higher upside in the AI infrastructure space.
SSR Mining dokončila prodej 80% podílu v dole Çöpler společnosti Cengiz Holding za 1,49 mld. USD v hotovosti. Výnosy chce použít na reinvestice, návrat kapitálu akcionářům a růst.
Key Takeaways SSR Mining closed the sale of its 80% stake in the Copler Mine to Cengiz.SSRM received $1.49B in cash and plans to reinvest, return capital and pursue growth.SSR Mining expects its 2026 gold equivalent output of 450,000-535,000 ounces from four mines. SSR Mining Inc. (SSRM - Free Report) announced that it closed its previously announced sale of 80% stake in the Çöpler Mine to Cengiz Holding A.S. Along with the prior announced sale of the 20% stake in the Hod Maden development project, the sale of the Çöpler Mine is consistent with SSR Mining's refocusing toward an Americas platform.
Details of SSR Mining’s Deal to Sell Çöpler Mine StakesOn March 4, 2026, SSR Mining inked a binding memorandum of understanding to sell its majority stake in the Çöpler Mine and related properties in Türkiye. Çöpler was a key contributor to SSRM’s output, which stopped operations on Feb. 13, 2024, following a significant slip on the heap leach pad.
SSR Mining worked toward the restart of the Çöpler Mine while securing the necessary regulatory approvals from Turkish authorities over the past two years. During this time, the company determined a strategic review to be the optimal path for the mine to maximize shareholder value.
SSR Mining received $1.49 billion in cash from the transaction, which it plans to use for continued business reinvestment, capital returns and accretive growth initiatives. SSRM expects the sale to yield immediate value for shareholders by exceeding current market expectations for the mine's net asset value and cash flow.
SSRM’s recent strategic actions, including the acquisition of the Cripple Creek & Victor Mine, position it as a leading producer in the United States focused on free cash flow and capital return. The company currently operates four active mines across the United States, Canada and Argentina. SSR Mining expects gold-equivalent ounces to be 450,000-535,000 for 2026.
SSRM Stock Price PerformanceThe SSRM stock has appreciated a whopping 125.2% in a year compared with the industry’s return of 40.8%.
Image Source: Zacks Investment Research
SSR Mining’s Zacks Rank & Stocks to ConsiderThe Zacks Consensus Estimate for Dow's current-year earnings is pegged at $2.61 per share, indicating a 377% year-over-year surge. Dow’s shares have gained 13.6% in a year.
Albemarle has an average trailing four-quarter earnings surprise of 74.5%. The Zacks Consensus Estimate for the company’s 2026 earnings is pegged at $12.45 per share, indicating year-over-year growth from a loss of 79 cents. ALB shares have skyrocketed 124% so far this year.
Avino Silver has an average trailing four-quarter earnings surprise of 125%. The Zacks Consensus Estimate for Avino Silver’s 2026 earnings is pegged at 39 cents per share, indicating 34.5% year-over-year growth. Its shares have surged 62.7% in a year.
Jefferies potvrdila pro AstraZeneca doporučení koupit a označila ji za Franchise Pick před klíčovým čtením dat ze studie CARDIO-TTRansform ve druhé polovině roku 2026. Cílová cena 18 000 p znamená asi 30% růst.
Jefferies has reiterated its 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) and named the drugmaker a Franchise Pick, framing an approaching late-stage trial readout as the next major catalyst for the shares.
The broker holds a price target of 18,000p, implying upside of around 30% to the current price.
At the centre of the call is CARDIO-TTRansform, a phase III study of eplontersen, marketed as Wainua, in transthyretin amyloidosis, a progressive condition in which misfolded proteins build up in the heart.
Data is due in the second half of 2026, and Jefferies argues a positive result could de-risk around $5 billion in future sales while adding a low single-digit percentage to its net present value estimate.
The analysts see the trial as well placed to succeed, citing a large patient population and the ability to test the drug both alone and alongside existing stabiliser therapies such as tafamidis.
A favourable outcome would validate eplontersen as a competitive silencing treatment and open the door to combination use, where Jefferies sees the larger long-term prize.
The broker frames the opportunity within a transthyretin amyloidosis market it expects to reach around $18 billion by 2030, driven by earlier diagnosis and a shift towards disease-modifying therapies in a condition that remains widely underdiagnosed.
Jefferies also points to AstraZeneca's broader pipeline, including the amyloid-clearing antibody cliramitug, as evidence of a multi-mechanism franchise rather than a single-product bet.
On the longer-term question of growth beyond 2030, the analysts estimate AstraZeneca must de-risk roughly $12.5 billion of incremental revenue by 2034 to sustain forecast top-line growth of about 3% a year, a target they consider achievable.
The price target places the stock at a premium of around 40% to the European pharmaceuticals sector on 2027 earnings, a valuation Jefferies says is justified.
Intel v 1. čtvrtletí vykázal non-GAAP EPS 0,29 USD při tržbách 13,58 mld. USD a divize Data Center a AI vzrostla meziročně o 22 %. TSMC zároveň zvýšila tržby o 21,4 % a čistý zisk o 43,82 %.
Intel (NASDAQ:INTC | INTC Price Prediction) and Taiwan Semiconductor Manufacturing (NYSE:TSM) both posted Q1 2026 results that frame the same question from opposite sides: who builds the world’s most advanced chips, and where. TSMC remains the engine of AI silicon. Intel is the Western alternative hyperscalers are quietly funding. Geography matters more than the numbers.
Foundry Bets Lift Intel. AI Wafers Carry TSMC. Intel’s Q1 came in at $0.29 in non-GAAP EPS on $13.58B revenue, with Data Center and AI up 22% YoY and Foundry up 16% YoY. CEO Lip-Bu Tan stated: “The next wave of AI will bring intelligence closer to the end user… This shift is significantly increasing the need for Intel’s CPUs and wafer and advanced packaging offerings.” A $4.07B Mobileye-related restructuring charge dragged GAAP results into a loss.
TSMC’s quarter was cleaner. Q1 revenue hit NT$1,134.10B, up 21.4% YoY, and net income jumped 43.82% to NT$572.48B. Gross margin reached 66.2%, a profitability profile Intel cannot match today. April monthly revenue rose 17.5% YoY, confirming AI wafer demand is accelerating.
Western Subsidies vs. Taiwanese Scale Intel’s foundry roadmap anchors a politically insulated U.S. manufacturing base: $8.9B in CHIPS Act funding, a $5.0B NVIDIA equity investment, $2.0B from SoftBank, and Intel 18A ramping at Fab 52 in Arizona. Xeon 6 was selected as the host CPU for NVIDIA’s DGX Rubin NVL8 systems. Intel joined the Terafab project alongside SpaceX, xAI, and Tesla. Hyperscalers are realizing that relying on a single island for over 90% of advanced chip fabrication is an unsustainable operational risk.
TSMC is diversifying with fabs in Arizona, Japan, and Germany, with its Arizona tax credit rate raised from 25% to 35%. Customer concentration is striking: the top 10 customers represent 84% of accounts receivable. Most leading-edge research stays in Hsinchu.
Lens Intel TSMC Core Bet U.S. foundry as secure second source Taiwan-anchored leading-edge dominance Key Vulnerability Execution on 18A yields and customer wins Geopolitical concentration risk Profit Engine Xeon, advanced packaging, foundry ramp 3nm and 2nm AI wafers The Next Test Is Intel 18A Customer Wins Watch whether Intel converts its Google ASIC partnership and NVIDIA wafer relationship into named 18A foundry customers before management decides on the Intel 14A go-ahead. For TSMC, monitor whether the 2D transistor and CoPoS packaging roadmap stays on schedule while Arizona expansion absorbs more capex. Intel guided Q2 to $13.8B-$14.8B in revenue with non-GAAP EPS of $0.20, so the margin path matters more than the headline.
Why Intel Offers Asymmetric Upside Intel fits investors seeking exposure to the structural reshoring trade, even with restructuring noise and a CFO who trimmed shares at $109.82. The stock is up 256.78% YTD, so the easy money is gone, but the foundry thesis has years to play out. TSMC remains the better business by every operating metric, with 46.5% profit margin proving it. TSMC may appeal to investors prioritizing quality compounding. If China-Taiwan tensions cool meaningfully, the relative case for TSMC strengthens. Until then, Intel’s political insulation is the edge the market is still underpricing.
DexCom potvrdil výhled růstu tržeb na rok 2026 o 11 % až 13 % a dál rozšiřuje adopci CGM díky novým produktům a širšímu pokrytí. Abbott naopak čelí slabosti diagnostiky, nejistotě v Číně a ředění EPS po akvizici Exact Sciences.
Key Takeaways Abbott faces Diagnostics weakness, China uncertainty and EPS dilution from the Exact Sciences deal.DXCM is expanding CGM adoption through new products, broader coverage and global market growth.DXCM reiterated 2026 revenue growth guidance of 11%-13% and expects wider G7 15 Day adoption. With the rising prevalence of diabetes worldwide, the demand for more efficient and real-time glucose monitoring solutions has intensified. Abbott (ABT - Free Report) and DexCom (DXCM - Free Report) are among the leading players in the continuous glucose monitoring (CGM) device market, valued at $13.4 billion in 2025 by Grand View Research.
Healthcare giant Abbott’s businesses span cardiovascular care, diagnostic testing, nutrition, pain and movement disorders, with Diabetes Care being a consistent top-line driver for the past several quarters. On the other hand, DexCom is a pure-play CGM company whose target market consists mainly of people with Type 1 and Type 2 diabetes using insulin therapy, as well as certain non-insulin users who struggle with hypoglycemia.
Here’s a closer look at both companies to determine which stock offers the more compelling investment opportunity today.
The Case for Abbott
Abbott’s flagship, sensor-based CGM system, FreeStyle Libre, has quickly established global leadership across both Type 1 and Type 2 diabetes. CGM sales reached $2 billion in the first quarter of 2026, up 7.5% year over year, though growth was affected by a delay in an international tender renewal and a difficult prior-year comparison tied to shelf restocking dynamics. CGM growth is forecasted to return to double-digits in the second quarter.
Abbott’s CEO also remains bullish on the long-term CGM opportunity, estimating that 70-80 million people globally should be using CGMs compared with the current market of roughly 10-12 million users. Recently, the company secured CE Mark for the first-ever dual glucose-ketone sensing technology for people with diabetes, branded as Libre Duo and Libre Duo 10 Day. The systems continuously measure glucose and ketone levels every minute and will integrate with the Libre digital health ecosystem.
Beyond Diabetes Care, Abbott’s Core Lab Diagnostics business is seeing robust demand across the United States, Europe and Latin America. However, Core Lab trends were flat in China, with the company continuing to expect a weaker market for the full year despite lapping prior pricing actions.
The March 2026 acquisition of Exact Sciences added a Cancer Diagnostics business, expanding presence in one of the fastest-growing areas of healthcare. Even so, the deal introduces a $0.20 dilution to the 2026 adjusted EPS guidance of $5.38 to $5.58.
Abbott’s Rapid and Molecular Diagnostics business suffered from lower demand for respiratory virus testing due to a much weaker respiratory season compared to last year. Management is taking a cautious view and is not assuming the shortfall will recover later in the year. The Established Pharmaceuticals Division benefits from branded generics positions in faster-growing geographies. Abbott is focused on restoring a healthier balance between price and volume over time in Nutrition, while its Medical Devices segment is gaining from scale advantages and new product cycles across the franchises.
Take a look at how analysts are projecting Abbott’s bottom line.
Image Source: Zacks Investment Research
The Case for DexCom
DexCom is benefitting from broader access to its CGM product portfolio, continued active base growth and new product launches. The company has partnered with several insulin delivery systems manufacturers to integrate its CGM products, with more than one million CGM users now connected to an automated insulin delivery (AID) system worldwide.
Internationally, DexCom’s 2026 first-quarter growth was widespread across core markets, with notable strong performance in countries such as France and Canada, where access has recently expanded. Management outlined a targeted international strategy aimed at gaining share through reimbursement progress and a portfolio tailored to local channels, including DexCom One+ in Europe.
In the quarter, DexCom made an expanded rollout of the G7 15 Day sensor across all U.S. channels. The platform is now available with all U.S. pump partners, helping minimize friction for AID users who upgrade within the installed base. DexCom expects nearly 50% conversion of the U.S. base to the 15-day sensor by year-end 2026, with an international launch expected to begin in the second half of the year. The company also introduced its next-generation G8 roadmap, designed to deliver a step-change improvement in glucose performance with a smaller form factor and self-adapting sensor.
DexCom continues to build out its software ecosystem, adding engagement tools for Stelo, including enhanced Smart Meal Logging features, and it has been expanding provider-facing capabilities through Direct EHR Integration. More than 320 health systems have already integrated or are in the process of onboarding this capability across the United States and international markets.
The company also continues to expand insurance coverage for its CGM sensors, particularly among Type 2 diabetes patients. The three largest U.S. Pharmacy Benefit Managers now cover DexCom CGM for all people with diabetes, including those with type 2 not using insulin.
ABT also reiterated its 2026 revenue guidance, calling for 11% to 13% growth over 2025 levels. Take a look below at how the company’s earnings estimates are shaping up.
Image Source: Zacks Investment Research
ABT & DXCM: Price Performance and Valuation
Year to date, ABT shares have declined 25.6%, whereas DexCom shares have climbed 4.1%.
Image Source: Zacks Investment Research
Abbott is trading at a forward, five-year Price/Sales (P/S) of 2.99X, below its median of 4.63X. Meanwhile, DXCM sits with a five-year P/S of 4.88X, also lower than its median of 9.93X.
Image Source: Zacks Investment Research
Conclusion
Both companies are poised to benefit from the long-term growth trends of the CGM market. However, Abbott continues to face respiratory testing volatility in Diagnostics, dilution risk following the Exact Sciences acquisition and ongoing uncertainty in China. DexCom is gaining from elevated CGM demand worldwide, new product launches and expanding coverage for its sensors.
While DexCom trades at a premium to Abbott, it remains well below its historical median. The stock has also delivered stronger YTD performance relative to Abbott. Coupled with positive earnings estimate revisions, existing DXCM holders may find it prudent to stay invested to enjoy growth prospects. Meanwhile, those holding ABT stock may find it wise to sell for now until the short-term operating visibility improves.
DXCM carries a Zacks Rank #3 (Hold), while ABT has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Morgan Stanley Wealth Management rozšířila přístup k PMAX - Balanced, odstranila požadavek na akreditovaného investora a spustila PMAX - Growth. Minimální investice je 10 000 USD.
NEW YORK--(BUSINESS WIRE)--Morgan Stanley Wealth Management announced that it has expanded access to the Morgan Stanley Private Markets and Alternatives Fund ("PMAX") by registering it as PMAX - Balanced. This change removes the accredited investor requirement, lowers minimum investment amounts, and introduces daily subscriptions, making private market strategies accessible to a broader range of clients through a simplified, professionally managed investment vehicle.
Morgan Stanley Wealth Management is also adding to its PMAX product suite with the launch of PMAX - Growth, a fund with a growth-focused allocation, and plans to introduce additional strategies with targeted investment objectives.
Historically, access to private markets was primarily limited to institutions and ultra-high-net-worth investors, but the PMAX fund platform now broadens access to institutional-quality private market investment managers for more clients.
This expansion comes as private markets continue to gain momentum. Global Alternatives AUM is expected to exceed $30 trillion in 2030, up from less than $10 trillion a decade ago, driven by companies staying private longer and increasing investor demand for opportunities beyond public markets.1 Over the same period, the number of public companies has declined significantly, while 84% of companies generating $100 million or more in revenue remain private.2
Morgan Stanley Wealth Management continues to see substantial growth in alternative investments, with over $300 billion in client assets under management.3 This achievement positions the Firm as a leading provider of alternative investment solutions in the wealth management sector and underscores its 45-year history of excellence in this space, extensive resources, and a dedicated team of nearly 350 alternatives professionals.
“Our PMAX platform reflects our commitment to broadening access to private markets through innovative products designed to meet a wider range of client needs,” said Alison Nest, Head of Investment Solutions Products. “By expanding the platform and making it easier to invest, we are giving clients and advisors more ways to build diversified portfolios aligned with their investment objectives.”
PMAX platform overview
PMAX - Balanced, with currently over $1B in AUM4, is a multi-manager portfolio offering diversified exposure across private equity, private credit, real estate and infrastructure through a simplified, single-ticket evergreen vehicle. With a diversified allocation across these strategies, it seeks to offer the potential for risk-adjusted higher returns, income and lower correlation relative to traditional investments.
PMAX - Growth is a growth-oriented private markets approach for clients seeking increased exposure to long-term capital appreciation opportunities. The fund provides diversified exposure to private equity through a curated, multi-manager portfolio across sectors, geographies and vintages, combining growth‑oriented and buyout strategies that seek to pursue long‑term capital appreciation while providing diversification.
The funds require a $10,000 initial investment and $5,000 for subsequent contributions. The funds permit daily purchases and allow clients to benefit from consolidated tax reporting and fully funded exposure without capital calls. Additionally, the streamlined investor experience removes the need for subscription documents, making the process simpler and more efficient for clients.
The funds are closed-end investment companies and do not offer daily redemptions. Liquidity is anticipated only through limited quarterly repurchase offers that occur at the discretion of each fund's Board of Trustees.
“The PMAX platform brings together Morgan Stanley Wealth Management’s scale, alternatives expertise and manager access in a way that is designed to make private markets investing more accessible and more flexible for clients,” said Brian Holzer, Head of Alternative Investments Distribution. “With these offerings, we are continuing to build a differentiated platform that helps advisors deliver institutional-quality private market strategies.”
Investment approach
The funds utilize the intellectual capital of Morgan Stanley Wealth Management’s Global Investment Committee for asset allocation and Global Investment Manager Analysis team for manager selection and due diligence.
PMAX - Balanced targets allocations to private equity, private credit and real assets. This calibrated mix is designed to pursue higher risk-adjusted returns, income and diversification across private market strategies that may have lower correlation to public markets. The strategy also seeks diversification across sub-strategy, geography, sectors and managers, while retaining flexibility to incorporate additional strategies as opportunities arise.
PMAX - Growth targets allocation ranges that emphasize buyout strategies, as a core component, complemented by growth equity and venture capital and other opportunistic strategies. Overall, the approach focuses on diversification within private equity through manager selection, asset allocation, and periodic rebalancing, with the goal of seeking attractive risk‑adjusted returns over time.
About Morgan Stanley Wealth Management
Morgan Stanley Wealth Management, a global leader, provides access to a wide range of products and services to individuals, businesses and institutions, including brokerage and investment advisory services, financial and wealth planning, cash management and lending products, annuities and insurance, retirement and trust services.
About Morgan Stanley
Morgan Stanley (NYSE MS) is a leading global financial services firm providing investment banking, securities, wealth management and investment management services. With offices in more than 41 countries, the Firm’s employees serve clients worldwide including corporations, governments, institutions and individuals. For more information, visit www.morganstanley.com.
Important Information
This press release is for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy any securities, nor does it constitute investment advice or a recommendation of any kind.
The PMAX funds are closed-end investment companies with limited to no liquidity. Shares are not listed on any securities exchange and no secondary market is expected to develop. Shareholders do not have the right to require the funds to redeem their shares. The funds may offer to repurchase shares on a quarterly basis in an amount not to exceed 3% of each fund's net asset value, subject to the discretion of each fund's Board of Trustees. No assurances can be given that a fund will conduct a repurchase in any given quarter and investors should not expect to be able to sell their shares regardless of how a fund performs.
The funds invest primarily in private market strategies for which valuations are generally provided on a quarterly basis by the underlying portfolio fund managers, while the funds calculate their net asset value and offer shares on a daily basis. Accordingly, the daily net asset value of a fund's shares may not fully reflect the current fair value of the fund's underlying investments and may be subject to adjustment as updated valuations become available.
Investing in the funds involves a high degree of risk, including the possible loss of the entire investment. The funds invest in non-traditional, alternative strategies, including private equity, private credit and real assets, that are subject to risks not typically associated with traditional investments, including but not limited to illiquidity, limited transparency, leverage, valuation uncertainty and potential for significant price volatility. Past performance is not indicative of future results, and there can be no assurance that the funds will achieve their investment objectives.
Investors should carefully read the applicable prospectus before investing for a more complete description of the risks involved. Copies of the prospectus may be obtained by contacting your Morgan Stanley Financial Advisor.
The sole purpose of this material is to inform, and it is in no way intended to be an offer or solicitation to purchase or sell any security, other investment or service, or to attract any funds or deposits. Products mentioned herein may not be appropriate for all investors and may be purchased only after an eligible investor has carefully reviewed the Fund’s offering materials and executed any applicable subscription documents. MSWM has not considered the actual or desired investment objectives, goals, guidelines, or factual circumstances of any investor in any fund(s). Before making any investment, each investor should carefully consider the risks associated with the investment, as discussed in the applicable offering materials, and make a determination, based upon their own particular circumstances, that the investment is consistent with their investment objectives and risk tolerance.
Past performance is no guarantee of future results. Actual results may vary. Diversification does not assure a profit or protect against loss in a declining market.
Alternative investments involve complex tax structures, tax inefficient investing, and delays in distributing important tax information. Individual funds have specific risks related to their investment programs that will vary from fund to fund. Clients should consult their own tax and legal advisors as MSWM does not provide tax or legal advice.
Interests in alternative investment products are only made available pursuant to the terms of the applicable offering materials, are distributed by MSWM and certain of its affiliates, and (1) are not FDIC-insured, (2) are not deposits or other obligations of MSWM or any of its affiliates, (3) are not guaranteed by MSWM or any of its affiliates, and (4) involve investment risks, including possible loss of principal. MSWM is a registered broker-dealer, not a bank.
Freeport-McMoRan rozšiřuje projekty v Chile, Arizoně a Indonésii, aby zvýšil kapacitu a produkci mědi. Konsensus ohledně EPS společnosti FCX pro roky 2026 a 2027 počítá s růstem o 6,1 % a 44,6 %.
Key Takeaways FCX is advancing expansion projects in Chile, Arizona and Indonesia to boost copper capacity and output.Freeport's organic growth pipeline positions itself well to benefit from future demand growth.Estimates for 2026 and 2027 for FCX point to 6.1% and 44.6% growth, trending higher over the past 60 days. Freeport-McMoRan Inc. (FCX - Free Report) remains committed to disciplined execution and the development of its organic growth projects. The company’s expansion efforts are designed to enhance production capacity, supported by solid financial strength.
FCX has completed the evaluation of a large-scale expansion at El Abra in Chile to define a large sulfide resource that could potentially support a major mill project similar to the large-scale concentrator at Cerro Verde, with an estimated resource of approximately 20 billion recoverable pounds of copper.
In Arizona, FCX is progressing with pre-feasibility studies at its Safford/Lone Star operations, with completion targeted for 2026, to assess a sizable sulfide expansion opportunity. It has expansion opportunities at Bagdad in Arizona that can more than double the concentrator capacity of the operation. Technical and economic studies have revealed the potential to build concentrating facilities to boost copper production by 200-250 million pounds annually.
PT Freeport Indonesia (PT-FI) is developing the Kucing Liar ore body within the Grasberg district with a targeted ramp-up to commence in 2030. FCX completed studies in 2025 that showed an opportunity to increase Kucing Liar’s design capacity to 130,000 metric tons of ore per day and reserves by roughly 20% at low costs.
FCX’s organic growth pipeline, designed to expand capacity and output, positions it well to benefit from future demand growth. Effective execution of these projects will strengthen its ability to drive shareholder value.
Among FCX’s peers, Southern Copper Corporation (SCCO - Free Report) has a strong pipeline of world-class copper greenfield projects and various other promising opportunities. Southern Copper continues to build its presence in Peru as the country is the second-largest producer of copper. The company’s key growth catalysts include the Tía María, Los Chancas and Michiquillay projects in Peru, along with El Pilar and El Arco in Mexico, all of which underpin SCCO’s long-term expansion pipeline.
BHP Group Limited (BHP - Free Report) continues to reshape its portfolio toward commodities such as copper and potash, allocating nearly 70% of its medium-term capital expenditure to these areas. This strategy positions BHP to benefit from decarbonization, electrification, population growth and rising living standards in emerging markets. BHP, in March 2026, submitted the Environmental Impact Declaration permit for the Escondida New Concentrator to replace the aging Los Colorados plant as it nears the end of operations, a move that backs its growth strategy while addressing asset longevity. With an estimated investment of $4.4-$5.9 billion, the project targets new capacity to produce 220-260 kt of copper annually.
The Zacks Rundown for FCXShares of Freeport-McMoRan have rallied 22% in the past six months compared with the Zacks Mining - Non Ferrous industry’s growth of 6.8%.
Image Source: Zacks Investment Research
From a valuation standpoint, FCX is currently trading at a forward 12-month earnings multiple of 20.82, a modest 3.2% premium to the industry average of 20.17X. It carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for FCX’s 2026 and 2027 earnings implies a year-over-year rise of 6.1% and 44.6%, respectively. The EPS estimates for 2026 and 2027 have been trending higher over the past 60 days.
Biogen uvedl, že jeho růstové produkty v 1. čtvrtletí vygenerovaly tržby 851 milionů USD, což je meziročně o 12 % více. Nové léky ale zatím nestačí kompenzovat pokles tržeb z franšízy na roztroušenou sklerózu.
Key Takeaways Biogen's newer drugs are growing but remain insufficient to offset declining MS franchise sales.Leqembi's subcutaneous autoinjector and blood-based diagnostics may support growth from 2027 onward.Biogen's growth products generated $851 million in Q1 sales, up 12% year over year. Biogen (BIIB - Free Report) is in the midst of a major portfolio transition. The company is seeing declining sales of its key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, due to generic erosion, increasing competition from newer therapies and pricing headwinds.
To combat the pressure on key drugs, Biogen has been aggressively building a new growth engine around recently launched products, Eisai-partnered Leqembi for Alzheimer’s disease, Skyclarys for Friedreich’s ataxia, Qalsody for amyotrophic lateral sclerosis (ALS) and Supernus Pharmaceuticals (SUPN - Free Report) -partnered Zurzuvae for depression.
The key question for investors is whether these products can eventually compensate for the erosion of blockbuster drugs like Tecfidera, Tysabri and Spinraza. Let us discuss.
Key Multiple Sclerosis Drugs, Spinraza Face Increased CompetitionBiogen’s MS sales are declining due to generic competition for Tecfidera globally, biosimilar competition for Tysabri in Europe and rising competitive pressure in the MS market.
In 2026, Biogen expects revenues for MS products, excluding Vumerity, to decline by a mid-teen percentage versus 2025 due to increased competitive pressure on the ex-U.S. MS business, particularly accelerating generic competition for Tecfidera in Europe.
Spinraza’s sales are also declining due to lower demand amid increasing competitive pressure from newer SMA treatments, including gene therapies and oral medicines that offer greater convenience. Spinraza faces competition from Novartis’ (NVS - Free Report) gene therapy, Zolgensma, and Roche and PTC Therapeutics’ (PTCT - Free Report) Evrysdi (risdiplam), which comes as either a liquid solution or an oral tablet.
BIIB’s New Drug Contributing to Top-Line GrowthAmid declining demand for MS drugs and Spinraza, Biogen believes its new products, Leqembi, Skyclarys and Zurzuvae have the potential to return the company to revenue growth.
The largest opportunity in Biogen's new portfolio is arguably Leqembi. Leqembi/lecanemab gained approval for early Alzheimer’s disease in the United States in 2023. Though the Leqembi launch was slow, it picked up in 2024 and 2025. Leqembi has also been launched in Japan, China, the EU and some other countries. Leqembi commands over 60% of the anti-amyloid therapy market share in the United States.
A less frequent maintenance intravenous dosing version of Leqembi was approved by the FDA in January 2025. A subcutaneous autoinjector for maintenance dosing called Leqembi Iqlik was launched in October 2025, while a supplemental filing seeking approval of the Leqembi Iqlik subcutaneous autoinjector for initiation dosing has been granted priority review by the FDA, with a decision expected in August. Biogen and Eisai believe that the introduction of blood-based diagnostics (which can help earlier detection of Alzheimer’s) and the subcutaneous autoinjector for maintenance and initiation should drive Leqembi’s growth from 2027 onward.
Other new products, Qalsody, Biogen/Supernus’ Zurzuvae and Skyclarys (added from the 2023 acquisition of Reata Pharmaceuticals) are also seeing strong demand trends in the United States.
Skyclarys is seeing strong demand trends in the United States as well as the EU. Biogen expects Skyclarys’ future growth to come from ex U.S. markets as the launches advance. Zurzuvae’s launch also exceeded the company’s internal expectations, with sales more than doubling in 2025. Skyclarys and Zurzuvae’s sales are expected to continue to rise in 2026.
Biogen’s growth products (Skyclarys, Qalsody, Zurzuvae, Vumerity and Spinraza plus Alzheimer’s revenues from the Leqembi collaboration) generated sales of $851 million in the first quarter, rising 12% year over year.
In April, Biogen closed its acquisition of Apellis Pharmaceuticals, adding the commercialized medicines Empaveli and Syfovre for immune-mediated retinal disease and nephrology to its commercial portfolio. These drugs should also contribute to Biogen’s growth in future quarters.
Can BIIB’s New Drugs Offset Key Drugs’ Erosion?After declining for several years, Biogen’s revenues have somewhat stabilized since 2024 due to contributions from newer products and pipeline progress. However, its newer drugs, Leqembi, Skyclarys, Qalsody and Zurzuvae, are currently insufficient to offset the near-term top-line decline of the MS franchise. Though all these new drugs are showing signs of growth, replacing lost revenues from Tecfidera, Tysabri and Spinraza will likely take time.
BIIB’s Price Performance, Valuation and EstimatesBiogen’s stock has risen 14.8% so far this year compared with an increase of 5.4% for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Biogen is reasonably priced. Going by the price/earnings ratio, the company’s shares currently trade at 13.44 forward earnings, which is lower than 17.72 for the industry. The stock is trading above its five-year mean of 13.17.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for earnings has declined from $15.04 per share to $13.99 per share for 2026 over the past 60 days. For 2027, the consensus mark for earnings has declined from $16.61 to $16.22 per share over the same time frame.
Image Source: Zacks Investment Research
Biogen has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Vaxart vyzvala akcionáře, aby na výroční schůzi hlasovali pro všech šest kandidátů do představenstva na základě bílé plné moci. Firma zároveň uvedla, že její vývoj vakcín pokračuje a má zajištěné financování i pokračující podporu BARDA.
Details Strategic Actions Taken by the Board to Advance the Company’s Pipeline and Drive Value Creation
Vaxart’s Purpose-Built Board Brings the Proven Expertise Needed to Oversee its Next Phase of Growth
Dissident Nominees Lack Relevant Clinical-Stage Biotech Expertise, Misrepresented Their Qualifications
and Offered No Credible Ideas for Value Creation
Vaxart Has Made Multiple Settlement Offers to the Dissident Shareholder Group – Daniel Houle Insists on Making This Proxy Contest About Winning a Seat for Himself
Visit Vote.Vaxart.com for Additional Information and Voting Resources
SOUTH SAN FRANCISCO, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today published a presentation urging shareholders to vote “FOR” ALL six of the Company’s highly qualified director nominees on the WHITE proxy card in connection with its upcoming Annual Meeting of Stockholders scheduled to be held on July 16, 2026.
Highlights of the presentation include:
Strategic Execution at a Pivotal Moment
Vaxart is developing game-changing oral vaccines with the potential to redefine vaccine delivery and immune responses:
Vaxart is advancing multiple vaccine programs across high-value markets, including COVID-19, norovirus and influenza.Management is pursuing a disciplined development strategy that prioritizes programs with the strongest scientific rationale, commercial opportunity and funding pathways.Through its Phase 2b COVID-19 trial, Vaxart is working toward topline 12-month safety and immunogenicity data from the approximately 400-participant Sentinel Cohort.Vaxart is also targeting a full efficacy and safety readout from its approximately 5,100-participant Main Cohort, representing a significant clinical and value-creation milestone.
Vaxart’s Board has taken prudent steps to enable Vaxart to continue advancing its programs in a challenging environment:
Vaxart has been executing through immense industry pressures brought upon by significant regulatory, funding and policy disruption, including two BARDA stop-work orders that impacted Vaxart and many other vaccine companies.Through CEO Steven Lo’s leadership and negotiations with government stakeholders, the Company secured the continuation of BARDA funding for its lead COVID-19 program.Vaxart entered into a $25 million share purchase agreement, providing flexible access to capital, if needed, to support continued execution toward key milestones.The Board’s decision to raise $40 million in 2025 extended the Company’s runway, enabling it to enter key partnerships and advance its programs.
The Right Board to Oversee the Path Forward
The Board is purpose-built to guide Vaxart through its next phase of value creation. The Board is aligned with the Company's evolving strategic priorities, with substantial expertise across biotech, vaccine development, clinical trials and regulatory affairs.The Board’s experience has helped secure continued BARDA funding, establish the Dynavax partnership and enable additional financing flexibility through the Lincoln Park Capital agreement.Mr. Lo, Dr. Elaine J. Heron and Dr. David Wheadon are instrumental to Vaxart's success and have the judgment, credibility and relationships needed to oversee the Company’s most important future opportunities. The Board is responsive to shareholder feedback and acts in shareholders’ best interests: The Board has added two new independent directors — Dr. James B. Breitmeyer and Kevin Finney — over the last 18 months as part of its ongoing refreshment efforts, resulting in an average director tenure of approximately 2.3 years.In 2025, the Board further strengthened independent oversight through the appointment of W. Mark Watson as Lead Independent Director.The Board maintains an active dialogue with shareholders and withdrew its reverse split proposal for this upcoming Annual Meeting following feedback. The Dissident Campaign is Risking Vaxart’s Momentum
Replacing ANY of Vaxart’s highly qualified directors with the dissident nominees is not in shareholders’ best interests: None of the dissident nominees has experience leading a public clinical-stage biotech company or with vaccine development, regulatory affairs and clinical trial oversight.The dissident nominees have drastically exaggerated their qualifications, and Daniel Houle’s reckless public statements show that he should not serve on Vaxart’s Board.Collectively, they present unacceptable risk for a company approaching critical inflection points like Vaxart. Vaxart has made good-faith efforts to resolve the proxy contest: Vaxart has made multiple settlement offers to the dissident shareholder group in an effort to resolve the proxy contest.The Board’s proposals are highly reasonable and reflect what it has heard other independent shareholders want to see.Mr. Houle is waging a self-interested campaign primarily focused on “winning” a Board seat for himself rather than reaching a constructive resolution that would benefit all Vaxart shareholders. Vote “FOR” ALL 6 of Vaxart’s highly qualified director nominees on the WHITE proxy card TODAY!
If you have questions or require assistance with voting your shares, please call Vaxart’s proxy solicitor:
Additional shareholder resources and voting information can be found at Vote.Vaxart.com.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Cautionary Language Concerning Forward-Looking Statements
This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” provisions created by those sections, that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this communication regarding Vaxart’s strategy, prospects, plans and objectives, results from preclinical and clinical trials, commercialization agreements and licenses, and beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as “should,” “believe,” “could,” “potential,” “will,” “expected,” “anticipate,” “plan,” “target,” “seek,” “intend,” “may,” “predict,” “project,” “would,” and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart’s ability to develop and commercialize its product candidates, including its vaccine booster products; Vaxart’s expectations regarding clinical results and trial data, and the timing of receiving and reporting such clinical results and trial data; Vaxart’s expected timing for future clinical trials; and Vaxart’s expectations with respect to the effectiveness of its product candidates; expectations regarding collaborations, including the collaboration with Dynavax; expectations regarding the pursuit of strategic partnerships and external funding opportunities for Vaxart’s programs; expectations regarding government funding; and expectations regarding Vaxart’s capital resources and funded runway. Vaxart may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates, and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart’s product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart’s product candidates may not achieve broad market acceptance; that a Vaxart collaborator may not attain development and commercial milestones; that Vaxart or its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxart’s or its partners’ control; difficulties in production, particularly in scaling up initial production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations; that Vaxart may not be able to obtain, maintain, and enforce necessary patent and other intellectual property protection; that Vaxart’s capital resources may be inadequate; Vaxart’s ability to resolve pending legal matters; Vaxart’s ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart, if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks and uncertainties described in the “Risk Factors” sections of Vaxart’s most recent Annual Report on Form 10-K, including amendments thereto, and Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. Vaxart undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.
Important Additional Information and Where to Find It
Vaxart has filed a definitive proxy statement and form of white proxy card with the U.S. Securities and Exchange Commission (the “SEC”) in connection with its solicitation of proxies for the 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Stockholders are able to obtain the Company’s proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC at no charge at the SEC’s website at www.sec.gov. Copies are also available at no charge at the Company’s website at https://investors.vaxart.com/financials-filings/sec-filings.
Paramount Skydance prodloužila lhůtu pro nabídky na výměnu a odkup dluhopisů do 15. července 2026. K 25. červnu bylo nabídnuto 24,38 % dluhopisů určených k odkupu a 44,27 % dluhopisů určených k výměně.
, /PRNewswire/ -- Paramount Skydance Corporation (NASDAQ: PSKY) ("Paramount") today announced the extension of the Expiration Dates in connection with the previously announced (i) offers to purchase (the "Tender Offers" and each, a "Tender Offer") for cash, upon the terms and subject to the conditions set forth in the related offer to purchase (the "Offer to Purchase"), any and all of the identified notes in each series of the Existing Tender Offer Notes (defined by reference to the table set forth below) issued by Discovery Global Holdings, Inc. (formerly WarnerMedia Holdings, Inc.) (the "DGH Issuer") and Discovery Communications, LLC (the "DCL Issuer" and together with the DGH Issuer, each a "WBD Issuer" and collectively the "WBD Issuers"), as applicable, and (ii) offers to exchange (the "Exchange Offers" and each, an "Exchange Offer" and, together with the Tender Offers, the "Offers" and each, an "Offer"), upon the terms and subject to the conditions set forth in the related exchange offer memorandum (the "Offering Memorandum"), any and all of the identified notes in each series of the Existing Exchange Offer Notes (defined by reference to the table set forth below) (together with the Existing Tender Offer Notes, the "Offer Notes") issued by the applicable WBD Issuer for notes to be newly issued by Paramount.
The Expiration Dates for the Tender Offers and Exchange Offers (as defined in each of the Offer to Purchase and Offering Memorandum, respectively) have been extended to 5:00 p.m., New York City time, on July 15, 2026, unless further extended. The Settlement Dates for the Tender Offers and Exchange Offers (as defined in each of the Offer to Purchase and Offering Memorandum, respectively) will occur promptly after the Expiration Date and are currently anticipated to occur in the third quarter of 2026. Paramount anticipates extending the Expiration Date for such Tender Offers and Exchange Offers until such time that would result in the Settlement Dates occurring on the closing date of the proposed acquisition (the "Acquisition") by Paramount of Warner Bros. Discovery, Inc. ("WBD") or within one business day thereof. Tenders of the Offer Notes in the Offers may be withdrawn at any time prior to the Expiration Date. The aforementioned extensions further extend the Expiration Dates previously extended by Paramount on June 12, 2026.
As of 5:00 p.m., New York City time, on June 25, 2026, approximately 24.38% and 44.27% of the aggregate principal amount of the Existing Tender Offer Notes and Existing Exchange Offer Notes, respectively, have been validly tendered in the applicable Offers. As Paramount previously announced that it anticipates extending the Offers to align with the closing date of the Acquisition, Paramount does not view these figures to be representative of the final results of the applicable Offers.
Information about each series of Offer Notes eligible to participate in the Offers is summarized below.
Type of Offer
Offer Notes to be Tendered
or Exchanged, as
Applicable
Issuer of Offer Notes
CUSIP No. / Common Code
/ ISIN Eligible to
Participate in the Offers (1)
Aggregate Principal
Amount of Offer Notes
Eligible to Participate in the
Offers (2)
Tender Offer
3.950% Senior Notes due 2028
DCL Issuer
25470D CP2
US25470DCP24
$1,234,458,000
Exchange Offer
4.125% Senior Notes due 2029
DCL Issuer
25470D CQ0
US25470DCQ07
$655,825,000
Exchange Offer
3.625% Senior Notes due 2030
DCL Issuer
25470D CR8
US25470DCR89
$914,183,000
Exchange Offer
5.000% Senior Notes due 2037
DCL Issuer
25470D CS6
US25470DCS62
$453,281,000
Exchange Offer
6.350% Senior Notes due 2040
DCL Issuer
25470D CT4
US25470DCT46
$438,102,000
Exchange Offer
4.950% Senior Notes due 2042
DCL Issuer
25470D CU1
US25470DCU19
$130,366,000
Exchange Offer
4.875% Senior Notes due 2043
DCL Issuer
25470D V91
CV9US25470DC
$141,584,000
Exchange Offer
5.200% Senior Notes due 2047
DCL Issuer
25470D W74
CW7US25470DC
$3,161,000
Exchange Offer
5.300% Senior Notes due 2049
DCL Issuer
25470D X57
CX5US25470DC
$247,860,000
Tender Offer
3.755% Senior Notes due 2027
DGH Issuer
254948 AH5
US254948AH58
254948 AN2
US254948AN27
U25483 AA3
USU25483AA38
$1,189,336,000
Exchange Offer
4.054% Senior Notes due 2029
DGH Issuer
254948 AJ1
US254948AJ15
254948 AP7
US254948AP74
U25483 AB1
USU25483AB11
$1,353,828,000
Exchange Offer
4.279% Senior Notes due 2032
DGH Issuer
254948 AK8
US254948AK87
254948 AQ5
US254948AQ57
$2,691,764,000
Exchange Offer
5.050% Senior Notes due 2042
DGH Issuer
254948 AL6
US254948AL60
254948 AR3
US254948AR31
U25483 AD7
USU25483AD76
$4,104,687,000
Exchange Offer
5.141% Senior Notes due 2052
DGH Issuer
254948 AM4
US254948AM44
254948 AS1
US254948AS14
$949,883,000
Exchange Offer
4.302% Senior Notes due 2030
DGH Issuer
XS3393993285
339399328
€234,382,000
Exchange Offer
4.693% Senior Notes due 2033
DGH Issuer
XS3393994507
339399450
€316,641,000
__________
(1) No representation is made as to the correctness or accuracy of the identifiers listed in this press release or printed on the Offer Notes. Such identifiers are provided solely for the convenience of the holders.
(2) Represents the aggregate principal amount of Offer Notes outstanding that are eligible to participate in the Offers.
The Exchange Offers are being made pursuant to an exemption from the registration requirements of the U.S. Securities Act of 1933, as amended (the "Securities Act"), and the rules and regulations of the Securities and Exchange Commission (the "SEC") promulgated thereunder, and are also not being registered under any state or foreign securities laws. Any securities offered pursuant to the Exchange Offers may not be offered or sold in the United States or to any U.S. persons (as defined below) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. The Exchange Offers will only be made, and the securities offered pursuant to the Exchange Offers are only being offered and issued, to holders of applicable Existing Exchange Offer Notes who are (a) reasonably believed to be "qualified institutional buyers" as defined in Rule 144A under the Securities Act or (b) not "U.S. persons," as defined in Rule 902 of Regulation S under the Securities Act (such holders, "Eligible Holders"), and only Eligible Holders who have completed and returned the eligibility certification are authorized to receive or review the Offering Memorandum or to participate in the Exchange Offers. The eligibility certification is available electronically at: https://gbsc-usa.com/eligibility/paramount.
General
Each Offer is a separate offer, and each may be individually consummated, amended, extended, terminated, or withdrawn, subject to certain conditions and applicable law, at any time in Paramount's sole discretion, and without also consummating, amending, extending, terminating, or withdrawing any other Offer with respect to any other series of Offer Notes. Paramount may terminate an Offer if any of the conditions of such Offer described in the Offer to Purchase or Offering Memorandum, as applicable, are not satisfied or waived by the applicable Expiration Date, subject to applicable law. In addition, Paramount may waive the conditions to an Offer without extending such Offer in accordance with applicable law.
The Offers are being made solely by Paramount and are not being made by WBD or the WBD Issuers. None of Paramount, WBD, the WBD Issuers, the Dealer Managers, the Exchange Agent (as defined below), the Information Agent (as defined below), the trustees under each of the indentures governing the Offer Notes, the trustee or collateral agent under the indenture that will govern the notes to be issued in the Exchange Offers, or any affiliate of any of them makes any recommendation as to whether any holder of Offer Notes should tender or refrain from tendering all or any portion of the principal amount of such holder's Offer Notes for cash or notes to be issued in the Exchange Offers. No one has been authorized by any of them to make such a recommendation. Holders must make their own decision whether to tender Offer Notes in any Offer and, if so, the amount of Offer Notes to tender.
Only Eligible Holders may receive a copy of the Offering Memorandum and participate in the Exchange Offers. Paramount has engaged Global Bondholder Services Corporation to act as the exchange agent (in such capacity, the "Exchange Agent") and information agent (in such capacity, the "Information Agent") for the Offers. Questions concerning the Offers, or requests for additional copies of the Offer to Purchase or Offering Memorandum or other related documents, may be directed to Corporate Actions by telephone at (855) 654-2014 (U.S. toll-free) or (212) 430-3774 (banks and brokers) or by email at [email protected]. Holders should also consult their broker, dealer, commercial bank, trust company or other institution for assistance concerning the Offers. The Exchange Offer documents and the Tender Offer documents can be accessed at the following link: https://gbsc-usa.com/paramount.
Paramount has engaged BofA Securities and Citigroup as dealer managers (in such capacity, the "Dealer Managers") for the Offers. Holders with questions regarding the Offers should contact BofA Securities, Inc. at +1 (888) 292-0070 (toll-free) or +1 (980) 388-3646 (collect) or [email protected] or Citigroup Global Markets Inc. at +1 (800) 558-3745 (toll-free) or +1 (212) 723-6106 or [email protected]. Latham & Watkins LLP is serving as legal counsel to Paramount and Cahill Gordon & Reindel LLP is serving as legal counsel to the Dealer Managers.
This press release is for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, any security, and does not constitute an offer, solicitation, or sale of any security in any jurisdiction in which such offer, solicitation, or sale would be unlawful.
About Paramount, a Skydance Corporation
Paramount, a Skydance Corporation is a next-generation global media and entertainment company, comprised of three business segments: Studios, Direct-to-Consumer, and TV Media. PSKY's portfolio unites legendary brands, including Paramount Pictures, Paramount Television, CBS, CBS News, CBS Sports, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount+, Pluto TV, and Skydance Animation, Film, Television, Interactive/Games, and Paramount Sports Entertainment.
This communication contains "forward-looking statements" regarding the Acquisition and the other transactions referred to herein. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Paramount. Risks and uncertainties include, but are not limited to: the risk that the closing conditions for the Acquisition will not be satisfied, including the risk that clearances under applicable antitrust or regulatory laws will not be obtained or will be obtained subject to conditions that are not anticipated; the possibility that the transactions described herein will not be completed in the expected timeframe or at all; the occurrence of any event, change or other circumstances that could give rise to the termination of the Acquisition; potential adverse effects to the businesses of Paramount or WBD during the pendency of the Acquisition, such as employee departures or distraction of management from business operations; negative effects of the announcement or the consummation of the Acquisition on the market price of WBD or Paramount stock; the risk of stockholder litigation relating to the Acquisition, including resulting expense or delay; the potential that the expected benefits and opportunities of the Acquisition, if completed, may not be realized or may take longer to realize than expected; risks related to the streaming business of the post-Acquisition combined business (the "Combined Company"); the adverse impact on the Combined Company's advertising revenues as a result of changes in consumer behavior, advertising market conditions, and deficiencies in audience measurement; risks related to operating in highly competitive and dynamic industries; the unpredictable nature of consumer behavior, as well as evolving technologies and distribution models; risks related to the Combined Company's decision to invest in new businesses, products, services, and technologies, and the evolution of the Combined Company's business strategy; the potential for loss of carriage or other reduction in, or the impact of negotiations for, the distribution of the Combined Company's content; damage to the Combined Company's reputation or brands; losses due to asset impairment charges for goodwill, content and long-lived assets, including finite-lived intangible assets; liabilities related to discontinued operations and former businesses; increasing scrutiny of, and evolving expectations for, sustainability initiatives; evolving business continuity, cybersecurity, privacy and data protection and similar risks; challenges in protecting and maintaining the Combined Company's intellectual property rights; domestic and global political, economic and regulatory factors affecting the Combined Company's business generally or the Acquisition; the inability to hire or retain key employees or secure creative talent; disruptions to the Combined Company's operations as a result of labor disputes; risks and costs associated with the integration of, and Paramount's ability to integrate, the businesses of Paramount Global, Skydance Media, LLC, and WBD successfully and to achieve anticipated synergies, including in the amounts or on the timelines anticipated to realize such synergies; litigation related to the Acquisition and other matters or transactions; risks associated with the Combined Company's holding company structure, including its dependence on distributions from its subsidiaries to meet tax obligations and other cash requirements; risks related to our indebtedness, including our substantial outstanding debt obligations, our ability to incur substantially more debt and our ability to meet the financial and other covenants contained in the agreements governing the indebtedness of Paramount, WBD, or the Combined Company. A further list and description of these risks, uncertainties and other factors and the general risks associated with the respective businesses of Paramount and WBD can be found in Paramount's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 25, 2026, including in the sections captioned "Cautionary Note Concerning Forward-Looking Statements" and "Item 1A. Risk Factors," Paramount's most recently filed Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 4, 2026, including in the sections captioned "Cautionary Note Concerning Forward-Looking Statements" and "Item 1A. Risk Factors," and Paramount's subsequent filings with the SEC, and in WBD's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 27, 2026, including in the section captioned "Item 1A. Risk Factors," WBD's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 6, 2026, and WBD's subsequent filings with the SEC. Neither Paramount nor WBD undertakes to update any forward-looking statement as a result of new information or future events or developments, except as required by law.
Šéf Rivian varuje, že automobilky soustředěné na zisk z benzinových aut budou na konci dekády technologicky pozadu. Klíčová je podle něj investice do softwaru a elektromobilů.
Carmakers that focus on selling fossil fuel engines are at risk of being “woefully behind” on technology by the end of the decade, according to the boss of Rivian, an Amazon-backed US electric carmaker.
RJ Scaringe, Rivian’s founder and chief executive, said the car industry has reached a “fork in the road” in the choice between short-term profits and the heavy investments, particularly in software, that will be required to survive.
In an interview this month in London, he said many have chosen profits, ramping up the production of petrol or hybrid pickup trucks and SUVs in the US and Europe.
Much of the automotive industry in the US and Europe has lobbied to slow the transition to electric vehicles, favouring instead polluting but profitable cars with internal combustion engines.
The retreat has been particularly striking in the US, where Donald Trump’s administration has gutted incentives to produce and buy EVs. Ford, General Motors, Honda, Stellantis and Volkswagen, all of which have large US operations, have collectively written off more than $70bn (£53bn) from their previous EV investments, according to Reuters.
Workers on the production line at Rivian’s headquarters in California. Photograph: Bloomberg/Getty ImagesScaringe said the decisions to focus on profitable petrol cars could come back to haunt manufacturers.
He said: “That looks really good financially for 2026, 2027, maybe even 2028. But as you get to the end of the 2020s and into the 2030s, I think we’re going to find a lot of companies are unfortunately woefully behind in terms of their technology.”
The turn against EVs has led to uncertainty over demand for Rivian, which has just started deliveries of its R2 SUV in the US. The car is “make or break” for the company as it tries to turn a profit for the first time, Scaringe said.
RJ Scaringe says focusing on the profitable petrol cars could come back to haunt manufacturers. Photograph: Kimberly White/Getty Images for RivianRivian was founded in 2009, and delivered its first electric vehicle in 2021, the same year as it floated on the stock market.
Rivian lost $3.6bn in 2025 amid heavy investment in the R2 and in autonomous driving abilities. After its market value soared above $100bn at its initial public offering, the carmaker has dropped back to $21bn – although Scaringe could be in line for share awards worth as much as $5bn if he can push the share price to targets well above its all-time high.
Rivian lost $3.6bn in 2025 amid heavy investment in the R2 and in autonomous driving abilities. Photograph: RivianScaringe said the “the more damaging and more dangerous aspect” of the turn against EVs was not the delayed transition from petrol engines to batteries but rather the failure to develop the software that increasingly controls every aspect of the vehicle.
He said petrol cars were stuck with a design that scatters computer chips throughout the car – from the engine to the seats and wing mirrors – rather than a centralised architecture that can be easily modified. Relying instead on a single computer reduces production costs by “thousands of dollars”, Scaringe said.
Rivian’s heavy investment in digital technology and software has at least partly paid off. Alongside the Amazon investment, which includes a deal for up to 100,000 delivery vans, Rivian and Germany’s Volkswagen agreed a $5.8bn electric tech and software joint venture in 2024, and Uber invested $1.25bn in a deal that could also lead to the sale of 50,000 robotaxis.
Scaringe said Rivian could help to increase the take-up of EVs in the US despite the White House backlash. Electric cars made up 7.8% of all US car sales in 2025, and Scaringe said the R2 alone could eventually increase the market share by three or four percentage points.
“The objective is to be a very large company” with annual sales in the millions, Scaringe said.
Scaringe said he was sceptical of carmakers’ claims that buyers do not want EVs, but rather that the dominance of Tesla’s Model 3 saloon car and Model Y SUV in the US was a “sign of a market starved for great choices”. Chinese carmakers dominate the global EV industry but are locked out of the US by prohibitive tariffs.
Rivian is also aiming to sell the R2 in the UK and mainland Europe, although that will not happen for at least a year.
DOMA Perpetual Capital Management odmítá nabídku na odkup InMode za 16,20 USD za akcii a plánuje hlasovat proti obchodu. Tvrdí, že cena společnost podhodnocuje.
DOMA Perpetual Capital Management LLC (PRNewsfoto/DOMA Perpetual) DOMA ASSERTS THAT THE $16.20 PER SHARE OFFER MATERIALLY UNDERVALUES INMODE AND ITS LONG-TERM POTENTIAL
DOMA BELIEVES THE BID EXPLOITS THE DEPRESSED VALUATIONS CREATED BY YEARS OF CEO-LED UNDERPERFORMANCE
DOMA EXPLICITLY REJECTS THE CURRENT TERMS AND URGES THE BOARD TO UPLHOLD ITS FIDUCIARY DUTIES
, /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board").
The letter can be downloaded here
The full text of the letter follows:
June 26, 2026
To the Board Member of InMode:
As of the date of this letter, DOMA Perpetual Capital Management LLC ("DOMA") and its affiliates beneficially own approximately 4.63% of the outstanding ordinary shares of InMode Ltd. ("InMode" or the "Company").
We are writing as a concerned shareholder regarding the recently proposed acquisition of the Company led by the Chief Executive Officer in partnership with a group of investors. The circumstances surrounding this proposal raise serious concerns about conflicts of interest, governance, the Board's fiduciary responsibilities, and the fairness of the proposed transaction.
We believe the proposal materially undervalues the Company, particularly in light of its long-term potential and intrinsic assets. It is difficult to ignore that this proposal also follows a long period of operational underperformance under the current CEO's leadership. We have previously asked the Board, in a public communication dated May 9, 2025, to replace the CEO precisely because of his sustained underperformance, and that same CEO now appears positioned to benefit from the proposed transaction.1 In our view, these circumstances warrant close scrutiny, and DOMA reserves all of its rights in connection with the proposed transaction.
We strongly believe the proposal would allow management to capitalize on a depressed valuation that developed during its own stewardship and that, in our view, management's performance helped create. Such dynamics are deeply troubling from a governance perspective.
The Board has fiduciary obligations to act in the best interests of all shareholders, not management or any specific investor group. In this context, we urge the Board to take the following actions:
Establish a fully independent special committee with no ties to management to evaluate the proposal. Retain international independent financial and legal advisors to conduct a rigorous valuation and fairness assessment. Conduct a broad and transparent market check inviting public offers to determine whether superior offers exist. Ensure that shareholders are provided with full and fair disclosure regarding the process, assumptions, and any potential conflicts of interest. Any transaction that allows insiders to acquire the Company at a price influenced by their own stewardship must be subject to the highest level of scrutiny. Failure to do so could expose the Company and the Board to significant shareholder value destruction, as well as reputational and legal risk.
Shareholders rely on the Board to uphold strong governance standards and to protect against precisely this type of conflicted transaction. I trust that you will take these responsibilities seriously and act accordingly.
At the current offer of $16.20/share DOMA does not support the proposal and intends to vote against the transaction.
Sincerely,
Pedro Escudero
CEO & CIO
DOMA Perpetual Capital Management LLC
This letter has been prepared by DOMA. The views expressed herein reflect DOMA's opinions and are based on publicly available information regarding the Company. DOMA recognizes that the Company or others may have information not available to DOMA that could lead them to disagree with DOMA's views or conclusions. DOMA reserves the right to change or modify its views, opinions, intentions, or positions at any time and for any reason, and disclaims any obligation to update or revise the information contained herein, except as may be required by applicable law.
This letter was not prepared by, and has not been endorsed by, InMode Ltd. This letter is provided for informational purposes only and is not intended to be, and should not be construed as, an offer to sell or a solicitation of an offer to buy any security, or as a recommendation to purchase or sell any security. DOMA is not currently soliciting proxies, consents, authorizations, or voting commitments with respect to any securities of the Company. One or more funds managed by DOMA currently beneficially own shares of the Company.
Certain statements in this letter may constitute forward-looking statements. These statements reflect DOMA's current views and expectations, speak only as of the date hereof, and are subject to risks, uncertainties, and assumptions that could cause actual results or developments to differ materially from those expressed or implied.
PR Newswire, May 9, 2025, DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Resume Share Repurchase Program (urging the Board, among other actions, to replace the Chief Executive Officer), https://www.prnewswire.com/news-releases/doma-perpetual-sends-letter-urging-board-of-directors-of-inmode-ltd-to-resume-share-repurchase-program-302451097.html SOURCE DOMA Perpetual
Biogen po akvizici Apellis za 5,6 miliardy USD pozastavil nebo ukončil financování většiny výzkumných programů a zrušil část míst ve výzkumu. Firma přesouvá zdroje k Empaveli a Syfovre.
Biogen logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab
CompaniesJune 26 (Reuters) - Biogen (BIIB.O), opens new tab said on Friday it had either paused or discontinued funding for most of Apellis Pharmaceuticals' research programs as it integrates the rare-disease drugs specialist it purchased for $5.6 billion earlier this year.
The U.S. drugmaker has also cut a small number of roles within the research organization as it shifts resources toward Empaveli and Syfovre, the approved therapies acquired through the deal.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
"As part of the integration of Apellis, Biogen is conducting a comprehensive review of the former Apellis clinical & preclinical portfolio to further evaluate strategic fit," a Biogen spokesperson said.
The company did not offer details on the number of roles or the specific programs impacted by the decision.
Biogen has suspended two trials evaluating Empaveli in two separate kidney-related conditions, according to updates posted earlier this month on the U.S. government's clinical trials database.
The Apellis deal, Biogen's largest since its 2023 buyout of Reata Pharmaceuticals, is expected to support the company's near-term growth as demand for its key multiple sclerosis franchise declines and sales of Alzheimer's drug Leqembi lag expectations.
Empaveli is approved for two rare kidney diseases and a rare blood disorder while Syfovre is authorized to treat geographic atrophy, an advanced eye condition that is a leading cause of blindness.
The two drugs generated a combined revenue of about $689 million last year and are expected to grow at a mid-to-high-teens rate at least through 2028, the companies had said when the deal was announced in March.
Reporting by Mariam Sunny in Bengaluru; Editing by Sriraj Kalluvila
Our Standards: The Thomson Reuters Trust Principles., opens new tab
First Graphene dokončila akvizici americké MITO® Material Solutions a posiluje expanzi v USA. Do firmy zároveň nastupuje CEO MITO® Haley Marie Keith jako viceprezidentka pro business development.
First Graphene Ltd (ASX:FGR, OTCQB:FGPHF, FRA:M11) earlier this week confirmed it had completed the acquisition of USA-based MITO® Material Solutions, with managing director and CEO Michael Bell telling Proactive the transaction had moved quickly and gave the company a stronger commercial platform in the United States.
Bell said First Graphene completed the deal within “sort of five or six days” of signing the agreement, describing the rapid turnaround as a reflection of the motivation shown by both teams. He said it was “a testament to both our team and the MITO® team being pretty motivated to get the deal across the line”.
The acquisition also brings MITO® Material Solutions chief executive officer Haley Marie Keith into First Graphene Ltd (ASX:FGR, OTCQB:FGPHF) as vice president of business development. Bell said Keith would lead US business operations, business development, commercial activity and promotion from Indiana.
For investors, the appointment appears to be an important catalyst in the company’s US expansion strategy. Bell said Keith brought “a huge amount of experience” in the US market, composites and the MITO® Material Solutions portfolio. He described her appointment as “a fairly clear line in the sand” that showed First Graphene Ltd was committed to growing its US business.
Bell said the scale of the US market required a focused approach. Drawing on previous experience, he said companies could not assume one person could represent a business across the entire country, noting that the market was vast and often required a state-by-state focus.
The company is initially looking at opportunities across aerospace, transportation and defence, although Bell said those sectors were likely to move more slowly. In the near term, First Graphene Ltd also intends to build on MITO® Material Solutions’ validation work in commercial sporting goods, where the acquired business already has clients.
Revenue growth and pipeline development were also highlighted. Bell said First Graphene Ltd had recently expanded from five new clients to six, with another footwear company coming across the line in recent days. He added that the time taken to move customers from inquiry to execution or production was speeding up.
Bell said the company had a pipeline approaching 700 opportunities, ranging from early-stage discussions to projects that had been in development for up to three years. He also pointed to a nearer-term group of around 30 to 40 potential clients in areas such as marketing releases and regulatory approvals, which he said could become contributors to revenue over the next six months.
Interview highlights First Graphene Ltd has completed the acquisition of USA-based MITO® Material Solutions within about five or six days of signing the agreement. Michael Bell said the fast completion reflected strong motivation from both the First Graphene Ltd and MITO® Material Solutions teams. MITO® Material Solutions chief executive officer Haley Marie Keith has joined First Graphene Ltd as vice president of business development. Keith will support US business operations, business development, commercial activity and promotion from Indiana. Bell said Keith brings significant experience in the US market, composites and the MITO® Material Solutions portfolio. First Graphene Ltd sees the appointment as a “line in the sand” showing its commitment to expanding in the United States. The company is targeting opportunities across aerospace, transportation, defence and commercial sporting goods. Bell said MITO® Material Solutions has already validated products in commercial sporting goods, giving First Graphene Ltd a base to grow from. First Graphene Ltd has added a sixth client in recent months, including another footwear company. The company has a pipeline approaching 700 opportunities, with 30 to 40 potential clients in later-stage areas such as marketing releases and regulatory approvals.
Proactive: Welcome back to Proactive Investors. I’m your host, Kerry Stevenson. I’ve asked Michael Bell to come back. He is the managing director and CEO of First Graphene Ltd, ASX code FGR. The reason I’ve asked Michael back is that the last time I had him on, which was only a couple of weeks ago, we were talking about the acquisition of MITO® Material Solutions. That has now closed. The deal is done, but First Graphene Ltd has also made its first hire in the United States. This looks like rapid global expansion. Michael, congratulations on closing the deal. We talked about the deal last time. Talk to us about closing the deal. It was a pretty quick turnaround.
Michael Bell: Yes, we managed to get it closed within sort of five or six days from signing the agreement. It was really a testament to both our team and the MITO® team being pretty motivated to get the deal across the line and get into it. We got it wrapped up the other week, and we also made our first hire as part of that deal.
Haley Marie Keith, who is the CEO of MITO® Material Solutions, has come across to First Graphene Ltd. She will head up our business operations, business development, commercial and promotion within the United States. She is based out of Indiana and brings a huge amount of experience in both the US market and composites, but also the MITO® portfolio. She will really help us drive that forward.
It is also a fairly clear line in the sand of our intent to grow the US business. There is huge opportunity there. As we immerse ourselves more, both in the MITO® materials as well as the First Graphene PureGRAPH line, we start to understand the true potential of the United States. It is a line in the sand saying we are committed to growing that side of the business.
Proactive: Is the US market a tough one to break into, Michael? I know it is a big market. It is huge, isn’t it?
Michael Bell: It is big. I have had previous experience of trying to grow businesses in the United States out of a company that I was a partner in, in New Zealand. That taught us some very hard lessons in terms of the size of the market. Where you think one person can represent you across the United States, you need to focus on a state basis because the market is so vast.
How I apply that to Haley Marie Keith is that she has a big role and a very broad opportunity. It will take some really critical focus on certain applications, certain client bases and so on.
Proactive: Talking about focus, are you going to focus more on government or are you going to focus more on private?
Michael Bell: It is a good question. The products that we have acquired from MITO® Material Solutions, and the ones that we see proving the most successful and having the fastest timeline, would be aerospace, transportation and defence. Those are probably slower-moving industries.
What MITO® Material Solutions has done is take its products and validate them in the commercial sporting goods segment. It has clients in those spaces and we have a pipeline to expand that. We will probably continue focusing on that, pushing that and growing the sporting goods side, while at the same time advancing the pipeline that MITO® Material Solutions has established in bigger industries like aerospace, transportation and defence.
Proactive: Before we finish up, it is important for our audience and investors to know that First Graphene Ltd has a very full pipeline, which means growth is happening. The company also already has revenue generation. What is that looking like?
Michael Bell: It is strong. It is growing. We mentioned previously, I think in our last call, that we had added five clients in the last couple of months. That has now expanded into a sixth client. We got another footwear company across the line just in the last few days.
That tax rate, or that time to get people from inquiry to executing or getting it into production, is speeding up. We have a big pipeline, somewhere up towards 700 different opportunities, somewhere between a week and three years deep in development. We have also got that really good next wave of clients, sort of 30 or 40 of them, that are in marketing releases, regulatory approvals and that sort of phase. Those are coming on and are our next contributors to revenue over the next six months.
Proactive: The US market is a major focus. MITO® Material Solutions has now been acquired, and the deal is done. More importantly, MITO® Material Solutions CEO Haley Marie Keith is joining First Graphene Ltd as vice president of business development as the company strikes out into a big US market. First Graphene Ltd’s ASX code is FGR. Michael is taking strides to expand and First Graphene Ltd is generating revenue. Michael, good to chat. Talk to you next time.
Arista Networks ve fiskálním 1. čtvrtletí roku 2026 zvýšila tržby o 35,1 % na 2,71 miliardy USD a zvedla výhled tržeb na 11,5 miliardy USD. Z AI má letos přijít 3,5 miliardy USD, tedy více než dvojnásobek oproti loňsku.
Networking company Arista Networks, Inc. (ANET) up 3,218% since 2015’s first outlier inflow.
ANET’s programmable networking equipment and low-latency switch solutions help many of the world’s largest organizations run their cloud and AI networks. The company’s first-quarter fiscal 2026 report showed $2.71 billion in quarterly revenue (up 35.1% year-over-year), diluted per-share earnings of $0.87 (a 31.8% gain), and raised 2026 revenue guidance to $11.5 billion (representing 27.7% annual growth), with $3.5 billion coming from AI (more than double the prior year).
No wonder ANET shares are up 26% so far this year – and they could rise more. MoneyFlows data shows how Big Money investors are again betting heavily on the stock.
Arista Networks Being Bought Institutional volumes reveal plenty. In the last year, ANET has enjoyed strong investor demand, which we believe to be institutional support.
Each green bar signals unusually large volumes in ANET shares. They reflect our proprietary inflow signal, pushing the stock higher:
Source: www.moneyflows.com Plenty of technology names are under accumulation right now. But there’s a powerful fundamental story happening with Arista Networks.
Arista Networks Fundamental Analysis Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, ANET has had strong sales and earnings growth:
Also, EPS is estimated to ramp higher this year by +22.7%.
Now it makes sense why the stock has been generating Big Money interest. ANET has a track record of strong financial performance.
Marrying great fundamentals with MoneyFlows software has found some big winning stocks over the long term.
Arista Networks has been a top-rated stock at MoneyFlows for years. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.
It’s had 90 Big Money outlier inflow signals since 2015 and is up 3,218% since then. The blue bar below shows when ANET was a top pick in the last year…institutions keep supporting gains:
Source: www.moneyflows.com Tracking unusual volumes reveals the power of money flows.
This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.
Arista Networks Price Prediction The ANET action isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.
Disclosure: the author holds no position in ANET at the time of publication.
If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level and follow our free weekly MoneyFlows insights.
H&R Block zvýšil čtvrtletní dividendu na 0,42 USD z 0,375 USD a zvedl výhled na upravený EPS pro FY2026 na 5,10 až 5,20 USD. Tržby ve 3. čtvrtletí vzrostly o 5,31 % na 2,40 miliardy USD.
Joel Greenblatt’s Magic Formula ranks stocks on two factors: earnings yield (EBIT divided by enterprise value) and return on capital. It surfaces good companies trading at cheap prices.
For retirees, “cheap and high-quality” is only the starting point. Income reliability, drawdown control, and earnings predictability matter as much as a low multiple. Here is a look at how three Magic Formula candidates stack up, ranked from least to most appropriate for a retirement portfolio.
3. Peabody Energy Peabody Energy (NYSE: BTU | BTU Price Prediction) screens as the deep-value, optionality-rich name Greenblatt enthusiasts love. Shares closed most recently at $23.69, with a price-to-book ratio of 0.85 and a forward P/E near 22x. The one-year return of 83.8% reflects renewed enthusiasm for coal tied to AI data-center power demand.
The retirement case breaks down on consistency. Q1 FY26 produced an EPS of −$0.26 versus a $0.22 estimate, a −218% earnings surprise, after Centurion mine commissioning issues caused roughly $80 million of damage to the Seaborne Met segment. CEO Jim Grech cited “temporary equipment and roof control challenges.” The $0.075 quarterly dividend has held since Q3 2023. However, the historical record shows cuts from $0.145 to $0.115 during the 2018 downturn and losses from 2015 through 2020. Cyclical coal is a trade, rarely a retirement holding.
2. Molina Healthcare Molina Healthcare (NYSE: MOH) is the classic Magic Formula recovery setup. The managed-care operator trades at a forward P/E of 38x against trailing revenue of $43.1 billion. Shares rebounded 24.5% year to date to $216.04, though that still is 26.6% below year-ago levels.
Q4 2025 delivered an ugly adjusted EPS of −$2.75 against a $0.50 estimate, but Q1 2026 turned with reported EPS of $2.35 versus $1.91 expected, a 23.04% beat. CEO Joseph Zubretsky stated: “We believe that the imbalance between rates and trend marks 2026 as a trough year for Medicaid industry margins.” Management guides to at least $5.00 in adjusted EPS for 2026, burdened by Florida contract costs and MAPD underperformance, with embedded earnings above $11.00 by 2027 to 2029.
For retirees, the problem is income. Molina pays no dividend, regulatory risk on Medicaid rates is real, and operating cash flow turned negative $535 million in FY2025. It is a value bet on a regulated turnaround that offers no income while investors wait..
1. H&R Block H&R Block (NYSE: HRB) is the cleanest fit for the Magic Formula and retirement portfolios. The tax-prep franchise trades at a trailing P/E of 6x and forward P/E of 6x, with a return on equity of 67.9% and an operating margin of 43.2%. That combination of a low multiple and high capital returns is precisely what Greenblatt targets.
Q3 FY26 results were strong: adjusted diluted EPS of $6.02 beat the $5.77 estimate, revenue of $2.40 billion grew 5.31% year over year, and net income rose 17.51%. Management raised FY2026 guidance to adjusted EPS of $5.10 to $5.20 on roughly $3.91 billion to $3.92 billion in revenue. CEO Curtis Campbell called the quarter “an important inflection point” as the assisted channel gained share for a third consecutive year.
Capital return crystallizes the retirement thesis. The quarterly dividend stepped up to $0.42 from $0.375, extending a 60-year streak of consecutive quarterly dividends. The board added an additional $100 million buyback authorization on top of the roughly $700 million remaining under the existing $1.5 billion program. Year-to-date capital returns reached $560.9 million. The dividend held flat through both the 2008 crisis and the 2020 pandemic. With a beta of 0.37 and a 4.7% yield, the volatility profile matches what an income-focused investor needs, though seasonal revenue concentration and AI-native tax competition remain genuine risks.
Bringing the Formula Back to Retirement Greenblatt’s framework surfaces all three names as cheap businesses generating real returns on capital. The retirement filter separates them. Peabody is a commodity play masquerading as a value stock. Molina is a regulated turnaround with no income to collect during the wait. H&R Block pairs a high-margin, cash-generative franchise with the longest dividend history in this group and a management team that is actively shrinking the share count. For a retiree using the Magic Formula as a starting point, H&R Block stock survives the second screen.
KULR prodloužila pozastavení programu ATM emise akcií do 30. září 2026. Firma chce růst financovat hotovostí a případně prodejem Bitcoinu, aby se vyhnula ředění.
HOUSTON, June 26, 2026 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the "Company" or "KULR"), a developer of safe, high-power energy systems that enable physical AI across space, defense, drones, data centers, robotics, and other mission-critical applications, today announced that, as part of its non-dilutive growth strategy, it has extended the pause of its at-the-market (“ATM”) equity offering program with Cantor Fitzgerald and Craig-Hallum through September 30, 2026.
KULR expects its existing liquidity, together with disciplined balance-sheet management, to support its planned operations and growth initiatives. Rather than issue equity under the ATM at current levels, the Company may, from time to time, sell its Bitcoin holdings to fund the following priorities:
Scale its flagship KULR ONE Space (K1S) architecture providing scalable, standardized battery solutions that meet rigorous human spaceflight safety standards.
Ramp production of its KULR ONE Air products for military and commercial drone applications.
Advance the development of its KULR ONE MAX battery backup solutions for AI data center and telecommunications applications.
"We do not intend to issue equity at these levels when we have more disciplined ways to fund our growth,” commented KULR Founder and CEO Michael Mo. “Keeping the ATM paused protects our shareholders from dilution and keeps our focus where it belongs -- building more batteries and getting them to customers.”
During this period, the Company intends to prioritize execution across its core platforms which was detailed in Mr. Mo's recent letter to shareholders.
About KULR Technology Group, Inc.
KULR Technology Group, Inc. (NYSE American: KULR) is an energy-systems platform company that designs and manufactures safe, high-power battery solutions for physical AI and other mission-critical applications. Its KULR ONE® platform integrates advanced battery architecture, thermal management, safety engineering, battery management systems, and power electronics to serve space and defense, drones and electric aviation, AI data-center backup, robotics, and Energy-as-a-Service markets. Based in Webster, Texas, KULR is scaling domestic production to support the growing energy demands of physical AI and autonomous systems. Learn more at KULR.ai.
Investor Relations:
KULR Technology Group, Inc.
Phone: 858-866-8478 x 847
Email: [email protected]
Safe Harbor Statement
This release contains certain forward-looking statements based on our current expectations, intentions and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our Form 10-K filed with the Securities and Exchange Commission on March 31, 2026, as may be amended or supplemented by other reports we file with the Securities and Exchange Commission from time to time. Forward-looking statements include statements regarding our expectations, beliefs, intentions, or strategies regarding the future and can be identified by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” and “would” or similar words. All such forward-looking statements that are provided by management in this release are based on information available at this time, and management expects that internal expectations may change over time. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Except as otherwise required by applicable law, we assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise.
SpaceX se po pátečním uzavření obchodování přidá do indexů Russell, což může vyvolat nákupy za téměř 3 miliardy USD a zvýšit volatilitu akcie. Titul už po vstupu na burzu prudce kolísá.
SpaceX logo as an employe looks at his phone while making his way to work at the company’s facility on the day of the SpaceX IPO, in Hawthorne, California, U.S. June 12, 2026. REUTERS/Mike... Purchase Licensing Rights, opens new tab Read more
June 26 (Reuters) - Even by SpaceX (SPCX.O), opens new tab standards, Friday is shaping up as an eventful trading session as investment funds tracking Russell indexes prepare to add billions of dollars' worth of Elon Musk's internet and rocket company to their holdings.
After a blockbuster initial public offering this month, SpaceX's stock has been on a wild ride, soaring 67% to its June 16 intraday high of $225.64 before tumbling to Thursday's $153 close.
The Reuters Inside Track newsletter is your essential guide during the World Cup. Sign up here.
The stock remains well above the $135 IPO price as investors assess how to value a company that lost $4.9 billion last year, but that backers expect to dominate the satellite internet, AI and commercial space launch markets that they believe will define the next decade of global infrastructure.
FTSE Russell will add SpaceX to its Russell U.S. indexes after Friday's close of trading as part of its semi-annual index reconstitution. That means passively managed exchange-traded funds that track Russell indexes, such as the iShares Russell 1000 ETF (IWB.P), opens new tab, will have to add SpaceX shares to their portfolios. The event will likely take place in a narrow window toward market close on Friday as fund managers attempt to minimize the "tracking error" between their funds' performance and the index that can result if their buy-in price differs from the closing price.
While SpaceX's $2 trillion market capitalization makes it almost as valuable as Amazon (AMZN.O), opens new tab, only about $100 billion of shares have been listed for trading on the stock market, with the rest owned by Musk, other insiders and employees. Passively managed funds will need to buy almost $3 billion worth of SpaceX shares to match the Russell indexes they track, Jefferies estimated in a report this month. That could mean a squeeze as Friday's closing auction approaches, though options positioning appeared muted.
SpaceX options contracts set to expire on Friday are priced for a share price swing of 3.6% in either direction by the end of the week, Trade Alert data showed.
SpaceX is also set to be added to the tech-heavy Nasdaq 100 (.NDX), opens new tab in July, an event that will force large index funds such as the Invesco QQQ ETF, which tracks that index, to buy its shares.
Following its losses in recent sessions, SpaceX is trading at 107 times its 2025 sales, an astronomical valuation. By comparison, AI heavyweight chipmaker Nvidia (NVDA.O), opens new tab recently traded at 21 times sales.
S&P Global blocked SpaceX from joining the S&P 500 index (.SPX), opens new tab after it said this month it would not change its inclusion criteria to accommodate megacap IPOs. To be included in the S&P 500, a company must be profitable in its most recent quarter as well as for the sum of its most recent four quarters, according to one of the rules S&P left unchanged.
The S&P 500 addition in 2020 of another Musk company, Tesla (TSLA.O), opens new tab, resulted in a closing squeeze that sent shares up 6%.
Reporting by Noel Randewich in San Francisco and Saqib Iqbal Ahmed in New York; editing by Colin Barr, Rod Nickel
Our Standards: The Thomson Reuters Trust Principles., opens new tab
San Francisco correspondent covering the stock market with a focus on Big Tech, semiconductors and other Silicon Valley companies
SpaceX po IPO zažívá prudké výkyvy, když akcie po úvodním růstu o více než 60 % následně spadly až o 16 %. Retailoví investoři v prvních pěti obchodních seancích nakoupili čistě za 405 milionů USD.
This report is from this week's The Tech Download newsletter. Like what you see? You can subscribe here.
Rollercoaster. That's probably the most accurate word to describe SpaceX's opening two weeks as a public company.
The stock surged for several successive days following a record-breaking IPO, briefly overtaking both Amazon and Microsoft in terms of market cap and rising more than 60% on the initial share offering price of $135.
But the good times weren't set to last. Daily drops of 5% and 4% were followed by a 16% slump as jitters crept into the market. Steadier days followed, with single point moves in either direction.
The volatility underscores the whipsaw nature of a story-driven stock.
Lofty sci-fi ambitions, huge coverage in the *ahem* media and a founder with a cult-like following whipped up a frenzy of excitement around the company.
"Most stocks trade based on how their multiple of earnings compares to other comparable stocks," Gil Luria, head of technology research at D.A. Davidson, told me.
"Elon Musk companies don't really do that." Musk's ventures instead trade on expectations, he added.
"Tesla trades more on [autonomous driving service] Robotaxi and [humanoid robot] Optimus than they do on selling cars, and SpaceX trades more on the promise of Mars exploration, or at least data centers in space," said Luria.
Retail investors bought into that forward-looking narrative in droves.
SpaceX "embodies many of the qualities that have historically resonated with retail investors: a transformational technology story, a bold vision of the future, a celebrity founder and unparalleled media attention," Viraj Patel, global macro strategist at Vanda, said.
In the first five trading sessions, retail investors bought a net $405 million of SpaceX shares, comfortably the strongest retail IPO debut in recent history, said research firm Vanda.
"For SpaceX, the 'cult of Elon' pulls in more retail investors and adds extra hype that can add a lot to volatility as we saw with Tesla share prices," Mike Coop, chief investment officer, EMEA at Morningstar Wealth, told me. Morningstar analysts caused a stir in the run-up to SpaceX's IPO, writing that the stock was worth less than half of its $1.75 trillion target.
After a bullish initial few days on the public markets, fundamentals became a bigger driver of the price causing a "hangover," said Kyle Rodda, senior market analyst at Capital.com.
Musk has been, in a somewhat predictable fashion, touting sky-high revenue growth in years to come. He said on June 14 that the company "might be able to reach approximately" $1 trillion revenue in 2030.
That would mark a huge jump from the $18.7 billion in revenue SpaceX made in 2025. The company posted a $4.9 billion net loss in 2025, and it lost $4.28 billion in the first quarter of this year.
Long term SpaceX faces two big challenges on the markets, said Coop.
"Firstly, the supply of shares will go up as early investors lighten up exposures and monetise gains," he said.
"Secondly, the current price is too high given the massive uncertainty around the company's prospects and its starting point of being heavily loss making and requiring huge capital investment."
Despite that, so far few have been willing to bet against the stock.
Michael Burry of "The Big Short" fame said on June 16 that he has no position in SpaceX, and argued that options used to wager against the stock remain too expensive even as he questioned the company's nearly $3 trillion market value.
And while SpaceX is seeing some interest from short sellers, many are still reluctant to bet against Musk.
Time will tell how far narrative takes SpaceX stock. In any case, expect more twists and turns on the rollercoaster.
Latest updatesAnthropic is racing to increase its AI compute capacity in the Asia-Pacific region, as the company scrambles to keep up with soaring demand for its products.
OpenAI and Broadcom on Wednesday unveiled their debut custom chip, called Jalapeño, marking the ChatGPT maker's first entry into artificial intelligence silicon.
A second worker has died at the construction site of BYD's electric vehicle factory in Szeged, Hungary, CNBC has learned.
Apple on Thursday announced price hikes on MacBooks and iPads, its first formal move to pass higher memory and storage costs on to consumers after CEO Tim Cook said increases had become unavoidable.
ON Semiconductor has agreed to buy Synaptics in a nearly $7 billion all-stock deal to bolster its push into physical artificial intelligence technology.
Stock of the week
Micron stock.
Memory chipmaker Micron had a good week as its third-quarter results topped analysts' estimates.
The U.S. company has been one of the main beneficiaries of the AI boom, with its stock price up more than 800% over the past year, lifting the company's market cap past $1 trillion.
Joaquin Duato vidí u Johnson & Johnson cestu k dvoucifernému růstu díky 28 platformám s tržbami přes 1 miliardu USD a investicím ve výši 55 miliard USD v USA během čtyř let.
Johnson & Johnson (JNJ +1.64%) is one of the most recognized names in the healthcare sector. It is a Dividend King with over 50 consecutive annual dividend increases and operates in both the pharmaceutical and medical device segments of the broader healthcare sector. And the company believes it has both the foundation and the opportunity to grow at double-digit rates. Here's what CEO Joaquin Duato wants you to know.
J&J has a broad foundation to build on J&J has 28 platforms generating $1 billion in revenue each, according to CEO Duato, who recently spoke to Fox News about his company's growth prospects. That's a powerful foundation for the company to support its research and development efforts. Notably, the company isn't reliant on just one segment of the broader healthcare sector, as it is a leader in both the drug and medical device segments.
Image source: Getty Images.
That said, a strong foundation isn't enough to support the CEO's double-digit growth projection. In fact, for a company as large as J&J, double-digit growth is hard to achieve. This is where a unique opportunity arises, with Duato highlighting changes in U.S. tax policies that will allow his company to invest more heavily in the United States. Over the next four years, J&J plans to invest $55 billion in its home market.
This healthcare giant is getting bigger and better Johnson & Johnson is so large that there's no single product or division that can be singled out as the main driver of its growth plans. That said, the first big investment was a "500,000 square foot, state-of-the-art biologics manufacturing facility" in North Carolina. This single facility is expected to further the company's opportunity in cancer, immune-mediated, and neurological diseases. And that's just the starting point for the company's $55 billion investment plan.
Today's Change
(
1.64
%) $
3.96
Current Price
$
244.96
J&J's outlook is basically pretty simple. It is an industry-leading company with an attractive investment opportunity ahead. And now it also has the tax policy to support increased investment in that growth opportunity. According to Duato, the end result will be double-digit growth.
Johnson & Johnson could be more exciting than you think If you are a dividend investor, you may want to take a second look at this Dividend King. J&J may be a reliable dividend stock, but that doesn't mean it will be a boring, slow-growth business. At least, that's what the CEO is trying to tell investors, if you are willing to listen.
BlackBerry oznámila v 1. čtvrtletí fiskálního roku 2027 růst tržeb o 26 % na 152,9 milionu USD a zvýšila celoroční výhled. Investory ale táhne hlavně příběh kolem physical AI a QNX.
This is a fair market value price provided by Massive. Learn more.
52-Week Range$3.12▼
$10.93P/E Ratio128.58
Price Target$7.17
BlackBerry Limited NYSE: BB delivered a Q1 fiscal 2027 earnings beat that impressed investors.
The June 25 report showed revenue surging 26% year-over-year to $152.9 million, well above the $139.8 million consensus.
Get BlackBerry alerts:
Adjusted earnings per share (EPS) of four cents topped the analysts’ estimate of three cents.
However, a double beat alone doesn’t explain BB’s nearly 20% post-earnings surge, or its more than 170% year-to-date rally.
The bigger story is about the company’s ongoing transformation. BlackBerry is now a pure-play software company with a real foothold in what many call AI's next leg: physical AI. The question for investors is whether the recent surge is too early or just the start of a longer rally.
BlackBerry Earnings Beat Shows Software Strategy Is WorkingAt a time when many technology stocks are being judged by a “what have you done for me lately?” standard, BlackBerry's latest earnings report gave the bulls a lot of ammunition. The numbers show that the company is converting its software pivot into durable profitability.
BlackBerry posted its fifth consecutive quarter of positive GAAP net income. Adjusted EBITDA grew 144% year-over-year. Both the QNX and Secure Communications segments achieved Rule of 40 performance, a benchmark that combines growth and margin into a single test of software-business quality. The company also generated $4.6 million in operating cash flow, marking its first positive operating cash flow quarter in nine years, excluding a prior patent sale.
Management raised full-year guidance to revenue of $594 million to $621 million and adjusted EPS between 16 cents and 20 cents.
How QNX Positions BlackBerry for the Physical AI Boom BlackBerry has fully exited handsets and now exclusively sells software. QNX, its real-time operating system, sits inside more than 275 million vehicles on the road today.
That installed base gives BlackBerry a strategic position in physical AI. Physical AI refers to systems where models drive real-world machines: autonomous vehicles, humanoid robots, surgical equipment and industrial automation. These applications need software that responds in microseconds with zero tolerance for failure.
This is where QNX shines. Its deterministic, safety-certified architecture is built for exactly these workloads. Cloud-trained AI must eventually run on certified embedded software when it touches the physical world, and that layer is QNX's value proposition.
The NVIDIA NASDAQ: NVDA partnership, which was announced at Hannover Messe in April, amplifies the opportunity. QNX OS for Safety 8.0 now integrates with NVIDIA's IGX Thor platform and Halos Safety Stack. The combination targets autonomous mobile robots, humanoids, surgical robotics, and industrial automation.
Those are categories NVIDIA CEO Jensen Huang has flagged as multi-trillion-dollar end markets. A separate design win with Chinese EV maker Leapmotor for its D19 SUV signals continued automotive traction even as QNX expands into new verticals.
Can BlackBerry's Valuation Support More Upside? After the post-earnings bump, BB shares trade around $10 with a trailing price-to-earnings (P/E) ratio just shy of 130x.
Current Price$10.29High Forecast$12.00Average Forecast$7.17Low Forecast$4.50BlackBerry Stock Forecast Details
The Blackberry analyst consensus forecasts on MarketBeat have the stock rated a Hold, with a consensus price target of around $7.
However, Canaccord Genuity nearly doubled its price target to $8.20 from $4.40 on June 24, and Stifel Nicolas initiated coverage with a $12 price target. Investors will be watching to see if these are outliers or the start of a trend.
The consensus Hold rating suggests analysts still view BB as a slow-growth business. But if price targets begin to chase the company’s fundamentals, the outlook will change.
For example, if QNX captures even a small slice of the physical AI software stack, the addressable market expands well beyond automotive. The NVIDIA partnership also opens distribution to a developer ecosystem numbering in the millions.
That is the "early" argument. Bears counter that the revenue base is still small relative to ambitions. Competition from open-source ROS 2 and established players like Wind River and Green Hills Software is real and well-funded.
The Catch: QNX Momentum May Take Time to ScaleSeveral risks deserve attention before chasing the rally. QNX revenue grew strongly in Q1, but automotive software design cycles are notoriously long. Royalty revenue depends on vehicle production volumes, which remain choppy globally.
Secure Communications growth runs in the mid-single digits. That segment generates steady cash but will not drive the multiple expansion needed to justify the current price.
Stock-based compensation and dilution are also persistent issues. A buyback program is in place, but the share count needs to fall further for per-share metrics to improve meaningfully.
Is BlackBerry Stock a Buy After Its Massive Rally? The Q1 print confirmed that BlackBerry's pivot is working. Physical AI gives the company a real growth narrative for the first time in over a decade. But at current prices, investors are paying for a story that needs several quarters of execution to fully play out.
For long-term holders, the thesis remains intact, and the guidance raise gives them another quarter of cover. For new buyers, waiting for a pullback or a clearer signal that QNX royalties are accelerating may be the more disciplined approach.
BlackBerry Limited (BB) Price Chart for Friday, June, 26, 2026
Should You Invest $1,000 in BlackBerry Right Now?Before you consider BlackBerry, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BlackBerry wasn't on the list.
While BlackBerry currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
EMA doporučila zrušit registraci Amgenu pro lék Tavneos kvůli nedostatečnému přínosu vůči rizikům. Noví pacienti by léčbu neměli zahajovat a stávající mají být převedeni na alternativy.
Item 1 of 2 The logo of Amgen biopharmaceutical company hangs at the Stripe Young Scientist and Technology exhibition at the RDS, in Dublin, Ireland, January 9, 2026. REUTERS/Clodagh Kilcoyne/File Photo
[1/2]The logo of Amgen biopharmaceutical company hangs at the Stripe Young Scientist and Technology exhibition at the RDS, in Dublin, Ireland, January 9, 2026. REUTERS/Clodagh Kilcoyne/File Photo Purchase Licensing Rights, opens new tab
CompaniesJune 26 (Reuters) - The European Medicines Agency on Friday recommended revoking the marketing authorisation for Amgen's (AMGN.O), opens new tab rare autoimmune disease drug, Tavneos, citing a lack of benefits that outweigh its risks.
In April, the U.S. FDA's Center for Drug Evaluation and Research had proposed withdrawing approval of Tavneos, after identifying 76 cases of drug-induced liver injury with evidence suggesting a causal link to the drug.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
The EMA said the clinical study supporting the medicine's EU approval breached good clinical practice principles and the data were found to be incorrect, misleading and no longer reliable for demonstrating Tavneos' effectiveness.
The data collected after the drug was approved, along with additional analyses carried out after the main study, were not enough to prove the medicine's benefits, the EMA said.
Tavneos, approved in 2022 in the EU, treats anti-neutrophil cytoplasmic autoantibody-associated vasculitis, a rare group of autoimmune diseases that cause inflammation in small- to medium-sized blood vessels.
Amgen said in a statement it was "deeply concerned" about the potential impact of the recommendation and that it "continues to believe that Tavneos is an important treatment option for people living with AAV."
The company said CSL Vifor, its partner in Europe, is leading interactions with the EMA regarding the next steps for patients and healthcare providers in Europe.
The EMA's Committee for Medicinal Products for Human Use has recommended that no new patients should start treatment with Tavneos, while existing patients should be switched to suitable alternatives.
Amgen has signed up a research firm to independently review the data on Tavneos, as it seeks to prove the drug's benefits before a hearing with the FDA.
The drugmaker said the deadline for submitting the data to the FDA has been extended to July 29 from June 29.
Reporting by Christy Santhosh in Bengaluru; Editing by Shreya Biswas
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Taiwan Semiconductor klesá kvůli slabšímu trhu, ne kvůli vlastní zprávě; Counterpoint Research uvedl, že globální trh Foundry 2.0 těží z trvalé poptávky po umělé inteligenci a že Taiwan Semiconductor má zůstat jedním z největších vítězů, protože AI investice pokračují do roku 2026.
The decline appears to reflect broad market weakness rather than company-specific news. Softer index futures prompted investors to reduce exposure to high-growth technology stocks, leading to profit-taking across semiconductor names following their strong gains in recent months.
AI Spending Keeps Taiwan Semiconductor Ahead While Intel Foundry Gains TractionSeparately, Counterpoint Research said on Friday the global Foundry 2.0 market is benefiting from sustained artificial intelligence demand, with Taiwan Semiconductor expected to remain one of the biggest winners as AI investments continue through 2026.
The research firm said Taiwan Semiconductor’s first-quarter revenue surged 41% year over year and forecast full-year 2026 revenue growth of about 36%, driven by strong demand for AI GPUs, AI ASICs and advanced packaging.
Senior Analyst William Li said the current AI cycle represents a “broader structural transformation” for the semiconductor industry rather than a typical cyclical recovery, citing unprecedented capacity reallocations, pricing changes, and persistent CoWoS packaging constraints.
“Growing TPU and ASIC demand could further tighten leading-edge capacity, creating opportunities for Intel Foundry and Samsung Foundry, with Apple M-series chip on Intel Foundry as a potential catalyst,” the research firm said.
Technical AnalysisDespite Friday’s pullback, TSM remains in a long-term uptrend. The stock continues to trade above its 50-day simple moving average of $411.50, its 100-day SMA of $381.83, and its 200-day SMA of $339.26. The 20-day SMA also remains above the 50-day SMA, while the 50-day SMA stays above the 200-day SMA, signaling a bullish long-term trend.
In the near term, however, momentum has cooled. TSM is trading about 1.5% below its 20-day SMA of $433.61 after retreating from its June peak and 52-week high. That suggests the stock is consolidating rather than extending its rally.
The relative strength index (RSI) stands at 52.43, indicating neutral momentum. A reading near 50 typically signals a balanced market where buyers and sellers remain evenly matched.
Key resistance sits near $450. A move above that level could revive bullish momentum. On the downside, support is around $405.50, just below the 50-day moving average. A break below that level could weaken the intermediate-term trend.
Earnings And Analyst OutlookTSM is expected to report second-quarter results on July 16.
Wall Street expects earnings of $3.77 per share, up from $2.47 a year earlier, on revenue of $39.76 billion, compared with $30.07 billion in the prior-year quarter.
The stock trades at about 37.5 times earnings, reflecting its premium valuation.
Analysts remain broadly bullish. The consensus rating is Buy, with an average price forecast of $489.17. Recent analyst actions include:
Bank of America Securities reiterated Buy and raised its price forecast to $590 on June 24. Susquehanna maintained a Positive rating and lifted its price forecast to $575 on June 22. Barclays reiterated Overweight with a $470 price forecast on April 22. Taiwan Semiconductor Benzinga Edge RankingsAccording to Benzinga Edge, TSM scores highly for Momentum (91.98), Growth (92.65), and Quality (97.54), while its Value score remains weak at 22.28 because of its premium valuation.
The combination suggests investors continue to reward the company’s strong earnings profile and AI-driven growth prospects, although valuation remains a key consideration.
ETF ExposureTSM is a major holding in several exchange-traded funds, including:
Large inflows or outflows in these funds can create additional buying or selling pressure for TSM shares.
Taiwan Semiconductor Price ActionTSM Stock Price Activity: Taiwan Semiconductor shares were down 1.61% at $428.00 during premarket trading on Friday, according to Benzinga Pro data.
Image via Shutterstock
Market News and Data brought to you by Benzinga APIs
Taiwan Semiconductor Manufacturing těží z prudké poptávky po AI čipech, když tržby v 1. čtvrtletí meziročně vzrostly o 40 %. Firma zároveň drží přes 70% podíl na globálním foundry trhu.
There are many ways to invest in artificial intelligence (AI), but overall, there is no business better positioned to compete than Taiwan Semiconductor Manufacturing (TSM 1.61%). It produces chips for Nvidia, Apple, and other leading tech companies. It's a wide-moat business that provides broad exposure to the AI chip market with one stock, making it the smartest way to invest in AI infrastructure.
The stock's price has climbed 110% over the past year. In the first quarter, revenue surged 40% year over year, driven by insatiable demand for AI chips powering advanced computing systems.
Image source: The Motley Fool.
It's not easy to replicate what TSMC does. It takes at least a few years to complete the production process, including testing and qualifying a new leading-edge process node. This makes it costly for customers to switch suppliers once a chip blueprint has been sent to TSMC for production.
Today's Change
(
-1.61
%) $
-7.11
Current Price
$
433.72
TSMC controls over 70% of the global foundry market, according to Counterpoint. This dominant lead is reflected in its high margins. Over the last year, TSMC's net profit margin was 47%.
There is growing competition from other foundries, including Intel and Samsung. Still, recent reports indicate that TSMC is raising prices for its process nodes amid strong demand and higher costs of memory components used in chipmaking. This reinforces its wide competitive moat in the industry. The stock trades at about 30 times this year's earnings estimate, which isn't cheap but reasonable, and analysts project 31% annualized earnings growth over the next several years.
John Ballard has positions in Nvidia. The Motley Fool has positions in and recommends Apple, Intel, Nvidia, and Taiwan Semiconductor Manufacturing. The Motley Fool has a disclosure policy.
Eli Lilly oznámila, že CHMP doporučil schválení Jaypirca pro dospělé s CLL v celé EU bez ohledu na předchozí léčbu BTK inhibitorem. Rozhodnutí Evropské komise se čeká během jednoho až dvou měsíců.
The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society of Hematology Annual Meeting and published in The Journal of Clinical Oncology
BRUIN CLL-313 is the first Phase 3 study to evaluate a non-covalent BTK inhibitor exclusively in patients with treatment-naïve CLL and BRUIN CLL-314 is the first Phase 3 CLL trial to compare non-covalent and covalent BTK inhibitors, as well as the first to compare any BTK inhibitors in the treatment-naïve setting
If granted marketing authorization, this would expand pirtobrutinib's indication as a treatment option for patients with CLL in the European Union across all lines of therapy
, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, for the treatment of adults with chronic lymphocytic leukemia (CLL) across all lines of therapy and regardless of prior BTK inhibitor treatment. Following this positive opinion, the application is now referred to the European Commission for final action. The European Commission's decision is expected in the next one to two months.
"Results from BRUIN CLL-313 and BRUIN CLL-314 provide compelling evidence that pirtobrutinib can make a meaningful difference for people living with CLL across multiple lines of therapy," said Paolo Ghia, M.D., professor, medical oncology, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy. "The strong efficacy and tolerability demonstrated in these trials underscores the clinical value pirtobrutinib may offer patients. This positive opinion from the CHMP is an exciting and significant milestone, bringing us closer to a future where pirtobrutinib is an option for more people with CLL across the European Union."
Results from BRUIN CLL-313 and BRUIN CLL-314 were presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in December 2025 and published in The Journal of Clinical Oncology.
"Based on the strong results from the BRUIN CLL-313 and CLL-314 studies, we believe Jaypirca has the potential to serve as a meaningful new option for newly diagnosed patients and those who have not yet received a BTK inhibitor," said Jacob Van Naarden, executive vice president and president of Lilly Oncology. "Thanks to the impact of contemporary CLL treatments, many patients may receive fewer lines of therapy over their lifetime, making treatment choices in earlier lines profoundly important. This CHMP opinion represents a step toward an important global approval for Jaypirca in this indication and reflects our ambition to make Jaypirca available to every CLL patient who may benefit, at any line of therapy. Today, we are on the brink of making that a reality across the European Union as we await the European Commission's final decision."
Lilly has also submitted these results to the U.S. Food and Drug Administration (FDA) for approval for adult patients with CLL, with a decision expected in the second half of 2026.
About BRUIN CLL-313
BRUIN CLL-313 is a Phase 3, global, randomized, open-label study of pirtobrutinib versus chemoimmunotherapy (BR) in people with CLL/SLL without 17p deletions who have not been previously treated. The trial enrolled 282 patients who were randomized 1:1 to receive pirtobrutinib (200 mg orally, once daily) or BR per labeled doses. BR is a chemoimmunotherapy regimen used in the treatment of CLL. The primary endpoint is PFS as assessed by blinded IRC. Secondary endpoints include investigator and IRC assessed ORR, duration of response (DoR), and PFS, OS, time to next treatment (TTNT), safety and tolerability and patient-reported outcomes (PRO).
About BRUIN CLL-314
BRUIN CLL-314 is a Phase 3, randomized, open-label study of Jaypirca (pirtobrutinib) versus Imbruvica (ibrutinib) in patients with CLL/SLL who were either treatment-naïve, or who were previously treated and were BTK inhibitor-naïve. The trial enrolled 662 patients who were randomized 1:1 to receive pirtobrutinib (200 mg orally, once daily) or ibrutinib (420 mg orally, once daily). The primary endpoint is ORR as assessed by blinded IRC. Secondary endpoints include investigator and IRC-assessed PFS, duration of response (DoR) and event-free survival (EFS), and time to next treatment (TTNT), OS, safety and tolerability, and patient-reported outcomes (PRO).
About Jaypirca (pirtobrutinib)
Jaypirca (pirtobrutinib, formerly known as LOXO-305) (pronounced jay-pihr-kaa) is a highly selective (300 times more selective for BTK versus 98% of other kinases tested in preclinical studies), non-covalent inhibitor of the enzyme BTK.1 BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).2,3 Jaypirca is a U.S. FDA-approved oral prescription medicine, 100 mg or 50 mg tablets taken as a once-daily 200 mg dose with or without food until disease progression or unacceptable toxicity.
About Chronic Lymphocytic Leukemia (CLL)
CLL is a form of slow-growing non-Hodgkin lymphoma that develops from white blood cells known as lymphocytes.4,5 CLL is one of the most common types of leukemia in adults.6 There are roughly 100,000 new cases of CLL globally each year, and the overall incidence of CLL in Europe is approximately 4.92 cases per 100,000 persons per year.6,7 In CLL, the cancer cells are present in the blood.6
INDICATIONS FOR JAYPIRCA (pirtobrutinib) (in the United States)
Adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. Adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical trial benefit in a confirmatory trial. IMPORTANT SAFETY INFORMATION FOR JAYPIRCA (pirtobrutinib)
Infections: Fatal and serious infections (including bacterial, viral, fungal) and opportunistic infections occurred in Jaypirca-treated patients. Across clinical trials, Grade ≥3 infections occurred (25%), most commonly pneumonia (20%); fatal infections (5%), sepsis (6%), and febrile neutropenia (3.8%) occurred. In patients with CLL/SLL, Grade ≥3 infections occurred (32%), with fatal infections occurring in 8%. Opportunistic infections included Pneumocystis jirovecii pneumonia and fungal infection. Consider prophylaxis, including vaccinations and antimicrobial prophylaxis, in patients at increased risk for infection, including opportunistic infections. Monitor for signs and symptoms, evaluate, and treat. Based on severity, reduce dose, temporarily withhold, or permanently discontinue Jaypirca.
Hemorrhage: Fatal and serious hemorrhage has occurred with Jaypirca. Across clinical trials, major hemorrhage (Grade ≥3 bleeding or any central nervous system bleeding) occurred (2.6%), including gastrointestinal hemorrhage; fatal hemorrhage occurred (0.3%). Bleeding of any grade, excluding bruising and petechiae, occurred (16%). Major hemorrhage occurred when taking Jaypirca with (2.0%) and without (0.6%) antithrombotic agents. Consider risks/benefits of co-administering antithrombotic agents with Jaypirca. Monitor for signs of bleeding. Based on severity, reduce dose, temporarily withhold, or permanently discontinue Jaypirca. Consider withholding Jaypirca 3-7 days pre- and post-surgery based on surgery type and bleeding risk.
Cytopenias: Jaypirca can cause cytopenias, including neutropenia, thrombocytopenia, and anemia. Across clinical trials, Grade 3 or 4 cytopenias, including decreased neutrophils (27%), decreased platelets (13%), and decreased hemoglobin (11%), developed. Grade 4 decreased neutrophils (15%) and Grade 4 decreased platelets (6%) developed. Monitor complete blood counts regularly. Based on severity, reduce dose, temporarily withhold, or permanently discontinue Jaypirca.
Cardiac Arrhythmias: Cardiac arrhythmias occurred in patients taking Jaypirca. Across clinical trials, atrial fibrillation or flutter were reported in 3.4% of Jaypirca treated patients, with Grade 3 or 4 atrial fibrillation or flutter in 1.6%. Other serious cardiac arrhythmias such as supraventricular tachycardia and cardiac arrest occurred (0.4%). Cardiac risk factors such as hypertension or previous arrhythmias may increase risk. Monitor and manage signs and symptoms of arrhythmias (e.g., palpitations, dizziness, syncope, dyspnea). Based on severity, reduce dose, temporarily withhold, or permanently discontinue Jaypirca.
Second Primary Malignancies: Across clinical trials, second primary malignancies, including non-skin carcinomas, developed in 9% of Jaypirca-treated patients, most frequently non-melanoma skin cancer (4.4%). Other second primary malignancies included solid tumors (including genitourinary and breast cancers) and melanoma. Advise patients to use sun protection and monitor for development of second primary malignancies.
Hepatotoxicity, Including Drug-Induced Liver Injury (DILI): Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of DILI, has occurred in patients treated with BTK inhibitors, including Jaypirca. Evaluate bilirubin and transaminases at baseline and throughout Jaypirca treatment. For patients who develop abnormal liver tests after Jaypirca, monitor more frequently for liver test abnormalities and clinical signs and symptoms of hepatic toxicity. If DILI is suspected, withhold Jaypirca. If DILI is confirmed, discontinue Jaypirca.
Embryo-Fetal Toxicity: Jaypirca can cause fetal harm. Administration of pirtobrutinib to pregnant rats caused embryo-fetal toxicity, including embryo-fetal mortality and malformations at maternal exposures (AUC) approximately 3-times the recommended 200 mg/day dose. Advise pregnant women of fetal risk and females of reproductive potential to use effective contraception during treatment and for one week after last dose.
Adverse Reactions (ARs) in Patients Who Received Jaypirca
The most common (≥30%) ARs in the pooled safety population of patients with hematologic malignancies (n=704) were decreased neutrophil count (54%), decreased hemoglobin (43%), decreased leukocytes (32%), fatigue (31%), decreased platelets (31%), decreased lymphocyte count (31%), calcium decreased (30%).
Mantle Cell Lymphoma
Serious ARs occurred in 38% of patients, with pneumonia (14%), COVID-19 (4.7%), musculoskeletal pain (3.9%), hemorrhage (2.3%), pleural effusion (2.3%), and sepsis (2.3%) occurring in ≥2% of patients. Fatal ARs within 28 days of last dose occurred in 7% of patients, most commonly due to infections (4.7%), including COVID-19 (3.1% of all patients).
Dose Modifications and Discontinuations Due to ARs: Dose reductions in 4.7%, treatment interruption in 32%, and permanent discontinuation of Jaypirca in 9% of patients. Permanent discontinuation in >1% of patients included pneumonia.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma from Single-Arm and Randomized Controlled Clinical Trials
Serious ARs occurred in 47-56% of patients across clinical trials. Serious ARs in ≥5% of patients in the single-arm trial were pneumonia (18%), COVID-19 (9%), sepsis (7%), febrile neutropenia (7%). Serious ARs in ≥3% of patients in the randomized controlled trial were pneumonia (21%), COVID-19 (5%), sepsis (3.4%). Fatal ARs within 28-30 days of last Jaypirca dose occurred in 8-11% of patients, most commonly due to infections (7-10%), including sepsis (5%), COVID-19 (2.7-5%), and pneumonia (3.4%).
Dose Modifications and Discontinuations Due to ARs: Dose reductions in 3.6-10%, treatment interruption in 42-51%, and permanent discontinuation of Jaypirca in 9-17% of patients. Permanent discontinuation in >1% of patients included second primary malignancy, pneumonia, COVID-19, neutropenia, sepsis, anemia, and cardiac arrythmias.
Strong CYP3A Inhibitors: Concomitant use increased pirtobrutinib systemic exposure, which may increase risk of Jaypirca ARs. Avoid using strong CYP3A inhibitors with Jaypirca. If concomitant use is unavoidable, reduce Jaypirca dose according to approved labeling.
Strong or Moderate CYP3A Inducers: Concomitant use decreased pirtobrutinib systemic exposure, which may reduce Jaypirca efficacy. Avoid using Jaypirca with strong or moderate CYP3A inducers. If concomitant use with moderate CYP3A inducers is unavoidable, increase Jaypirca dose according to approved labeling.
Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP Substrates: Use with Jaypirca increased their plasma concentrations, which may increase risk of ARs related to these substrates for drugs sensitive to minimal concentration changes. Follow recommendations for these sensitive substrates in their approved labeling.
Use in Specific Populations
Pregnancy and Lactation: Due to potential for Jaypirca to cause fetal harm, verify pregnancy status in females of reproductive potential prior to starting Jaypirca. Presence of pirtobrutinib in human milk is unknown. Advise women to use effective contraception and to not breastfeed while taking Jaypirca and for one week after last dose.
Geriatric Use: In the pooled safety population of patients with hematologic malignancies, patients aged ≥65 years experienced higher rates of Grade ≥3 ARs and serious ARs compared to patients <65 years of age.
Renal Impairment: Because severe renal impairment increases pirtobrutinib exposure, reduce Jaypirca dose in these patients according to approved labeling.
PT HCP ISI MCL_CLL Q42025
Please see Prescribing Information and Patient Information for Jaypirca.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY
Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Jaypirca (pirtobrutinib), as a potential treatment for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), and the timeline for future readouts, presentations, and other milestones relating to Jaypirca and its clinical trials, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that Jaypirca will receive additional regulatory approvals, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Endnotes & References
Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397(10277):892-901. doi:10.1016/S0140-6736(21)00224-5 Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J Hematol Oncol. 2020;13(1):79. Published 2020 Jun 17. doi:10.1186/s13045-020-00914-1 Gu D, Tang H, Wu J, Li J, Miao Y. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. J Hematol Oncol. 2021;14(1):40. Published 2021 Mar 6. doi:10.1186/s13045-021-01049-7 Mukkamalla SKR, Taneja A, Malipeddi D, et al. Chronic Lymphocytic Leukemia. [Updated 2023 Feb 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470433/ The Leukemia and Lymphoma Society. NHL Subtypes. Access here: https://www.lls.org/lymphoma/non-hodgkin-lymphoma/nhl-subtypes. Accessed on October 25, 2023. Ou Y, Long Y, Ji L, et al. Trends in Disease Burden of Chronic Lymphocytic Leukemia at the Global, Regional, and National Levels From 1990 to 2019, and Projections Until 2030: A Population-Based Epidemiologic Study. Front Oncol. 2022;12:840616. Published 2022 Mar 10. doi:10.3389/fonc.2022.840616 Sant M, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010. 116:3724–34. https://pubmed.ncbi.nlm.nih.gov/20664057/ Refer to: Kyle Owens; [email protected] (Media)
Michael Czapar; [email protected] (Investors)
Raytheon získal od amerického námořnictva zakázku za 1,1 miliardy USD na výrobu střel AIM-9X Block II. Firma chce kvůli rostoucí poptávce zvýšit kapacitu na 2 500 kusů ročně.
Award continues program expansion capacity to meet rising domestic and international demand
, /PRNewswire/ -- Raytheon, an RTX (NYSE: RTX) business, was awarded a $1.1 billion contract from the U.S. Navy to produce AIM-9X Block II missiles to bolster U.S. military inventory and meet increased demand from allied nations.
Under the contract, Raytheon will produce AIM-9X missiles along with associated hardware and software for U.S. and Foreign Military Sales customers.
"Our teams have streamlined production, shortened lead times and ramped up deliveries of AIM-9X missiles to keep pace with growing demand," said Barbara Borgonovi, president of Naval Power at Raytheon. "This contract, along with our close partnership with the U.S. Navy, allows us to sustain that momentum and ensure U.S. and allied forces have this advanced, combat-proven capability they depend on in high threat environments."
AIM-9X is the most advanced infrared tracking, short-range air-to-air and surface-to-air missile, and it is combat-proven in multiple theaters around the world. The system is configured for easy installation on a wide range of modern aircraft and provides layered defense options with ground launched capabilities, including the National Advanced Surface to Air Missile System (NASAMS).
Trusted by the U.S. and more than 35 allied and partner nations, AIM-9X is a critical asset for ensuring strategic deterrence and operational advantage worldwide. To meet growing demand, Raytheon is increasing its production capacity to 2,500 missiles per year.
A majority of the work under this contract will take place in Tucson, Arizona. Raytheon is significantly expanding its engineering workforce in Tucson to support critical military programs across domains. Engineers with active security clearances and relevant technical experience ready to make a difference helping connect and protect our world can learn more by visiting our website.
About Raytheon
Raytheon, an RTX business, is a leading provider of defense solutions to help the U.S. government, our allies and partners defend their national sovereignty and ensure their security. For more than 100 years, Raytheon has developed new technologies and enhanced existing capabilities in integrated air and missile defense, smart weapons, missiles, advanced sensors and radars, interceptors, space-based systems, hypersonics and missile defense across land, air, sea and space.
About RTX
With more than 180,000 global employees, we push the limits of technology and science to redefine how we connect and protect our world. With industry-leading capabilities, we advance aviation, engineer integrated defense systems for operational success, and develop next-generation technology solutions and manufacturing to help global customers address their most critical challenges. The company, with 2025 sales of more than $88 billion, is headquartered in Arlington, Virginia.
For questions or to schedule an interview, please contact [email protected].
McCormick & Company ve 2. čtvrtletí překonal odhady zisku i tržeb, když upravený EPS činil 0,80 USD a tržby 1,94 miliardy USD. Tahounem byl růst divize Flavor Solutions, který kompenzoval slabší americký spotřebitelský byznys.
Key Takeaways MKC says Flavor Solutions growth offset softer U.S. consumer trends, led by foodservice and CPG demand.MKC is refining pricing, packs, distribution and marketing to improve consumer trends by the third quarter.MKC topped earnings and revenue estimates, with gross margin up 270 basis points and operating income up 30%. McCormick & Company, Incorporated (MKC - Free Report) used its second-quarter call to make a clear case that Flavor Solutions is carrying the business, while management works to restore better volume trends in U.S. consumer spices.
Management reaffirmed its 2026 outlook, but much of the investor focus shifted to how quickly the company can fix pressure in the Americas consumer business and sustain the stronger industrial and foodservice backdrop.
MKC Finds Its Main Engine in Flavor SolutionsChairman, president and CEO Brendan Foley said the quarter’s most important feature was the acceleration in Flavor Solutions, where growth broadened across Flavors and Branded Foodservice customers. That strength more than offset softer consumer trends in the Americas.
Flavor Solutions' organic sales rose 3% in the quarter, with gains split nearly evenly between price and volume. In the Americas, the segment posted 4% organic growth, helped by large CPG customers, private label, high-growth innovators and stronger branded foodservice demand.
Foley also pointed to reformulation activity, beverage innovation and health-and-wellness projects as key demand drivers. In Q&A, he said those projects are commercializing faster than initially expected, which adds support to the second-half outlook for the segment.
McCormick Targets a Consumer Volume ResetThe softer spot remained Global Consumer, especially U.S. spices and seasonings. Foley said shifting demand patterns, wider price gaps and heavier competitive promotion hurt consumption in certain segments, even as the broader category still grew.
Management’s response is familiar but more targeted this time. Foley said McCormick is refining revenue growth management, adjusting price-pack architecture, expanding distribution and increasing value-focused marketing to improve trends by the third quarter and return to volume growth in the fourth.
That issue surfaced repeatedly in analyst questions. Barclays, BofA and TD Cowen all pressed management on whether the company can restore sustainable volume momentum. Foley’s answer was consistent: the playbook is similar to the one used two years ago, but execution is faster, more digital and aimed at narrower pockets of weakness.
MKC Uses Margin Gains to Fund ReinvestmentThe second quarter still showed strong financial leverage. Adjusted EPS came in at $0.80, which beat the Zacks Consensus Estimate of $0.69 by 15.9%. Revenues of $1.94 billion topped the Zacks Consensus Estimate of $1.90 billion by 2%. Gross margin expanded 270 basis points, and adjusted operating income rose 30%.
CFO Marcos Gabriel said the largest moving pieces behind margin expansion were accretion from McCormick de Mexico, productivity savings, surgical pricing and a tariff refund. The refund lowered the cost of goods sold by $28 million in the quarter and added about $0.07 to adjusted EPS.
Just as important, Gabriel said most of that tariff benefit is being used to absorb higher inflation tied to the Middle East conflict and other cost pressures. That framing mattered because management presented the quarter’s margin upside as a source of funding for reinvestment, not as a clean earnings windfall.
McCormick Pushes Ahead on Unilever FoodsFoley also spent time reinforcing confidence in the pending Unilever Foods combination. He said integration planning is advancing with a dedicated management office, 20 functional teams and more than 200 people working across both organizations.
Management reiterated the deal’s financial targets, including a 21% operating margin at close, mid- to high-single-digit adjusted EPS accretion within the first 12 months after closing and mid- to high-teens accretion by year three.
Analysts also tested the durability of that future margin profile. Foley and Gabriel argued the model does not assume unusually lean SG&A, and Gabriel said the path to 23% to 25% operating margins comes from layering synergies on top of the 21% starting point.
MKC Flags a Softer Third-Quarter Profit CadenceThe other area of scrutiny was the third quarter. Gabriel said adjusted operating income should grow in the high-single-digit to low-double-digit range, with continued gross margin expansion offset by heavier ERP spending, higher incentive compensation and a significant increase in brand marketing.
JPMorgan and BNP Paribas pushed on whether this reflected a change in expectations. Gabriel said it was more about SG&A phasing than a change in the company’s internal view, though he also acknowledged inflation is tracking toward the high end of the company’s mid-single-digit cost outlook.
Cash flow was one cleaner positive. First-half operating cash flow rose to $431 million from $161 million a year earlier, helped by profitability and working capital improvement, particularly in inventory days and payables. Leverage ended the quarter at about 2.9 times.
McCormick Leaves the Call on OffenseThe overall tone coming out of the call was constructive but not complacent. Management repeatedly pointed to the resilience of flavor categories, the breadth of the portfolio and the ability to redirect margin gains into brand support, innovation and distribution.
At the same time, executives did not underplay the strain on the U.S. consumer. The company’s message was that Flavor Solutions is performing ahead of plan, while consumer remediation is now the central execution task for the back half of fiscal 2026.
MKC’s Zacks Signals Still Lean CautiousMKC currently carries a Zacks Rank #4 (Sell), along with a Value Score of C, Growth Score of F, Momentum Score of C and VGM Score of D. Under the Zacks framework, weaker ranks reflect less favorable earnings estimate revision trends, while Style Scores help gauge value, growth and momentum characteristics.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
That combination points to a more cautious near-term setup than the quarter’s headline beat alone would imply. The Zacks system places the greatest weight on estimate revisions, and the current rank can change as analysts update forecasts after the just-reported results.
